![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
KOL Resume for Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Influence Statistics
Concept | World rank |
---|---|
children behavioral | #1 |
adhd phenotypes | #1 |
adhd drug dependence | #1 |
adulthood genetic architecture | #1 |
stimulants comorbidity | #1 |
bpi probands | #1 |
“forgetfulness | #1 |
disorder relatives | #1 |
siblings males | #1 |
adhd conduct disorder | #1 |
trypotphan | #1 |
cgsq ermph | #1 |
shr iiv | #1 |
stress adhd severity | #1 |
criteria 14 children | #1 |
clinically diagnosed obesity | #1 |
rs550818 | #1 |
rs552655 | #1 |
trait impulsivity adhdct | #1 |
evidence sud phenotypes | #1 |
suds neurocognitive functions | #1 |
parental probands | #1 |
31item | #1 |
adhd probands | #1 |
odd relatives | #1 |
adhd social class | #1 |
psychiatric conditions adults | #1 |
children motor competence | #1 |
neuropsychological testing individuals | #1 |
adhd adult adhd | #1 |
children idiopathic adhd | #1 |
deficits time | #1 |
chinese outpatient sample | #1 |
adhd degree relatives | #1 |
pdd criteria | #1 |
treatment masxr | #1 |
adhd context | #1 |
adhd structural abnormalities | #1 |
school reliability | #1 |
adhdi prenatal exposure | #1 |
sensitive adhd | #1 |
treatment mts | #1 |
memory adults | #1 |
disorder versus disability | #1 |
type attention | #1 |
efds bpi disorder | #1 |
subtype adhd | #1 |
rs3916970 | #1 |
sud adolescent patients | #1 |
bpd anx relatives | #1 |
bpd anx | #1 |
nplz | #1 |
risk childhood onset | #1 |
dsmiiir dsmiv adhd | #1 |
diagnostic continuity | #1 |
offspring behavioral disinhibition | #1 |
pain tolerance fm | #1 |
dsm5 adult adhd | #1 |
adults life | #1 |
tourettes syndrome adhd | #1 |
validity adhd | #1 |
psychopharmacologic | #1 |
oros methylphenidate orosmph | #1 |
impulsive drive | #1 |
teacher combined | #1 |
haplotypes adhd | #1 |
adhd proband | #1 |
childhood adhd adulthood | #1 |
mph controls | #1 |
scales risk | #1 |
ermph cgsq | #1 |
parents behavioral disinhibition | #1 |
rare protective allele | #1 |
candidate genes adhd | #1 |
hyperactivity child child | #1 |
bpi sza | #1 |
common genetic risk | #1 |
adhd antisocial disorders | #1 |
attention deficit | #1 |
differences medications | #1 |
adhd control probands | #1 |
paliperidone monotherapy | #1 |
adhdmethodcurves | #1 |
manic children pdd | #1 |
rs1799835 | #1 |
mr006 | #1 |
adhd genetic variants | #1 |
inattentive symptoms adults | #1 |
predictors adhd | #1 |
fhrscz | #1 |
neurocognitive functions suds | #1 |
social adjustment inventory | #1 |
48basepairrepeat | #1 |
amses amrs | #1 |
greater risk add | #1 |
dao gene schizophrenia | #1 |
disorders hypothesis | #1 |
schizotaxia negative symptoms | #1 |
treatment bsd | #1 |
adhd dyscalculia | #1 |
nonreferred subjects | #1 |
anxiety disorders baseline | #1 |
relatives greater activation | #1 |
rs9627183 | #1 |
qms adult adhd | #1 |
adhd france | #1 |
adhd prss adhd | #1 |
interaction adhd severity | #1 |
asrs | #1 |
cbcldesr | #1 |
comorbid odd adhd | #1 |
dbds adhd | #1 |
symptoms adult | #1 |
anxiety disorders twins | #1 |
parents proband youth | #1 |
relatives conduct disorder | #1 |
affs add | #1 |
marijuana smoking metaanalysis | #1 |
motorendophenotype | #1 |
idir proteins siblings | #1 |
adhd cognition | #1 |
actual motor performance | #1 |
schizophrenia families smoking | #1 |
pharmacological treatment adolescents | #1 |
conduct disorder aspd | #1 |
subthreshold adhd subjects | #1 |
bpi relatives | #1 |
2327ct | #1 |
adhd mdd prss | #1 |
adhd long term | #1 |
braingenie | #1 |
combination scientific data | #1 |
chi25762 | #1 |
association psychiatric comorbidity | #1 |
sex bpi disorder | #1 |
adhd functional | #1 |
adhd desr | #1 |
drug dependence relatives | #1 |
oral methylphenidate treatment | #1 |
cacng2 genes schizophrenia | #1 |
rates relatives | #1 |
comorbid adult adhd | #1 |
ats siblings | #1 |
comt intelligence | #1 |
df39 | #1 |
medications adult adhd | #1 |
adhd maternal smoking | #1 |
pdag mdd mdd | #1 |
youth informant source | #1 |
rs1076560t | #1 |
transmission adhd | #1 |
adhd sex | #1 |
familiar disease | #1 |
sud bpdsud | #1 |
family‐based association test | #1 |
scz palau | #1 |
prescription stimulant nmu | #1 |
opd add | #1 |
adhd linkage | #1 |
parents md | #1 |
executive functioning adults | #1 |
adolescent sud | #1 |
d10s2327 | #1 |
sud risk offspring | #1 |
adhd genetic correlation | #1 |
adhd chinese population | #1 |
adhd subjects controls | #1 |
persons rels | #1 |
infas | #1 |
longitudinal analysis childhood | #1 |
referred parents | #1 |
gender adhd | #1 |
gene aggressive behavior | #1 |
adolescents genetic risk | #1 |
mothers fam | #1 |
association evidence schizophrenia | #1 |
120 normal controls | #1 |
biased maternal reporting | #1 |
population screen | #1 |
paternal over‐transmission | #1 |
distal genomic region | #1 |
abnormalities adhd | #1 |
substantial genetic component | #1 |
onset chronological age | #1 |
rutters | #1 |
referred samples | #1 |
control probands | #1 |
adult persistence | #1 |
anx relatives | #1 |
autism‐associated brain regions | #1 |
substance disorders relatives | #1 |
genetics adhd | #1 |
snpssnpsa | #1 |
molecular psychiatric genetics | #1 |
severe emotional dysregulation | #1 |
growth outcomes adhd | #1 |
adhd neuropsychological functioning | #1 |
229 families | #1 |
child psychiatry referrals | #1 |
aud alcohol disorders | #1 |
manic symptoms disorder | #1 |
exposure maternal smoking | #1 |
controls rels | #1 |
treatment stimulants | #1 |
adhd slc6a3 genotype | #1 |
rs9610449 | #1 |
rs11568324 | #1 |
fhraff | #1 |
adhd personality traits | #1 |
efs girls | #1 |
fspds | #1 |
risk factors opd | #1 |
psychiatric comorbidities adhd | #1 |
9r allele | #1 |
schizophrenic probands1portions | #1 |
risk anxiety disorders | #1 |
onset distributions | #1 |
adherence stimulant treatment | #1 |
disorder follow | #1 |
disorder schizotaxia | #1 |
intellectual delays | #1 |
weaknesses comorbidity | #1 |
pdd pdd subjects | #1 |
familial disorders adhd | #1 |
familial evidence | #1 |
hyperactivity comorbidity humans | #1 |
add opd | #1 |
findings adhd | #1 |
efficacy outcome week | #1 |
antisocial disorders risk | #1 |
prescription stimulant nonmedical | #1 |
a409p | #1 |
ptsd adhd probands | #1 |
lifetime impairment | #1 |
genetic frontal schizophrenia | #1 |
schizophrenia code | #1 |
faraone | #1 |
behaviors substances | #1 |
adolescents concurrent adhd | #1 |
bpi disorder adhd | #1 |
genetic association rorb | #1 |
vntr haplotype | #1 |
dysfunctional gene | #1 |
genomesignificance | #1 |
manic symptoms vcfs | #1 |
iiv hyperactivity behavior | #1 |
odd disruptive behavior | #1 |
robust familiality | #1 |
shlod | #1 |
snps drd4 gene | #1 |
consensus combination | #1 |
mania pdd subjects | #1 |
1350t | #1 |
15q13 deletions | #1 |
prss psychiatric disorders | #1 |
74±77 | #1 |
adhde | #1 |
pdd subjects mania | #1 |
endophenotypic construct | #1 |
schizophrenia current knowledge | #1 |
adhd somatosensory functioning | #1 |
asthma motor preference | #1 |
adhd pdics | #1 |
children pdag parents | #1 |
prsanalyses | #1 |
add aff | #1 |
versus disability | #1 |
relatives diagnoses | #1 |
volumes participants | #1 |
htf9c | #1 |
genes disorder | #1 |
elevated rates adhd | #1 |
galantamine hydrogen bromide | #1 |
moderating effects patterns | #1 |
relatives children | #1 |
features adhd | #1 |
multiplex sample | #1 |
bpprss | #1 |
chi28783 | #1 |
serotonin genetic | #1 |
adhd clinical trial | #1 |
productivity adhd | #1 |
diagnoses adhd | #1 |
trypotphan hydroxylase | #1 |
diagnoses relatives | #1 |
smoking wm microstructure | #1 |
schizophrenia notch4 | #1 |
hyperactivity female | #1 |
adhd clinical obesity | #1 |
aadhd cadhd | #1 |
druggable genome adhd | #1 |
subjects lateonset adhd | #1 |
adhd girls | #1 |
adhd learning | #1 |
educational failure | #1 |
parental sud adhd | #1 |
bpd firstdegree relatives | #1 |
downward extension adolescents | #1 |
odd control | #1 |
studies adhd | #1 |
patients adhdct | #1 |
adhd antisocial | #1 |
disorder meta | #1 |
asd weaknesses | #1 |
relatives multiplex families | #1 |
adhd adolescent | #1 |
genetic correlations schizophrenia | #1 |
relatives bpi probands | #1 |
adhd medications placebo | #1 |
treatment stimulant | #1 |
time reproduction children | #1 |
adhd stimulant treatment | #1 |
persistence disorder | #1 |
psud adhd probands | #1 |
nmu oral | #1 |
rs41084 | #1 |
motor problems adhd | #1 |
adhd | #1 |
p97e−03 | #1 |
illness child comorbidity | #1 |
kiaa1292 | #1 |
stimulant misuse | #1 |
hyperactivity pdi | #1 |
preschool comorbidity | #1 |
bipolar disorder parents | #1 |
psychopathology reward dysfunction | #1 |
girls disorder | #1 |
fm pain tolerance | #1 |
youth adhd | #1 |
sob association adhd | #1 |
loci asd symptoms | #1 |
disorder molecular | #1 |
adhd switches | #1 |
adhd dsm | #1 |
n55374 | #1 |
time qualitative review | #1 |
motor preference asthma | #1 |
snp quantitative phenotype | #1 |
adhd module mwq | #1 |
highiq adults | #1 |
measurement invariance study | #1 |
controls adhd children | #1 |
regions lgi | #1 |
maoa impulsivity | #1 |
4q3121 | #1 |
aklt01 tova api | #1 |
adhd adhd probands | #1 |
criteria age | #1 |
neural network correlates | #1 |
adhd smoking | #1 |
adhd adverse impact | #1 |
low attention | #1 |
hyperactivity disorder scores | #1 |
rf025 | #1 |
2064 trios | #1 |
neuropsychological impairments relatives | #1 |
nmu nasal nmu | #1 |
loci adhd | #1 |
key conceptual issues | #1 |
treatment moderated | #1 |
adhd symptom counts | #1 |
motor skills attention | #1 |
nonreferred | #1 |
add 73 probands | #1 |
anxiousdepressed | #1 |
“3 | #1 |
dat1 vntr | #1 |
prs rtv | #1 |
biological schizophrenia stress | #1 |
controls adhd probands | #1 |
patterns psychiatric comorbidity | #1 |
validity diagnosis | #1 |
adhd alleles | #1 |
adhd total score | #1 |
ldx sizes adults | #1 |
subjects adhd | #1 |
genes adhd | #1 |
pediatric bipolari disorder | #1 |
adult adhd diagnosis | #1 |
23 candidate genes | #1 |
adhd neuroimage study | #1 |
impact tic disorders | #1 |
repeat allele | #1 |
risk female relatives | #1 |
age 7repeat allele | #1 |
adult samples adhd | #1 |
adhd responders | #1 |
adhd african | #1 |
smoking adhd | #1 |
adhd ads | #1 |
sob adhd | #1 |
2276ct | #1 |
nonreferred siblings probands | #1 |
behavioral inhibition parents | #1 |
adhd valid | #1 |
git1 adhd | #1 |
drd5 vntr | #1 |
adhd psychiatric conditions | #1 |
pediatric bpi disorder | #1 |
desr adults | #1 |
remission definition | #1 |
genetic risk severity | #1 |
prs58502974 | #1 |
psychiatric comorbidity girls | #1 |
adhd euphoria | #1 |
apol1 schizophrenia | #1 |
adhd alcohol dependence | #1 |
mania criteria | #1 |
risk substance disorders | #1 |
add antisocial disorders | #1 |
report adhd | #1 |
metabias | #1 |
taf9bp2 | #1 |
male adolescents adhdct | #1 |
relatives alcohol dependence | #1 |
adhd snps | #1 |
valid diagnosis | #1 |
neurocognitive marker | #1 |
adolescent attention | #1 |
adhd fam | #1 |
visual memory deficit | #1 |
mania clinical interview | #1 |
1236a | #1 |
p647e07 | #1 |
neuropsychological probes | #1 |
dsmiv subtypes adhd | #1 |
p27e05 | #1 |
expressed emotion children | #1 |
adhd increased | #1 |
adult probands siblings | #1 |
idir aversion | #1 |
cbcl clinical scales | #1 |
years adhd | #1 |
add pdics | #1 |
neurocognitive traits | #1 |
new diagnoses age | #1 |
comorbidity conduct | #1 |
bpd bpd anx | #1 |
nonaffected siblings children | #1 |
dna methylation adhd | #1 |
linkage wave | #1 |
overlapping symptoms | #1 |
17yearold boys | #1 |
ldx sizes children | #1 |
relatives 1 probands | #1 |
temperamental risk factor | #1 |
adhd mp | #1 |
git1 association adhd | #1 |
ldx sizes | #1 |
akt1 snp markers | #1 |
individuals attention | #1 |
ldx masir | #1 |
adhd higher | #1 |
rels persons | #1 |
etiology adhd | #1 |
lateonset adhd | #1 |
benefit‐risk ratio | #1 |
children general psychopathology | #1 |
diagnostic efficiency analysis | #1 |
starsadhd | #1 |
prospective datasets | #1 |
adhddbds adhd | #1 |
major depression youth | #1 |
persistence childhood adhd | #1 |
aff add | #1 |
c2orf82 | #1 |
non‐random error | #1 |
allele adhd | #1 |
personality traits adults | #1 |
schizophrenia hrscz | #1 |
siblings adhd children | #1 |
exposure parental adhd | #1 |
adhd gsprs | #1 |
iiv shr | #1 |
quantitative phenotype snp | #1 |
adhd highiq youths | #1 |
adhd efds | #1 |
height ldx | #1 |
genes hallucinations states | #1 |
ptsd bpi disorder | #1 |
longacting medications | #1 |
2276tc | #1 |
adhd risk factors | #1 |
subcortical structure volume | #1 |
maoa adhd | #1 |
twin adoption | #1 |
structured interview mania | #1 |
rs2498799 | #1 |
smd greater severity | #1 |
efficacy adderall | #1 |
adherence stimulant medication | #1 |
comt fsiq | #1 |
masir ldx | #1 |
authors adhd | #1 |
anterior insular lobule | #1 |
adhd scores | #1 |
inattention shr | #1 |
probands adhd | #1 |
schizophrenia familybased studies | #1 |
racial heterogeneity | #1 |
morbidity bipolar disorder | #1 |
adhd genetic exome | #1 |
concurrent adhd | #1 |
subsets linkage | #1 |
genotype calling procedures | #1 |
parental children | #1 |
potential endophenotypes adhd | #1 |
hamiltondepression | #1 |
conduct bipolar disorders | #1 |
morbidity adhd | #1 |
bipolar adhd | #1 |
dyscalculia adhd | #1 |
disorders comorbid mania | #1 |
familial vulnerability schizophrenia | #1 |
schizotypal relatives | #1 |
stimulant treatment | #1 |
notch4 polymorphisms schizophrenia | #1 |
increasing resource demand | #1 |
adhd prss | #1 |
diagnoses probands | #1 |
familially | #1 |
p44e05 | #1 |
adhd comorbid disorders | #1 |
adhdrsivinv | #1 |
distribution child | #1 |
hyperactivity child | #1 |
sp067 | #1 |
adhd serotonin | #1 |
efficacy medications | #1 |
5‐generation | #1 |
adhd concurrent sud | #1 |
onset distribution | #1 |
juvenile antisocial traits | #1 |
adhd conclusions | #1 |
sbrv | #1 |
cases adhd | #1 |
stimulant nonmedical | #1 |
psud relatives | #1 |
autistic traits youth | #1 |
studies method | #1 |
efds youth | #1 |
probands rates | #1 |
addictive drugs dust | #1 |
adhd gender | #1 |
hyperactivity body | #1 |
adhd siblings | #1 |
adhd familial | #1 |
insular lobule | #1 |
adhd sexes | #1 |
s034 | #1 |
or133 | #1 |
adhd educational deficits | #1 |
childhoodonset mania | #1 |
normal sexual dimorphisms | #1 |
adhd disorder | #1 |
offspring parental md | #1 |
adhd females | #1 |
adhd risk alleles | #1 |
adhd community sample | #1 |
motor preference | #1 |
adhd screening | #1 |
adhd follow | #1 |
adolescent psychiatric cohort | #1 |
comorbid psychopathology childhood | #1 |
parental panic depression | #1 |
exposure clinical features | #1 |
dsm bipolar disorder | #1 |
stable behavioral inhibition | #1 |
adhd diagnosed | #1 |
rs11133767 | #1 |
oih cpt | #1 |
prevalence attention | #1 |
tass adhd | #1 |
bpdsud bpd | #1 |
adhd efficacy outcome | #1 |
rs1051312 | #1 |
diagnosis adhd | #1 |
pediatric bipolar spectrum | #1 |
oih fm | #1 |
n6979 | #1 |
childhood genetic background | #1 |
model adult samples | #1 |
children motor domain | #1 |
adhd depressed children | #1 |
model ermph | #1 |
inflation personal satisfaction | #1 |
adhd genetic | #1 |
evidence stimulant treatment | #1 |
age stimulant treatment | #1 |
nonreferred samples | #1 |
probands clinical status | #1 |
biomarkers adhd | #1 |
unique impairments | #1 |
adhdrs5 | #1 |
adhd volumetric reductions | #1 |
adhd gene | #1 |
unfamiliar challenges | #1 |
proband child | #1 |
adhd oppositional | #1 |
desr adhd | #1 |
female individuals adhd | #1 |
sud phenotypes | #1 |
adolescent follow youth | #1 |
adhd iiv | #1 |
rs7124601 | #1 |
persistent adhd adults | #1 |
parental suds | #1 |
relatives risk adhd | #1 |
parental md | #1 |
highiq youths | #1 |
rs9325032 | #1 |
sud nicotine dependence | #1 |
disorder familial | #1 |
cortical thickness adhd | #1 |
sud adolescent | #1 |
bmi ldx | #1 |
adhd asm snps | #1 |
drd4 7repeat allele | #1 |
rorb bipolar disorder | #1 |
cadhd aadhd | #1 |
falconer3 | #1 |
20183 | #1 |
adhdtd siblings | #1 |
specific psychopathology children | #1 |
tomoxetine adult adhd | #1 |
fiveminutespeechsample | #1 |
mph adult adhd | #1 |
siblings adhd | #1 |
adhd familial risk | #1 |
siblings adolescent | #1 |
administration marijuana | #1 |
familial links | #1 |
adhd seconddegree relatives | #1 |
mania rates | #1 |
association tph2 | #1 |
deficit | #1 |
diagnosis bpi disorder | #1 |
bipolar disorder girls | #1 |
slc6a4 gene risk | #1 |
growth delays weight | #1 |
motor preference disability | #1 |
adhd haplotype block | #1 |
depression offspring variables | #1 |
studies depressed children | #1 |
adhdassociated alleles | #1 |
nonpsychotic relatives controls | #1 |
expected height weight | #1 |
adhd rat | #1 |
p902e−07 | #1 |
smaller total brain | #1 |
children adolescents cohorts | #1 |
consensus statement combination | #1 |
aspd youth | #1 |
adhd sample | #1 |
disorder boys | #1 |
disorder attention | #1 |
aklt01 adhd | #1 |
standardized manner | #1 |
volume alterations | #1 |
oral nmu | #1 |
daodisc1 | #1 |
age groups cohorts | #1 |
nonreferred siblings | #1 |
adhd comorbid odd | #1 |
rs3792452 | #1 |
nonmental diseases adhd | #1 |
african children adhd | #1 |
adhd obesity overweight | #1 |
14 children pdd | #1 |
psychiatric risk vcfs | #1 |
latrophilin 3 gene | #1 |
stress exposure connectivity | #1 |
teenage parents individuals | #1 |
5ht1b receptor gene | #1 |
clinical correlates ocd | #1 |
adhd outcome | #1 |
paediatric patients adhd | #1 |
drd2 risk gene | #1 |
adhd cbcl | #1 |
dat1 adhd | #1 |
association maoa | #1 |
aisrs asrs | #1 |
2327t | #1 |
dbds adhddbds | #1 |
female gender boys | #1 |
depression adhd child | #1 |
rs1040399 | #1 |
bpi disorder aspd | #1 |
rationaleadhd | #1 |
adhd symptoms crf | #1 |
higher prevalence girls | #1 |
adhd druggable genes | #1 |
competitivep | #1 |
studies adhd children | #1 |
learning disabilities girls | #1 |
interviews disease humans | #1 |
mdd pdag mdd | #1 |
antisocial disorder relatives | #1 |
adhd children bpd | #1 |
rs2449340 | #1 |
“schizotypes | #1 |
adhd psychiatric | #1 |
reproducibility adolescent | #1 |
re‐review | #1 |
18 items impairment | #1 |
methylphenidate efficacy | #1 |
disorder adhd | #1 |
adherence xr | #1 |
adhd youth ld | #1 |
based association study | #1 |
locus adhd | #1 |
association snap25 | #1 |
suds relatives | #1 |
bipolar mdd | #1 |
diagnostic criteria adhd | #1 |
siblings adhd probands | #1 |
endosomal genes asds | #1 |
european treatment guidelines | #1 |
siblings antisocial families | #1 |
comorbid oppositional | #1 |
adhd candidate genes | #1 |
adhd adhdtd | #1 |
adhd maternal | #1 |
nhe inhibitors adhd | #1 |
deletioncarrier | #1 |
children mania diagnosis | #1 |
type adhd | #1 |
palauans maps loci | #1 |
motorendophenotypes | #1 |
male individuals adhd | #1 |
palau scz | #1 |
adolescent patients adhd | #1 |
nfspd | #1 |
adhd clinical characteristics | #1 |
association slc6a3 | #1 |
risk psud | #1 |
intron8 | #1 |
healthy cortical development | #1 |
adhd children | #1 |
hyperactivity | #1 |
higher pdi | #1 |
neuropsychological performance adhd | #1 |
concurrent adhd sud | #1 |
adhd psychoactive substance | #1 |
addh dmi | #1 |
desr siblings | #1 |
inattention items | #1 |
bpi disorder relatives | #1 |
hyperactive impulsive symptoms | #1 |
adhd adult disorder | #1 |
genes etiology | #1 |
disorder hyperactivity | #1 |
association attention | #1 |
maoa neuropsychological functioning | #1 |
24 gm day | #1 |
mwq inattention items | #1 |
comt odd | #1 |
hamshere | #1 |
cbclbp profile children | #1 |
cortical networks attention | #1 |
high‐risk adolescent offspring | #1 |
risk aggressive symptoms | #1 |
lateandmoderate | #1 |
opd add opd | #1 |
regions age | #1 |
cardinal symptom mania | #1 |
adult adhd differences | #1 |
variance oppositional symptoms | #1 |
ainslbl | #1 |
adhd asthma | #1 |
adhd findings | #1 |
association syp | #1 |
adolescents sud treatment | #1 |
conduct disorder probands | #1 |
genetic variation nr3c1 | #1 |
prescription stimulant adults | #1 |
mania referred children | #1 |
12allele | #1 |
qms adhd | #1 |
relatives bpi | #1 |
deficits expected growth | #1 |
adhd maoa | #1 |
valid disorder | #1 |
35191 controls | #1 |
positive peer affiliation | #1 |
77e08 | #1 |
affective symptoms children | #1 |
1 relatives | #1 |
nonreferred adults | #1 |
bpi disorder children | #1 |
paediatric adhd | #1 |
17year | #1 |
h2053 | #1 |
fsiq comt | #1 |
rf041 | #1 |
ld addh children | #1 |
firstdegree relatives children | #1 |
trait educational attainment | #1 |
studies attention | #1 |
comorbidity major depression | #1 |
gene comt | #1 |
relation stress exposure | #1 |
childhood predictors adhd | #1 |
intelligence additive effects | #1 |
adhdfamilies | #1 |
adhd prs rtv | #1 |
relatives multiplex | #1 |
probands add | #1 |
adults diagnosis | #1 |
maf⩾1 | #1 |
adhd hyperactivity automobile | #1 |
disorders aa | #1 |
subthreshold pediatric | #1 |
anxiety disorders findings | #1 |
nonreferred adult | #1 |
age onset criterion | #1 |
emotional symptoms adhd | #1 |
drugplacebo response curve | #1 |
112 80 | #1 |
83097 | #1 |
association evidence | #1 |
distinct subtype | #1 |
comt maoa | #1 |
hyperactivity disorder | #1 |
teachers cbt intervention | #1 |
genetic heterogeneity adhd | #1 |
rtv adhd prs | #1 |
analysis adhd | #1 |
adhd income loss | #1 |
association dopamine receptors | #1 |
antisocial families | #1 |
13052159 | #1 |
suggestive linkage signals | #1 |
bpd hypothesis | #1 |
abstinence pharmacological treatment | #1 |
parental bpd | #1 |
adhd followup | #1 |
bipolar disorders psud | #1 |
druggable genome disorder | #1 |
stimulants height | #1 |
adhd sample model | #1 |
hyperactivity biomarkers | #1 |
pregnancy adhd | #1 |
smoking cessation controls | #1 |
clinical controls | #1 |
142 combined subtype | #1 |
ptsd siblings | #1 |
future dsm | #1 |
paternal smoking conception | #1 |
genes sexdifferentiated effects | #1 |
genetic correlation adhd | #1 |
rs916455 | #1 |
desr adult probands | #1 |
unaffected siblings volumes | #1 |
mddprss | #1 |
onset mania | #1 |
schizotaxia schizophrenia | #1 |
expression adhd | #1 |
adhd candidate | #1 |
md parents | #1 |
ldx expected height | #1 |
children behavioral inhibition | #1 |
peer environmental factors | #1 |
rs2272080 | #1 |
late‐onset adhd | #1 |
bpd girls | #1 |
clock genes rorb | #1 |
adhd methods | #1 |
suds nicotine dependence | #1 |
relatives drug dependence | #1 |
lifetime impairment survey | #1 |
sbrv adhd | #1 |
clinical features adhd | #1 |
youth adhd prss | #1 |
adhd disorders comorbidity | #1 |
african‐american pedigrees | #1 |
adhd attention | #1 |
disorders parents | #1 |
postmortem brain identifies | #1 |
etiology disorder | #1 |
children disorder | #1 |
35191 | #1 |
bpi disorder | #1 |
adults adhd subjects | #1 |
medications adhd | #1 |
nimh genetics initiative | #1 |
relatives adhd girls | #1 |
cacng2 gene | #1 |
adhd probands adhd | #1 |
adhd neuropsychological | #1 |
parental sud sud | #1 |
mtbi adhd | #1 |
adhd prs gwas | #1 |
pepple | #1 |
psychiatric comorbidity md | #1 |
relatives pediatric probands | #1 |
aggressive symptoms risk | #1 |
matter volumes volumes | #1 |
hyperactivity cognition | #1 |
adhd familial disorder | #1 |
timely renewal | #1 |
paternal overtransmission | #1 |
cdh13 memory performance | #1 |
tidqam | #1 |
pair health | #1 |
compared adhd | #1 |
higher adhd | #1 |
predictors persistence | #1 |
referred juveniles | #1 |
896 cases | #1 |
non‐adhd children | #1 |
adhd genetic receptors | #1 |
placebo ldx treatment | #1 |
pdd mania mania | #1 |
groundskeeper | #1 |
expected growth children | #1 |
135–526 | #1 |
21 circadian genes | #1 |
disorganized symptom dimensions | #1 |
connectivity executive control | #1 |
siblings control probands | #1 |
teacher report | #1 |
adhd adoption studies | #1 |
rs2469770 | #1 |
adhd children depression | #1 |
tass adhdrs | #1 |
parental adhd sud | #1 |
nr3c1 stress exposure | #1 |
fidgety philipp | #1 |
relatives control | #1 |
daorasd2 | #1 |
boys female gender | #1 |
relatives adhd status | #1 |
oral nmu nmu | #1 |
placebo cgsq | #1 |
adhd oxidative stress | #1 |
disorder report | #1 |
adhd child comorbidity | #1 |
noninhibited children | #1 |
tass internal consistency | #1 |
ldx adult adhd | #1 |
earlyandmoderate | #1 |
bmi mts | #1 |
genes association studies | #1 |
putamen volume alterations | #1 |
p0499 | #1 |
hyperactivity biomarkers aadhd | #1 |
cbt intervention adolescents | #1 |
adhd desr probands | #1 |
stimulant treatment alcohol | #1 |
diagnoses valid | #1 |
adhd highly | #1 |
items 99item cbs | #1 |
4q28 | #1 |
gene interaction comt | #1 |
structural differences children | #1 |
european treatment guideline | #1 |
phenotype adhd | #1 |
vcfsadhd adhd | #1 |
offspring parental adhd | #1 |
thermenos | #1 |
major depression share | #1 |
5q23q31 | #1 |
depressed children adhd | #1 |
unexplored void | #1 |
nonmental diseases | #1 |
elevated risk adhd | #1 |
pdi impulsiveness | #1 |
effects lisdexamfetamine dimesylate | #1 |
psychopathology implications | #1 |
hyperactivity comorbidity | #1 |
proband youth bpdsud | #1 |
bpd anx bpd | #1 |
hyperactivity case | #1 |
female humans inhibition | #1 |
comorbid problems adhd | #1 |
familial underpinnings | #1 |
relatives girls | #1 |
asrs scores | #1 |
p179e06 | #1 |
slc9a9 | #1 |
adhd antisocial comorbidity | #1 |
offspring sud parents | #1 |
adhd clinical | #1 |
prodromal overt psychosis | #1 |
fbxo33 | #1 |
p81e06 | #1 |
adhdoddcd | #1 |
clinical interview mania | #1 |
mania manic features | #1 |
adhd children mania | #1 |
palau early | #1 |
adhd 11 years | #1 |
187 children | #1 |
onset adult subjects | #1 |
metaanalysis controlled study | #1 |
mitigates stimulant | #1 |
adhdtd | #1 |
relatives wm performance | #1 |
mwq adhd module | #1 |
drd4 association | #1 |
suds crosssectional studies | #1 |
norepinephrine transporter gene | #1 |
relatives 3 probands | #1 |
risk adhd | #1 |
adhd baseline | #1 |
context adhd | #1 |
slc9a9 disease associations | #1 |
co‐expression modules | #1 |
d15s1012 | #1 |
mgh studies | #1 |
hypothesized precursors | #1 |
chronological age age | #1 |
2 familial factors | #1 |
np functioning chr | #1 |
dat1 untranslated regions | #1 |
–rs2272080 | #1 |
alcohol dependence relatives | #1 |
neurocognitive dysfunctions | #1 |
51 genes | #1 |
stimulant treatment adhd | #1 |
subthreshold adhd | #1 |
genetic studies sud | #1 |
overweight obesity males | #1 |
neuroleptic nonresponse | #1 |
neuropsychologic function schizophrenia | #1 |
adolescent response inhibition | #1 |
rs3746544 rs1051312 | #1 |
motheronly | #1 |
genetic sexual dimorphism | #1 |
psychiatric disorders adhd | #1 |
ldx size children | #1 |
aadhd hyperactivity biomarkers | #1 |
behavioral disinhibition offspring | #1 |
odd disorders follow | #1 |
adult persistence adhd | #1 |
daily parent rating | #1 |
sodasmph | #1 |
association adhd | #1 |
youth bpi disorder | #1 |
criteria mania | #1 |
adhd female individuals | #1 |
mspi allele | #1 |
proband youth bpd | #1 |
subthreshold diagnoses valid | #1 |
stimulants childhood | #1 |
parental polygenic risk | #1 |
zmynd17 genes | #1 |
relatives bipolar | #1 |
relatives add probands | #1 |
children growth delays | #1 |
large controlled study | #1 |
gender familial risk | #1 |
treating adhd | #1 |
adhd bpi disorder | #1 |
bpd bpdsud | #1 |
adhd gwas | #1 |
asd youth adhd | #1 |
pinslbl | #1 |
cbclbp | #1 |
network‐level assessment | #1 |
selfreport adhd symptoms | #1 |
hyperactivity cross | #1 |
rs1482337–rs2252471 | #1 |
hyperactivity disorder adults | #1 |
outcome adhd | #1 |
longitudinal outcome boys | #1 |
bipolars unipolar relatives | #1 |
unipolar relatives bipolars | #1 |
stimulant treatment profiles | #1 |
ldx growth | #1 |
bpi disorder sexes | #1 |
familybased studies association | #1 |
shifting sands | #1 |
impairments adults | #1 |
anxious depressed subscales | #1 |
rs3776512 | #1 |
4‐year follow‐up study | #1 |
ermph placebo groups | #1 |
stimulant treatment adults | #1 |
vcfs manic symptoms | #1 |
masir | #1 |
adhd social disability | #1 |
psud controls | #1 |
aggregate cutoff score | #1 |
confusability analyses | #1 |
ctcata | #1 |
adhd reliability | #1 |
pain tolerance oih | #1 |
parents sud | #1 |
gene studies | #1 |
subcortical volumes adhd | #1 |
add relatives | #1 |
interobserver agreement measures | #1 |
boys social disability | #1 |
patients adhdpi | #1 |
children bpi disorder | #1 |
inattentive subtype adhd | #1 |
bpd probands | #1 |
drugplacebo | #1 |
individuals adhd | #1 |
criteria☆ | #1 |
hyperactivity databases | #1 |
greater risk adhd | #1 |
drug frequency variables | #1 |
alcohol disorders offspring | #1 |
ldx bmi | #1 |
adhd bipolar comorbidity | #1 |
female adhd | #1 |
pippi longstocking | #1 |
molecular genetics network | #1 |
laboratory driving simulation | #1 |
neuroanatomic predictors | #1 |
interaction adhd | #1 |
brain activity flow | #1 |
familial risk analyses | #1 |
rs2469758–rs2461489 | #1 |
adhd single nucleotide | #1 |
vulnerability indicators schizophrenia | #1 |
new phenotype definition | #1 |
growth deficits deficits | #1 |
stimulants abuse potential | #1 |
adhd aes | #1 |
adhd children ld | #1 |
adhd girls adhd | #1 |
impulsiveness inattention | #1 |
impactnl | #1 |
dopamine receptor polymorphism | #1 |
desr probands siblings | #1 |
140 adhd | #1 |
ldx amses | #1 |
adhd treatment treatment | #1 |
rs7118422 | #1 |
shared endophenotypes | #1 |
odd affective symptoms | #1 |
groups girls | #1 |
sexdifferentiated effects traits | #1 |
adolescence longitudinal analysis | #1 |
selfreport adhd | #1 |
emotional problems pmee | #1 |
cigarette smoking siblings | #1 |
adhd susceptibility genes | #1 |
impulsive subtype | #1 |
cyp2d6 hypothesis | #1 |
callingalgorithms | #1 |
cohorts age groups | #1 |
multi‐stage study | #1 |
adhd dat1 gene | #1 |
sexes bpi disorder | #1 |
bpi disorder efds | #1 |
families adhd | #1 |
mr005 | #1 |
vivo neuroreceptor imaging | #1 |
sud adolescence | #1 |
cognitive endophenotypes adhd | #1 |
sud parents | #1 |
stimulant treatment youth | #1 |
symptoms aggregation | #1 |
notch4 polymorphisms | #1 |
nfspds | #1 |
alphaglx | #1 |
children antisocial disorders | #1 |
risk suds | #1 |
inattentive hyperactive | #1 |
caregiver strain cgsq | #1 |
onset criterion adhd | #1 |
adhd vntr | #1 |
odd familial disorders | #1 |
adhddbds | #1 |
schizophrenia european samples | #1 |
gsprss | #1 |
nonverbal social–emotional cues | #1 |
comparison subjects participants | #1 |
anxiety disorders families | #1 |
bipolar disorder switches | #1 |
euphoria cardinal symptom | #1 |
suds adhd | #1 |
innovative sms intervention | #1 |
asds clinical scales | #1 |
antisocial disorders bpd | #1 |
2455 controls | #1 |
efficacy outcome adhd | #1 |
ermph clinical response | #1 |
snps quantitative phenotypes | #1 |
late onset adhd | #1 |
relatives adhd probands | #1 |
risk subsequent substance | #1 |
140 adhd probands | #1 |
tdt analysis | #1 |
new psychometric definition | #1 |
symptoms versus impairment | #1 |
cortical surface adhd | #1 |
adhd asd youth | #1 |
males overweight obesity | #1 |
adhd baseline assessment | #1 |
daonrg1 | #1 |
transmission parents | #1 |
sob sob association | #1 |
ptsd familial disorders | #1 |
stimulant treatment differences | #1 |
adhd dbds | #1 |
add parent report | #1 |
parental panic disorder | #1 |
anxiety disorders relatives | #1 |
risk opioid dependence | #1 |
mp adhd | #1 |
experts abstinence | #1 |
clinical response orosmph | #1 |
gsprs adhd | #1 |
girls learning disabilities | #1 |
schizophrenia fhrs | #1 |
motor preference adhd | #1 |
onset attention | #1 |
association behavioral inhibition | #1 |
disability asthma | #1 |
stimulant treatment risk | #1 |
levels dysfunction | #1 |
desipraminestimulants | #1 |
relbps | #1 |
nonreferred sample | #1 |
d10s195 | #1 |
adolescent outcome adhd | #1 |
adhd african children | #1 |
treatment effects values | #1 |
switches bipolar disorder | #1 |
n122 | #1 |
adhd comorbid | #1 |
patients attentional disorders | #1 |
p446e08 | #1 |
tova api aklt01 | #1 |
adhd specific | #1 |
pediatric panic disorder | #1 |
larger samples | #1 |
children teaes | #1 |
age1542 | #1 |
convergent functional genomic | #1 |
lobe mri measures | #1 |
method authors | #1 |
cbclbp profile | #1 |
subjects ldx | #1 |
slc9a9 adhd | #1 |
adhd drd4 | #1 |
increased expression methylation | #1 |
osa genetic heterogeneity | #1 |
learning disorders adhd | #1 |
relatives default network | #1 |
anxiety disorders siblings | #1 |
99item cbs | #1 |
vall66 | #1 |
fam mothers | #1 |
95 hrr | #1 |
efds functional outcomes | #1 |
adhd probands relatives | #1 |
adhd brain alterations | #1 |
bpi disorder youth | #1 |
adhd module | #1 |
pdd mania | #1 |
schizophrenia nonpsychotic relatives | #1 |
hyperactive impulsive | #1 |
tic persistence | #1 |
relszs | #1 |
dat110 6 | #1 |
adhd stronger connectivity | #1 |
adhd population | #1 |
adults stimulant sizes | #1 |
prss adhd | #1 |
adults neurodevelopmental disorder | #1 |
relatives control probands | #1 |
anachronisms | #1 |
rs6000200 | #1 |
probands comorbidity | #1 |
adhd smoking risk | #1 |
adhd studies | #1 |
scqscore | #1 |
adhd pattern | #1 |
familial risk gender | #1 |
comt maoa interaction | #1 |
aud adhd | #1 |
meaningful anxiety phenotype | #1 |
sud remittent adhd | #1 |
severe dysregulation | #1 |
9 nhe9 | #1 |
10repeats | #1 |
adhd comorbid dbds | #1 |
highiq adults adhd | #1 |
hyperactivity child genome | #1 |
hartsough | #1 |
rs6077690 | #1 |
risk disorder | #1 |
genetic variants adhd | #1 |
pdics | #1 |
pdi hyperactivity | #1 |
qelbree | #1 |
mania pdd | #1 |
twin adoption studies | #1 |
schizotaxia negative schizotypy | #1 |
matching fallacy | #1 |
assess adult adhd | #1 |
discordant twin study | #1 |
elaborative verbal encoding | #1 |
illness adolescent | #1 |
disorder | #1 |
acting medications | #1 |
predicted clinical response | #1 |
familial moderators | #1 |
sample adhd | #1 |
cigarette smoking metaanalysis | #1 |
genetic overlap adhd | #1 |
inattention adhd | #1 |
stimulant therapy youths | #1 |
persistent adhd symptoms | #1 |
20183 cases | #1 |
adult adhd treatment | #1 |
adhd background | #1 |
quantitative analyses treatment | #1 |
adoption studies | #1 |
impaired sensorimotor timing | #1 |
familial subtype | #1 |
adhd neuropsychological impairments | #1 |
ldx growth delays | #1 |
adhd adhd cases | #1 |
adults cadhd | #1 |
c759t | #1 |
lod213 | #1 |
pathways adhd | #1 |
pooleddata | #1 |
valid psychiatric disorder | #1 |
suds genetic studies | #1 |
bipolar disorder bpprss | #1 |
familial transmission adhd | #1 |
bpd relatives | #1 |
deficit hyperactivity | #1 |
arch ger psychiatry | #1 |
adult adhd | #1 |
week treatment response | #1 |
smd higher rates | #1 |
neuropsychological functioning boys | #1 |
foursnp | #1 |
comorbid problems | #1 |
adhd aud | #1 |
covariates dopamine receptors | #1 |
adults ldx sizes | #1 |
affective symptoms dbds | #1 |
adhd children exposure | #1 |
marijuana cocaine crack | #1 |
followup assessment | #1 |
pharmacogenetics predictors | #1 |
adhd community | #1 |
adhd 5 | #1 |
depressed children depression | #1 |
adhd cigarette smoking | #1 |
training raters | #1 |
molecular genetic studies | #1 |
copy organization | #1 |
symptom burden adults | #1 |
oih pain tolerance | #1 |
schizophrenia rs1076560t | #1 |
life adult adhd | #1 |
discipline problem | #1 |
chronic emotional dysregulation | #1 |
rs12843268 | #1 |
rs3027400 | #1 |
rate symptoms | #1 |
transient financial stress | #1 |
desr subjects | #1 |
highiq youths adhd | #1 |
dopamine d4 gene | #1 |
dust addictive drug | #1 |
depression symptoms aggregation | #1 |
self‐reported adhd | #1 |
genetic studies adhd | #1 |
drd2 disrupts | #1 |
affective psychosis hraff | #1 |
p758e08 | #1 |
diagnostic continuity adhd | #1 |
autism symptoms adhd | #1 |
adhd teenage parents | #1 |
variants aggressive behavior | #1 |
risk comt gene | #1 |
hypothesis disorders | #1 |
regulation desr | #1 |
adhd mini | #1 |
risk tourette spectrum | #1 |
persistence adhd | #1 |
orosmph adult adhd | #1 |
structured interview pdd | #1 |
lifetime adhd | #1 |
schizophrenia bipolar psychoses | #1 |
rs2279805 | #1 |
syp female adhd | #1 |
adhd genetic studies | #1 |
40basepairrepeat | #1 |
smoking schizophrenia families | #1 |
gene attention | #1 |
stimulant nmu | #1 |
masxr treatment | #1 |
children ermph | #1 |
anx bpd | #1 |
hyperactivity child humans | #1 |
adult samples model | #1 |
risk factor psud | #1 |
asrs‐v11 | #1 |
mania conduct disorder | #1 |
adhd adolescent patients | #1 |
impulsive behavioral aggression | #1 |
suggestive linkage | #1 |
schizotaxia subjects | #1 |
adhd predictors | #1 |
increased adhd symptoms | #1 |
familial association adhd | #1 |
asrs aisrs | #1 |
adverse impact adhd | #1 |
criteria pdd | #1 |
dependence controls | #1 |
nasal nmu nmu | #1 |
impulsive symptoms | #1 |
persistence pediatric disorder | #1 |
maternal inattention anxiety | #1 |
increased methylation genes | #1 |
rs1633445 | #1 |
pilot study adhd | #1 |
autistic traits presence | #1 |
adhd bipolar studies | #1 |
htf9c gene | #1 |
p20e04 | #1 |
bpd parents | #1 |
cdbpd | #1 |
adhd relatives | #2 |
informant source | #2 |
factors adhd | #2 |
disorder children | #2 |
dsmiv subtypes | #2 |
adhd autism symptoms | #2 |
disease humans inhibition | #2 |
affective probands | #2 |
bpd sud | #2 |
familial risk analysis | #2 |
140 girls | #2 |
investigator ratings | #2 |
millennium consortium | #2 |
6‐year longitudinal study | #2 |
disorder add | #2 |
youth rates | #2 |
dsm subtypes | #2 |
chromosomes inclusion | #2 |
disorders similarities | #2 |
diagnosis attention | #2 |
hyperactivity diagnostic | #2 |
naltrexone adults | #2 |
risk female cases | #2 |
adhd disability | #2 |
n1934 | #2 |
18 dsm | #2 |
relatives schizophrenic | #2 |
stimulants adults | #2 |
idiopathic adhd | #2 |
familial adhd | #2 |
allele schizophrenia | #2 |
specific haplotype | #2 |
pdd overlap | #2 |
wm deficits | #2 |
derived phenotypes | #2 |
neuropsychological function girls | #2 |
disorders suds | #2 |
dsmiv adhd | #2 |
separation attention deficit | #2 |
psychiatric comorbidity | #2 |
efds | #2 |
masxr | #2 |
strong heritability | #2 |
consecutively referred children | #2 |
add probands | #2 |
scales sex | #2 |
patterns comorbidity | #2 |
comorbid oppositional defiant | #2 |
adult samples | #2 |
structured diagnostic interviews | #2 |
adhd mph response | #2 |
combinedtype | #2 |
n‐acetylcysteine treatment | #2 |
shared genetic background | #2 |
adhd height | #2 |
regions studies | #2 |
clinically referred | #2 |
cbsk | #2 |
6 17 years | #2 |
manic children | #2 |
enigma adhd | #2 |
deficits sustained attention | #2 |
wiatii | #2 |
ermph children | #2 |
expanded versions | #2 |
ldsc heritability | #2 |
psychoactive substance disorders | #2 |
adhd physical conditions | #2 |
families schizophrenia patients | #2 |
relatives add | #2 |
bipolar disorder sud | #2 |
lgi regions | #2 |
control subjects adhd | #2 |
youth meaningful | #2 |
n17666 | #2 |
proinflammatory expansion | #2 |
adhd birth | #2 |
adhd combined subtype | #2 |
serum neuroleptic activity | #2 |
schizophrenia parahippocampal gyrus | #2 |
deficit sustained attention | #2 |
multigenic inheritance | #2 |
schizophrenia twin studies | #2 |
comorbid conduct disorder | #2 |
childhood adolescent adhd | #2 |
wky nhsd | #2 |
schizophrenia calcineurin | #2 |
dimesylate treatment | #2 |
cbcl profile | #2 |
adra2a polymorphism | #2 |
jackknife procedure | #2 |
scale asrs | #2 |
schizotaxia discussion | #2 |
iii adhd | #2 |
adhd major depression | #2 |
chromosomes 6 14 | #2 |
adhd assessed | #2 |
youth selfreports | #2 |
consortium neuroscience | #2 |
hyperactivity female humans | #2 |
items screener | #2 |
conjfdr005 | #2 |
correlates adhd | #2 |
adhd conduct | #2 |
antisocial disorders | #2 |
aklt01 | #2 |
quetiapine monotherapy treatment | #2 |
subjects conduct disorder | #2 |
method subjects | #2 |
selfmedicating | #2 |
deficits adults | #2 |
adhdonly | #2 |
adhd combined | #2 |
variants adhd | #2 |
wky ncrl | #2 |
7point | #2 |
actively reducing severity | #2 |
deficits efds | #2 |
status rating scales | #2 |
adhd report | #2 |
adhd neuropsychological deficits | #2 |
youth attention | #2 |
disorders findings | #2 |
adolescents substance disorder | #2 |
disorder oppositional | #2 |
subjects adults | #2 |
risk add | #2 |
preventing schizophrenia | #2 |
cbcl clinical | #2 |
underlying bipolarity | #2 |
key cognitive phenotypes | #2 |
variance adult | #2 |
bpd adhd | #2 |
efds adults | #2 |
mood disorders adhd | #2 |
activation trigger | #2 |
adhd families | #2 |
adhdprss | #2 |
conners adult adhd | #2 |
systematized delusions | #2 |
iii attention | #2 |
adhd outcomes | #2 |
prior reports | #2 |
psychotic relatives | #2 |
cigarette smoking suds | #2 |
adhd psychiatric disorders | #2 |
bidirectional overlap | #2 |
adhd impact | #2 |
adhd comparison subjects | #2 |
childhoodonset adhd | #2 |
s038 | #2 |
subsyndromal manifestations | #2 |
postcleavage | #2 |
rs1801028 | #2 |
effects paternal smoking | #2 |
hantac | #2 |
bias child child | #2 |
twin studies adhd | #2 |
adhd genes | #2 |
efficacy stimulants | #2 |
blind raters | #2 |
schizophrenia interactions | #2 |
small literature | #2 |
methylphenidate attention | #2 |
stimulant therapy | #2 |
cognition youth | #2 |
comorbid aggression | #2 |
support genetic factors | #2 |
multicenter adhd | #2 |
genome‐wide association data | #2 |
disorders adhd | #2 |
disorder inattentive | #2 |
sud bpd | #2 |
current adult adhd | #2 |
adhd method | #2 |
cnvs copy variants | #2 |
stimulants | #2 |
adhd adhd patients | #2 |
acpts | #2 |
adhd comparison | #2 |
adults adhd | #2 |
role adhd | #2 |
10092 | #2 |
elusive indicators | #2 |
dsmjbd | #2 |
concurrent attention | #2 |
alleles attention | #2 |
amses | #2 |
6 17 | #2 |
ncrl wky | #2 |
stress adhd | #2 |
disorder conclusions | #2 |
pilot adult | #2 |
infancy complications | #2 |
rates odd | #2 |
cacng2 genes | #2 |
case subjects adhd | #2 |
persistent attention | #2 |
bmi adhd symptoms | #2 |
relatives simplex families | #2 |
addicted | #2 |
dsm adhd | #2 |
bsfq | #2 |
adhd surface area | #2 |
disease humans receptors | #2 |
child comorbidity | #2 |
male psychiatric | #2 |
schizotypy handedness | #2 |
psychotic mood disorder | #2 |
g72 daao | #2 |
comparison probands | #2 |
galantamine hbr placebo | #2 |
adhd suds | #2 |
default network schizophrenia | #2 |
disorder girls | #2 |
n328917 | #2 |
drug abuse dependence | #2 |
hyperactivity attention deficit | #2 |
deficits executive | #2 |
adhd genetics | #2 |
attentional control effects | #2 |
subthreshold diagnoses | #2 |
anx bipolar disorder | #2 |
schizophrenia genetic studies | #2 |
6p243 | #2 |
euphorigenic effects | #2 |
major depression findings | #2 |
nonpsychotic relatives | #2 |
n11221 | #2 |
d2s410 | #2 |
referred youth | #2 |
unweighted screener asrs | #2 |
genetic transmission | #2 |
suggestive linkage loci | #2 |
relatives adhd | #2 |
immune disorder | #2 |
structured diagnostic | #2 |
comorbidity disorders comorbidity | #2 |
problems adhd | #2 |
young adult years | #2 |
function deficits | #2 |
performancemeasures | #2 |
derived diagnosis | #2 |
parents major depression | #2 |
findings children | #2 |
executive function outcome | #2 |
diabetes disorders | #2 |
disorder adults | #2 |
adhd adhd children | #2 |
weaknesses youth | #2 |
comorbidity probands | #2 |
overlap mania | #2 |
genome‐wide association scan | #2 |
somatosensory functioning | #2 |
modest evidence | #2 |
galantamine hbr | #2 |
adhd ldx | #2 |
polygenic resilience score | #2 |
studies adderall | #2 |
maternal smoking mothers | #2 |
ppv hyperactivity diagnostic | #2 |
qtl linkage adhd | #2 |
subjects criteria | #2 |
girls adhd | #2 |
juvenile antisocial | #2 |
treatment sud patients | #2 |
oral prescription | #2 |
cbcl desr | #2 |
eye vergence responses | #2 |
desr children | #2 |
models adhd | #2 |
disorder impact | #2 |
adhd control subjects | #2 |
disorder studies | #2 |
familybased studies | #2 |
adhd objective | #2 |
2q143 | #2 |
association mtbi | #2 |
adhd icv | #2 |
subjects desr | #2 |
hypothetical task | #2 |
hypothesis adhd | #2 |
screening diagnosis treatment | #2 |
asrs health organization | #2 |
morning behavior | #2 |
hyperactivity impulsiveness | #2 |
initial stimulant | #2 |
adhd comorbid problems | #2 |
adhd emotional symptoms | #2 |
cpt oih | #2 |
child comorbidity illness | #2 |
neuroleptic dose reduction | #2 |
consecutively referred | #2 |
work needed | #2 |
child behavioral inhibition | #2 |
disorder adolescent | #2 |
enigma adventure | #2 |
familial association | #2 |
adhd adults | #2 |
siblings youth | #2 |
juvenile bipolar phenotype | #2 |
age onset distribution | #2 |
comorbidity disorder | #2 |
adults attention | #2 |
adhd odd | #2 |
rates adhd | #2 |
adhd major | #2 |
deficit hyperactivity disorder | #2 |
trauma adhd | #2 |
aggressive symptoms | #2 |
subsequent substance | #2 |
scz data | #2 |
disorder findings | #2 |
rates bpd | #2 |
adhd choice | #2 |
treatment childhood adhd | #2 |
life social adjustment | #2 |
testretest reliability screener | #2 |
attention‐deficit hyperactivity | #2 |
ratio081 | #2 |
adhd bpd | #2 |
adhd bipolar | #2 |
target features | #2 |
health organization asrs | #2 |
risk panic disorder | #2 |
parents disorder | #2 |
reward‐related activation | #2 |
d0·18 | #2 |
≥210 | #2 |
boys maoa | #2 |
viloxazine extendedrelease | #2 |
adhd lower | #2 |
adhdliability | #2 |
wwwhapmaporg | #2 |
disorder background | #2 |
adhd acc | #2 |
eye vergence | #2 |
qualitative literature review | #2 |
female probands | #2 |
bipolar disorder symptomatology | #2 |
tourette spectrum | #2 |
factors attention | #2 |
adherence stimulants | #2 |
comparative profile analysis | #2 |
rs3746544 | #2 |
n2246 | #2 |
adhd risk factor | #2 |
familial trait | #2 |
probands relatives | #2 |
developmental subtype | #2 |
risk factor adhd | #2 |
actively reducing | #2 |
maoa comt | #2 |
dsmiiir adhd | #2 |
comorbidity adhd | #2 |
neuropsychoanalytic treatment | #2 |
ncrl | #2 |
adhd risk gene | #2 |
unipolar relatives | #2 |
p161e05 | #2 |
odd girls | #2 |
stin2vntr | #2 |
comorbidity attention | #2 |
adhd neuropsychological tests | #2 |
background attention | #2 |
mirsky | #2 |
pediatrically | #2 |
probands | #2 |
personal satisfaction | #2 |
emf impairments | #2 |
symptoms neuropsychological | #2 |
qualitative review | #2 |
comorbid conduct | #2 |
molecular genetics schizophrenia | #2 |
dysfunction offspring | #2 |
comorbid conduct problems | #2 |
psychiatrically | #2 |
versus controls | #2 |
candidate genetic pathways | #2 |
adverse effects subjects | #2 |
rs40184 | #2 |
hrscz | #2 |
n3199 | #2 |
expert clinician | #2 |
hypothalamic abnormalities | #2 |
snp12snp2ctgn | #2 |
evidence adhd | #2 |
adhd subjects | #2 |
adhd risk icv | #2 |
heterogeneity schizophrenia | #2 |
expanded symptom criteria | #2 |
antisocial disorders relatives | #2 |
nicotine substance | #2 |
levels comorbidity | #2 |
5 loci adhd | #2 |
lallele homozygotes | #2 |
manic switches | #2 |
spectrum phenotypes | #2 |
sex differences adhd | #2 |
association data | #2 |
association meta analysis | #2 |
parental anxiety disorders | #2 |
morbidity dysfunction | #2 |
checklist scales | #2 |
cbcljbd children | #2 |
ldsc genetic correlations | #2 |
d10s1432 | #2 |
clinically referred children | #2 |
relatives | #2 |
adhd case subjects | #2 |
methodological complexities | #2 |
parent rating | #2 |
assessed structured | #2 |
n2455 | #2 |
opioid induced hyperalgesia | #2 |
schizophrenia pedigrees | #2 |
scales adolescent | #2 |
structure adult adhd | #2 |
adhd growth | #2 |
adhd african americans | #2 |
age onset distributions | #2 |
internal distractibility | #2 |
adhd lifespan | #2 |
stimulants adhd | #2 |
large controlled | #2 |
bipolar disorder relatives | #2 |
617 years | #2 |
rs1800955 | #2 |
checklist clinical | #2 |
rs6938431 | #2 |
variance severity | #3 |
non500 | #3 |
bipolar disease | #3 |
experienced pain | #3 |
enigma wgs wgs | #3 |
neuropsychiatric disorders similarities | #3 |
international adhd | #3 |
inattentive subtype | #3 |
defined adhd | #3 |
syndromatic | #3 |
morbidity risk | #3 |
abstraction verbal memory | #3 |
parents panic disorder | #3 |
cbcl scales | #3 |
nonpsychotic relatives persons | #3 |
childhood attention‐deficit | #3 |
comorbidity panic disorder | #3 |
asthma adhd | #3 |
observed age | #3 |
teacher reports | #3 |
mania disorders | #3 |
comt promoter | #3 |
hyperactivity attention | #3 |
checklist cbcl | #3 |
bpd rates | #3 |
youths ocd | #3 |
adhd emotional | #3 |
sexdifferentiated effects | #3 |
508e7 | #3 |
dose response effects | #3 |
smoking probands | #3 |
naltrexone methylphenidate | #3 |
psychotic behaviour | #3 |
probands parental | #3 |
md adhd | #3 |
9rcarriers | #3 |
comorbidities adhd | #3 |
snps haplotype | #3 |
adhd metaanalysis | #3 |
risk factors sud | #3 |
7 repeat | #3 |
disproportionate impairment | #3 |
methylphenidate studies | #3 |
sud youths | #3 |
prenatal adversities | #3 |
manic symptoms children | #3 |
adhd comorbid conditions | #3 |
vulnerability indicators | #3 |
excess transmission | #3 |
adhd mania | #3 |
n2323 | #3 |
psychiatric comorbidity adhd | #3 |
adhd polygenic | #3 |
pdd adhd | #3 |
subjects sud | #3 |
ermph | #3 |
children adhd | #3 |
relationship adhd | #3 |
dat1 | #3 |
sud offspring | #3 |
interactions schizophrenia | #3 |
common disorders brain | #3 |
longitudinal follow | #3 |
enigma neuroimaging genetics | #3 |
drd5 marker | #3 |
vcfsadhd | #3 |
md females | #3 |
“negativity | #3 |
schizophrenia allele | #3 |
z280 | #3 |
qtl linkage | #3 |
intra‐individual variability | #3 |
mania children | #3 |
studies square | #3 |
adhd rare cnvs | #3 |
response methylphenidate | #3 |
hyperactivity central | #3 |
enigma global neuroscience | #3 |
children vcfsadhd | #3 |
disabilities male | #3 |
girls attention | #3 |
tsuang | #3 |
adhdpi | #3 |
neurological polymorphism | #3 |
n2271 | #3 |
adhd wm deficits | #3 |
adhd control | #3 |
substances symptoms | #3 |
7repeat allele | #3 |
disease humans interviews | #3 |
chromosome 10q22 | #3 |
sirolimus 12 months | #3 |
27 risk loci | #3 |
rs6565113 | #3 |
resilience score | #3 |
learning disabilities adhd | #3 |
potential gene | #3 |
remittent | #3 |
topic adolescent | #3 |
association confounders | #3 |
impairment adhd | #3 |
genetic receptors serotonin | #3 |
adolescents mania | #3 |
adhd presence | #3 |
adhd pairwise correlations | #3 |
evidence genetic association | #3 |
bipolar psychoses | #3 |
educational deficits | #3 |
control probands relatives | #3 |
adult psychiatric outcomes | #3 |
faraone reply | #3 |
adhd data | #3 |
reln promoter | #3 |
smds scz | #3 |
anxiety disorders parents | #3 |
67e07 | #3 |
adhd ptsd | #3 |
pairwise correlations disorders | #3 |
sud children | #3 |
cigarette smoking children | #3 |
caarsss | #3 |
notch4 schizophrenia | #3 |
controls 6 disorders | #3 |
weight effects | #3 |
ptsd adhd | #3 |
desr | #3 |
nmu prescription stimulants | #3 |
metadoxine extended release | #3 |
impact adhd | #3 |
predisposition schizophrenia | #3 |
disorder comorbid | #3 |
relatives bipolar disorder | #3 |
sibling trait | #3 |
hyperactivity bipolar | #3 |
nicotine disorders | #3 |
comorbidity diagnosis | #3 |
cognition comorbidity | #3 |
asd ocd groups | #3 |
simulated workplace laboratory | #3 |
adhd stimulant medication | #3 |
brain methylation | #3 |
familial nature | #3 |
cgsq | #3 |
relatives proband groups | #3 |
adhd systematic review | #3 |
13q222 | #3 |
asrs v11 | #3 |
familial risk factors | #3 |
wonderlic personnel test | #3 |
nervous stimulants | #3 |
oprm1 variants | #3 |
ocd groups asd | #3 |
gsprs | #3 |
clinically referred adults | #3 |
networks adhd | #3 |
drug nicotine | #3 |
deficient emotional | #3 |
adhd mental disorders | #3 |
candidate gene studies | #3 |
dmi addh | #3 |
lbw adhd | #3 |
npl scores | #3 |
genetics initiative | #3 |
zakzanis | #3 |
amphetamines attention | #3 |
risk panic | #3 |
deficits height | #3 |
schizoaffective bipolar disorder | #3 |
manic symptoms youth | #3 |
psychopathologic conditions | #3 |
emotional dysregulation adhd | #3 |
schizotaxia | #3 |
parental substance disorders | #3 |
persistence psychiatric disorders | #3 |
dsmiiir diagnosis | #3 |
adhd psychiatric comorbidity | #3 |
adhd psud | #3 |
adhd combined type | #3 |
intron13 | #3 |
stimulants treatment | #3 |
adhd bipolar disorder | #3 |
global neuroscience decade | #3 |
ldx amphetamine | #3 |
children mania | #3 |
disorders conclusions | #3 |
adhd risk | #3 |
anxiety behavioral inhibition | #3 |
disorder conduct | #3 |
european‐american | #3 |
structural imaging findings | #3 |
children adhd diagnosis | #3 |
siblings young | #3 |
large battery | #3 |
adhd implications | #3 |
morning school | #3 |
social perception skills | #3 |
anxiety disorders authors | #3 |
temperamental correlates | #3 |
lambdasib | #3 |
drd4 7 | #3 |
substance disorders adhd | #3 |
htr1e | #3 |
schizophrenia neurocognitive performance | #3 |
comt adhd | #3 |
schizophrenic outpatients | #3 |
tic disorders adhd | #3 |
impulsivity errors | #3 |
model adhd | #3 |
atomoxetine response | #3 |
adhd common | #3 |
alcohol adhd | #3 |
parents panic | #3 |
schizophrenia schizotaxia | #3 |
firstdegree relatives | #3 |
n5827 | #3 |
adolescent adhd | #3 |
schizophrenia genotype | #3 |
growth deficits | #3 |
adhd mdd | #3 |
petronis | #3 |
highly heritable disorder | #3 |
cortical thickness cases | #3 |
mtbi studies | #3 |
similarities genetic etiology | #3 |
cpt deficits | #3 |
adhd mtbi | #3 |
n1777 | #3 |
relatives persons | #3 |
major depression comorbidity | #3 |
conduct disorder adhd | #3 |
enuresis adhd | #3 |
adderall methylphenidate | #4 |
neuropsychoanalytic | #4 |
openlabel studies | #4 |
quantitative models | #4 |
snps intelligence | #4 |
pediatric mania | #4 |
sd133 | #4 |
neuropsychological performance schizophrenia | #4 |
transporter genotypes | #4 |
panic disorder pregnancy | #4 |
adhd control children | #4 |
4year followup | #4 |
global neuroscience | #4 |
enrichment adhd | #4 |
risk gene schizophrenia | #4 |
boys higher prevalence | #4 |
distinct disorder | #4 |
mts growth | #4 |
expected height | #4 |
fmri replication | #4 |
rs1079727 | #4 |
genetic heterogeneity schizophrenia | #4 |
height deficits | #4 |
anxiety disorders mdd | #4 |
adolescent years | #4 |
md individuals | #4 |
odd adhd | #4 |
jbd | #4 |
rates psychiatric | #4 |
addictive drug | #4 |
scores adhd | #4 |
sud bpd sud | #4 |
impaired intellect | #4 |
parents bpd | #4 |
notch4 locus | #4 |
comorbid psychiatric | #4 |
developmental improvement | #4 |
adhd md | #4 |
bipolar disorder linkage | #4 |
families girls | #4 |
pord05 | #4 |
maoa | #4 |
psc35 | #4 |
differences adults | #4 |
support mechanism | #4 |
psychiatrically referred youth | #4 |
angerirritability | #4 |
relatives controls | #4 |
inhibition anxiety | #4 |
rs3916968 | #4 |
treatment adult adhd | #4 |
disorders attention | #4 |
humans lisdexamfetamine | #4 |
gender children | #4 |
vcfs sample | #4 |
strattera | #4 |
health female | #4 |
bpd sud patients | #4 |
phenotypes adhd | #4 |
children comorbid adhd | #4 |
remittent adhd | #4 |
findings risk | #4 |
lgi age | #4 |
metaanalyzes | #4 |
child behavior checklist | #4 |
cbclaps | #4 |
adhd youth | #4 |
choice adhd | #4 |
treatment adhd | #4 |
report scale | #4 |
adhd association | #4 |
adhd individuals | #4 |
chinese sample | #4 |
adhd status | #4 |
snpbased | #4 |
enigmaadhd | #4 |
comorbid attention | #4 |
inattentive adhd | #4 |
executive function deficits | #4 |
46222 | #4 |
safren | #4 |
asd mood disorders | #4 |
increased neural responses | #4 |
rs3785143 | #4 |
depression parental depression | #4 |
time reproduction | #4 |
secondary psychotic symptoms | #4 |
quantitative phenotype | #4 |
psychiatric comorbidity risk | #4 |
disease genome humans | #4 |
psud | #4 |
handedness schizotypy | #4 |
reported adhd | #4 |
disorder objective | #4 |
d4s2361 | #4 |
reported findings | #4 |
adhd substance abuse | #4 |
subjects schizotaxia | #4 |
homogeneous subtypes | #4 |
subthreshold | #4 |
risk factors adhd | #4 |
disorders panic | #4 |
mhlod | #4 |
adhd controls | #4 |
adhd pdd | #4 |
attention adhd | #4 |
disorders neuropsychological | #4 |
subsequent substance disorders | #4 |
motor coordination problems | #4 |
hemmings | #4 |
coordination problems | #4 |
treatment stimulant medication | #4 |
gxr adhd | #4 |
rutters indicators | #4 |
vulnerability schizophrenia | #4 |
psychiatrically referred | #4 |
suds adolescents | #4 |
adhd based | #4 |
adhd neuropsychological performance | #4 |
adhd pharmacogenetic studies | #4 |
adhd reported | #4 |
stimulantnaïve | #4 |
4th international meeting | #4 |
cbcljbd phenotype | #4 |
shr ncrl | #4 |
adhd brain regions | #4 |
nonoral routes administration | #4 |
adhd adulthood | #4 |
adhd children mph | #4 |
primary substance abuse | #4 |
17q111q12 | #4 |
selenbp1 schizophrenia | #4 |
controls basal ganglia | #4 |
deficits executive functioning | #4 |
growing literature | #4 |
presence adhd | #4 |
roh risk | #4 |
hypescheme | #4 |
schizophrenia genetic factors | #4 |
maternal smoking alcohol | #4 |
relatives normal controls | #4 |
parental panic | #4 |
familial vulnerability | #4 |
rs3916971 | #4 |
adolescent outcome | #4 |
independent transmission | #4 |
functioning adhd | #4 |
treatment seeking patients | #4 |
receiver operator characteristic | #4 |
tests psychiatric | #4 |
psychiatric gene discoveries | #4 |
female probands relatives | #4 |
cbcl | #4 |
adhd etiology | #4 |
adults | #4 |
poor motor performance | #4 |
adhd impairments | #4 |
rels | #4 |
rate switching | #4 |
bpd sud bpd | #4 |
comorbid aggression adhd | #4 |
adhd pharmacotherapy | #4 |
disorders comorbidity | #4 |
rs140700 | #4 |
offspring sud | #4 |
image sample | #4 |
anxiety disorders offspring | #4 |
factors substance | #4 |
onset adhd | #4 |
pavgrnk000417 | #4 |
reward dysfunction | #4 |
total score week | #4 |
objective studies | #4 |
adhd symptom | #4 |
risk factors bpd | #4 |
preterm sample | #4 |
achievement goal orientation | #4 |
behavior checklist | #4 |
adhd subgroups | #4 |
vcfs adhd | #4 |
risk variants adhd | #4 |
comorbidity humans | #4 |
substance disorders suds | #4 |
adhd participants | #4 |
acting formulations | #4 |
aggregation adhd | #4 |
d4s1644 | #4 |
intelligence snps | #4 |
lifetime dimensions | #4 |
metadoxine placebo | #4 |
rutter | #4 |
clinical obesity | #5 |
asrs screener | #5 |
study genetic factors | #5 |
cbcl data | #5 |
psychosis velocardiofacial syndrome | #5 |
maternal reports | #5 |
impairment baseline | #5 |
ascertainment source | #5 |
iiv adhd | #5 |
pdmd | #5 |
2nd cohort | #5 |
familial subtypes | #5 |
familial risk adhd | #5 |
adolescent alleles | #5 |
adhd inattentive type | #5 |
mothers anxiety disorders | #5 |
anxiety disorders anx | #5 |
adhd bupropion | #5 |
torture review | #5 |
wcst scores | #5 |
diagnosis mania | #5 |
child child behavior | #5 |
effects adhd | #5 |
referred children | #5 |
proband risk | #5 |
combined subtype | #5 |
year prospective | #5 |
bipolar disorder bpd | #5 |
function adhd | #5 |
behavioral inhibition children | #5 |
mood disorders asd | #5 |
children ldx | #5 |
adult probands | #5 |
schizophrenia palau | #5 |
referred youths | #5 |
3q13 | #5 |
shared haplotypes | #5 |
tass | #5 |
adhd treated | #5 |
parental adhd | #5 |
memantine hydrochloride | #5 |
criteria schizotaxia | #5 |
disorder anxiety | #5 |
social disability | #5 |
serum neuroleptic | #5 |
xr adults | #5 |
intellectually capable adults | #5 |
impairment survey | #5 |
disorder genetic | #5 |
youth vcfs | #5 |
oosterlaan | #5 |
genetic linkage schizophrenia | #5 |
auditory vigilance | #5 |
adhdlike symptoms | #5 |
initial responsiveness | #5 |
risk relatives | #5 |
humans interview | #5 |
parents psychiatric | #5 |
boys attention | #5 |
interview psychological | #5 |
lifetime impact | #5 |
impaired parents humans | #5 |
oppositional defiant disorder | #5 |
nt5dc1 | #5 |
resilience project | #5 |
sex adhd | #5 |
highly heritable | #5 |
disorder sud | #5 |
children dbds | #5 |
dopamine risk | #5 |
comorbid disorders | #5 |
psychiatric disorders study | #5 |
depression panic disorder | #5 |
report screening | #5 |
pleiotropic effects disorders | #5 |
referred sample | #5 |
rs1799836 | #5 |
methylphenidate adults | #5 |
adhd comorbid anxiety | #5 |
large collaborative study | #5 |
pdd subjects | #5 |
neuropsychological risk | #5 |
disorders follow | #5 |
adhd response | #5 |
inattentive symptoms | #5 |
hyperactivity clinical trials | #5 |
prembr | #5 |
adhd adult | #5 |
adolescence adhd | #5 |
disorders psychiatric | #5 |
adult attention | #5 |
multivariate endophenotypes | #5 |
nonaffected siblings | #5 |
psychiatric correlates | #5 |
kiddieschedule | #5 |
sms intervention | #5 |
risk factors schizophrenia | #5 |
3 probands | #5 |
height weight | #5 |
severe scores | #5 |
dsm age | #5 |
pathways association | #5 |
psychosis scale | #5 |
etiopathologies | #5 |
panic disorder parents | #5 |
onset criterion | #5 |
nonmedical nmu | #5 |
risk anxiety | #5 |
checklist child | #5 |
female individuals | #5 |
disorder parents | #5 |
desipramine placebo | #5 |
d22s683 | #5 |
relatives female probands | #5 |
conventional medications | #5 |
major depression parents | #5 |
adhd ld | #5 |
familial distribution | #5 |
screener | #5 |
kuntsi | #5 |
neuropsychiatric comorbidity | #5 |
aagc | #5 |
grubb | #5 |
ncrl rats | #5 |
growth dysregulation | #5 |
parental sud | #5 |
hyperactivity caregivers | #5 |
adhd tic disorders | #5 |
adhd nonaffected siblings | #5 |
ppp3cc schizophrenia | #5 |
inhibited children | #5 |
desistent | #5 |
organization adult | #5 |
palauan | #5 |
adults adult | #5 |
adhd youths | #5 |
adhd cases | #5 |
disorder rating | #5 |
sud | #5 |
symptoms hyperactivity | #5 |
unipolar mdd | #5 |
scale adhd | #5 |
zmynd17 | #5 |
bipolar disorder pedigrees | #5 |
elevated rates | #5 |
puwma | #5 |
hechtman | #5 |
mania adhd | #5 |
cardinal symptom | #5 |
combined subtypes | #6 |
adhd compared | #6 |
normal sexual dimorphism | #6 |
oppositional defiant | #6 |
literature efficacy | #6 |
t518 | #6 |
xp114p113 | #6 |
premorbid cognitive ability | #6 |
relatives probands | #6 |
gxr efficacy | #6 |
risk attention | #6 |
psychiatric | #6 |
enigma wgs | #6 |
loci autism | #6 |
prior stimulant treatment | #6 |
specific predictor | #6 |
downward extension | #6 |
adhd genetic factors | #6 |
clinical features children | #6 |
adhd mental retardation | #6 |
adults disorder | #6 |
objective marker | #6 |
male odds | #6 |
adhd life | #6 |
dnajc9 | #6 |
driving simulation | #6 |
genome‐wide | #6 |
schizophrenia deficit | #6 |
environmental adversity | #6 |
p1e04 | #6 |
genetic child | #6 |
vulnerability indicator | #6 |
disorder combined | #6 |
pediatric mood disorders | #6 |
irmph | #6 |
prevalence adult adhd | #6 |
adhd mood disorders | #6 |
child delayed | #6 |
4634 | #6 |
referred adults | #6 |
bpd controls | #6 |
parental major depression | #6 |
t515 | #6 |
tmcq | #6 |
placebo response response | #6 |
ppp3cb | #6 |
symptoms adhd | #6 |
nonparanoid schizophrenia | #6 |
neuropsychological functioning | #6 |
psychoactive substance | #6 |
hyperactivity child chromosomes | #6 |
total gray matter | #6 |
concurrent validation | #6 |
neuroleptic activity | #6 |
maniclike symptoms | #6 |
adhd variability | #6 |
teenage parenthood | #6 |
pavgrnk | #6 |
depression panic | #6 |
individual alleles | #6 |
referred children adolescents | #6 |
bpd comorbid | #6 |
males adhd | #6 |
pediatric bipolar | #6 |
psychopathology children | #6 |
pediatric bpd | #6 |
benefitrisk ratio | #6 |
adhd tic | #6 |
dopamine transporter gene | #6 |
seidman | #6 |
cognition adults | #6 |
value09 | #6 |
taan | #6 |
clinical scales | #6 |
chromosome 15 locus | #6 |
adhd children adults | #6 |
risk sud | #6 |
large heterogeneous | #6 |
psychiatric disorders prss | #6 |
dsm iii | #6 |
familial loadings | #6 |
adhdia | #6 |
anxiety disorder relatives | #6 |
altered neural connectivity | #6 |
pseudocontrols | #6 |
liability schizophrenia | #6 |
combined condition | #6 |
paternal age schizophrenia | #6 |
schizophrenia spectrum schizophrenia | #6 |
adhd women | #6 |
bpdsud | #6 |
association studies schizophrenia | #6 |
children relatives | #6 |
adhd increased risk | #6 |
nhe inhibitors | #6 |
fspd | #6 |
adhd firstdegree relatives | #6 |
disorders adolescent | #6 |
interpreting estimates | #6 |
scales psychometrics | #6 |
differences cortical thickness | #6 |
schizophrenic probands | #6 |
parents major | #6 |
symptoms disorder | #6 |
ascertained | #6 |
niacin schizophrenia | #6 |
disorders relatives | #6 |
criteria adhd | #6 |
schizophrenia g72 | #6 |
cbcljbd | #6 |
females adhd | #6 |
mixed amphetamine | #6 |
stimulant prescription | #6 |
cpg sites methylation | #6 |
groups adults | #6 |
followup studies | #6 |
schizophrenia premorbid | #6 |
druggable genome | #6 |
unfamiliar situations | #6 |
year recall | #6 |
facial memory | #6 |
oceanic palau | #6 |
hierarchical factor model | #6 |
stimulant treatment children | #6 |
life adults | #6 |
140 children | #6 |
genetic linkage genome | #6 |
behavioral inhibition | #6 |
wm performance patients | #6 |
nmu | #6 |
hyperactivity disease models | #6 |
cognitive impairments adhd | #6 |
methylphenidate therapy | #7 |
adhd authors | #7 |
parent reports | #7 |
dimensional measures | #7 |
asd asd youth | #7 |
odd | #7 |
child impaired | #7 |
adhd improvement | #7 |
adhd symptoms association | #7 |
association cdh13 | #7 |
ldx treatment | #7 |
mph adhd adults | #7 |
asd youth | #7 |
adhd boys girls | #7 |
neuroimage study | #7 |
controls probands | #7 |
adhdct | #7 |
haplotype schizophrenia | #7 |
outpatient child | #7 |
adhd emotional dysregulation | #7 |
pdqr | #7 |
myosin5b | #7 |
pdag mdd | #7 |
hraff | #7 |
wonderlic | #7 |
confusability | #7 |
measures adhd | #7 |
markov chain analysis | #7 |
relatives risk | #7 |
boys adhd | #7 |
adhd sud sud | #7 |
adhdrs | #7 |
adhd asrs | #7 |
tomoxetine | #7 |
disorders probands | #7 |
systematic chart review | #7 |
nmu prescription | #7 |
conduct disorder girls | #7 |
childhood disorder | #7 |
kgas | #7 |
attention task | #7 |
children tourettes syndrome | #7 |
mdd pdag | #7 |
nrp104 | #7 |
long repeats | #7 |
snap25 adhd | #7 |
n1031 | #7 |
pmee | #7 |
statistical measure | #7 |
coming years | #7 |
flush response | #7 |
combined type adhd | #7 |
saica | #7 |
velo‐cardio‐facial | #7 |
dependence rates | #7 |
authors goal | #7 |
members schizophrenia | #7 |
drd5 | #7 |
6 psychiatric disorders | #7 |
studies dopamine | #7 |
sensorimotor timing | #7 |
exon15 | #7 |
mph adhd | #7 |
development adhd | #7 |
relatives schizophrenic patients | #7 |
seeking substance | #7 |
nalysis | #7 |
chromosome workshop | #7 |
persistence anxiety disorders | #7 |
children bpd | #7 |
locus haplotypes | #7 |
neurocognitive performances | #7 |
genome‐wide association | #7 |
qlesqsf | #7 |
parents psychiatric disorders | #7 |
palauans | #7 |
polygenic scores adhd | #7 |
adhd symptoms | #7 |
highrisk siblings | #7 |
hyperactivity brain | #7 |
adhd persistence | #7 |
candidate gene schizophrenia | #7 |
idir | #7 |
spn812 | #7 |
adhd substance disorders | #7 |
ancestry attention | #7 |
bipolar unipolar disorders | #7 |
methylomics | #7 |
prevention schizophrenia | #7 |
children learning disorders | #7 |
implicating | #7 |
adhd criteria | #7 |
skin flush response | #7 |
disorder substance | #7 |
swedish registry data | #7 |
exome chip analyses | #7 |
adhd overweight obesity | #7 |
parents prevalence | #7 |
teachers boys | #7 |
pediatric major depression | #7 |
rs3916965 | #8 |
symptoms impairment | #8 |
adhd boys | #8 |
diagnosis major depression | #8 |
disease humans polymorphism | #8 |
onset bpd | #8 |
treatment lead | #8 |
male multifactorial inheritance | #8 |
control adhd | #8 |
stimulanttreated | #8 |
link adhd | #8 |
psychiatric genomics | #8 |
analysis association | #8 |
attention | #8 |
symptoms behaviors | #8 |
unaffected siblings adhd | #8 |
volumetric reductions | #8 |
controls relatives | #8 |
behavior attention | #8 |
adhd associations | #8 |
subjects children | #8 |
negative symptoms scale | #8 |
affairs cooperative | #8 |
agreement measures | #8 |
offspring trios | #8 |
autistic traits children | #8 |
differential utility | #8 |
mph adults | #8 |
10q223 | #8 |
familybased association study | #8 |
promising directions | #8 |
studies provide | #8 |
adhd inattentive | #8 |
disorders families | #8 |
childhood mania | #8 |
pvalues005 | #8 |
adhd remission | #8 |
aversion adhd | #8 |
pempirical | #8 |
adhdcd | #8 |
pliszka | #8 |
adhd adolescence | #8 |
rs3916966 | #8 |
n1314 | #8 |
biederman | #8 |
schizophrenia polymorphisms | #8 |
disorder probands | #8 |
disorders baseline | #8 |
adhdhi | #8 |
bpd disorders | #8 |
biological relatives | #8 |
metaanalysis schizophrenia | #8 |
treatment sirolimus | #8 |
euphoria | #8 |
probands risk | #8 |
presence autistic traits | #8 |
prescription stimulant | #8 |
hemideletion | #8 |
avoidant disorder | #8 |
participants adhd | #8 |
cadhd | #8 |
diagnosed adhd | #8 |
ordered subsets | #8 |
therapeutic dilemmas | #8 |
gender effects | #8 |
adhd stimulant | #8 |
substantial evidence | #8 |
behavioral inhibition anxiety | #8 |
schizophrenia members | #8 |
notch4 | #8 |
adhd manic symptoms | #8 |
dimesylate ldx | #8 |
human aggression | #8 |
adhd rtv | #8 |
multigenerational pedigree | #8 |
indicators schizophrenia | #8 |
adhd dat1 | #8 |
nonpsychotic | #8 |
chromosome schizophrenia | #8 |
abbreviated questionnaire | #8 |
impulsivity adhd | #8 |
impaired motor performance | #8 |
shared familial effects | #8 |
adhd symptom scores | #8 |
nonverbal social | #8 |
behavioral inhibition risk | #8 |
adhd unaffected | #8 |
familial aggregation adhd | #8 |
attention deficit adhd | #8 |
mwq | #8 |
child diagnostic | #8 |
polygenic associations | #8 |
sample youth | #8 |
crossover comparison | #8 |
rs685012 | #9 |
comorbidity female | #9 |
etiologically | #9 |
sustained attention schizophrenia | #9 |
adhd article | #9 |
stimulant medication | #9 |
endophenotypic | #9 |
depression offspring | #9 |
schizotaxic | #9 |
dao gene | #9 |
neuropsychologic function | #9 |
alzheimer disease schizophrenia | #9 |
festschrift | #9 |
taiwanese families | #9 |
aisrs | #9 |
haplotype snps | #9 |
netherlands twin registry | #9 |
hyperactivity automobile | #9 |
lag sequential analysis | #9 |
ecpbhs | #9 |
children assessed | #9 |
comparison girls | #9 |
male nuclear | #9 |
hyperactivity humans | #9 |
deficit disruptive | #9 |
symptoms mania | #9 |
hum genet | #9 |
ldps | #9 |
serotonin gene polymorphisms | #9 |
25e07 | #9 |
disruptive behavior disorders | #9 |
moderate sensitivity | #9 |
nonparanoids | #9 |
nuremberg code | #9 |
39 datasets | #9 |
snp7 | #9 |
nonreplications | #9 |
adhd loci | #9 |
pregnancy depression | #9 |
proband groups | #9 |
addh | #9 |
adhd healthy | #9 |
orosmph irmph | #9 |
gwas psychiatric disorders | #9 |
adhd enuresis | #9 |
blindly | #9 |
serotonin genes | #9 |
g×s interaction disorders | #9 |
adderall | #9 |
disorders sex interaction | #9 |
adult symptoms | #9 |
hhrr | #9 |
inattentive | #9 |
extendedrelease methylphenidate | #9 |
genes risk factors | #9 |
subtypes adhd | #9 |
rasd2 | #9 |
childhood psychosis | #9 |
n41 | #9 |
schizophrenia resilience | #9 |
sud bipolar disorder | #9 |
diagnostic efficiency | #9 |
adult report | #9 |
mdd youth | #9 |
adhdi | #9 |
ads individuals | #9 |
substantial risk | #9 |
rpdr | #9 |
comorbidity depressive | #10 |
adult years | #10 |
cbclap | #10 |
evidence genetic | #10 |
psychiatric clinic | #10 |
asd tourette syndrome | #10 |
pthreshold | #10 |
systematic qualitative review | #10 |
gwas adhd | #10 |
severity adhd | #10 |
comorbid odd | #10 |
genes disorders | #10 |
adhd unaffected siblings | #10 |
d4 receptor gene | #10 |
adhd quality | #10 |
normal sexual | #10 |
amphetamine salts | #10 |
shared neurobiology | #10 |
probands bpd | #10 |
panic depression | #10 |
case identification | #10 |
childhood adhd symptoms | #10 |
genetic vulnerability schizophrenia | #10 |
4th | #10 |
association dat1 | #10 |
nephews | #10 |
aged attention | #10 |
untreated adhd | #10 |
small effects | #10 |
dms1 | #10 |
rorb | #10 |
stimulants child | #10 |
deficits adhd | #10 |
caadid | #10 |
preteen | #10 |
adhd substance disorder | #10 |
kruglyak | #10 |
rates abuse | #10 |
adhd difficulties | #10 |
bipolar disorder probands | #10 |
irmph orosmph | #10 |
image project | #10 |
sexual dimorphisms | #10 |
groups boys | #10 |
anxiety disorders children | #10 |
comorbid bpd | #10 |
stimulants humans | #10 |
disorder age | #10 |
adhd sud | #10 |
conduct disorder | #10 |
reassessed | #10 |
slod | #10 |
adhd childhood | #10 |
noninhibited | #10 |
risk md | #10 |
genetics network | #10 |
linkage analyses | #10 |
parent‐of‐origin effects | #10 |
nonpharmacologic treatments | #10 |
comorbidity | #10 |
preschool depressive | #10 |
association death | #10 |
adulthood association | #10 |
young adult outcome | #10 |
drd4 | #10 |
ascertainment methods | #10 |
diminished risk | #10 |
new specialty | #10 |
sleep problems adhd | #10 |
psychiatric genetic studies | #10 |
juvenile mania | #11 |
cardinal symptoms | #11 |
nosologists | #11 |
disease humans schizophrenia | #11 |
rs1137070 | #11 |
lisdexamfetamine ldx | #11 |
adhd time | #11 |
adhd substance | #11 |
n136 | #11 |
informativeness | #11 |
nonadhd controls | #11 |
study perspective | #11 |
fbatpc | #11 |
diagnosis adults | #11 |
adhd psychopathology | #11 |
dopamine d5 receptors | #11 |
defiant disorder | #11 |
psychiatric disorders youth | #11 |
ppp3cc | #11 |
children bipolar | #11 |
sample adults | #11 |
adolescents adhd | #11 |
familybased association test | #11 |
disorders mothers | #11 |
major depression adhd | #11 |
paternal smoking | #11 |
shared familial | #11 |
deficits schizophrenia patients | #11 |
polymorphism 5 | #11 |
maternal antenatal anxiety | #11 |
adhd onset | #11 |
shr model | #11 |
release methylphenidate | #11 |
offspring bipolar parents | #11 |
differences parents | #11 |
preschool depressive disorder | #11 |
achievement adolescent | #11 |
pediatric bipolar disorder | #11 |
growth delays | #11 |
studies mtbi | #11 |
gene adhd | #11 |
adhd female humans | #11 |
serotonin genetic receptor | #11 |
rora rorb | #11 |
agoraphobia anxiety | #11 |
4372 | #11 |
dimesylate | #11 |
differentiated genetic | #11 |
female relatives | #11 |
prodromal psychosis | #11 |
hydrochloride attention | #11 |
adult relatives | #11 |
inhibition adhd | #11 |
panic disorder comorbidity | #11 |
differences adhd | #11 |
comorbidity patterns | #11 |
remission adhd | #11 |
etiology pathophysiology | #11 |
vcfs | #11 |
attention deficit disorder | #11 |
markers adhd | #11 |
disorder pedigrees | #11 |
cutraits | #11 |
effects genes | #11 |
adhd intellectual disability | #11 |
ldx placebo | #11 |
symptom subtype | #11 |
youth bpd | #11 |
hyperactivity child cross | #11 |
multiple domains | #11 |
disorders | #11 |
neuropsychological test scores | #11 |
inattentive type | #11 |
children addh | #11 |
real progress | #11 |
cnvs risk | #12 |
obesity adhd | #12 |
studies relatives | #12 |
disorder adult | #12 |
comorbidity diagnostic | #12 |
sexually dimorphic effects | #12 |
juvenile bipolar | #12 |
unaffected sibs | #12 |
psychiatric genetics | #12 |
salts extended | #12 |
adhd core symptoms | #12 |
cbcl children | #12 |
striatal sensitivity | #12 |
systematized | #12 |
amfetamine | #12 |
treatment attention | #12 |
scales treatment | #12 |
ksadse | #12 |
perceived motor competence | #12 |
sample consisted | #12 |
sud adhd | #12 |
twins humans models | #12 |
adhd age | #12 |
metan | #12 |
assessment adhd | #12 |
nonoral | #12 |
test wcst | #12 |
sec23ip | #12 |
adolescent adult age | #12 |
onelevel | #12 |
covid19 restrictions children | #12 |
impaired parents | #12 |
effects time | #12 |
common disorders | #12 |
lossavoidance | #12 |
dat1 polymorphism | #12 |
n1397 | #12 |
symptom rating | #12 |
psychotic mood disorders | #12 |
pleiotropic mechanisms | #12 |
genes methylation | #12 |
treatment paliperidone | #12 |
digital treatment | #12 |
neurocognitive measures | #12 |
sud patients adhd | #12 |
deficits attention | #12 |
early psychosis study | #12 |
psychiatric clinics | #12 |
functional impairments | #12 |
youths bpd | #12 |
convergent functional | #12 |
stimulant medication children | #12 |
epilepsy mothers | #12 |
comorbid disorder | #12 |
multiplex schizophrenia | #12 |
adhd offspring | #12 |
rs947267 | #12 |
nhe9 | #12 |
disorder subjects | #12 |
response atomoxetine | #12 |
girls relationship | #12 |
hawi | #12 |
adult outcome | #12 |
impaired parents child | #12 |
adhd dopamine | #12 |
adhd symptoms adults | #12 |
probands siblings | #12 |
common psychiatric | #12 |
kappa coefficients | #12 |
rs778293 | #12 |
obesity risk alleles | #12 |
defiant | #12 |
thalamic activation | #12 |
unaffected siblings individuals | #12 |
psychotic behavior | #12 |
impulsivity children | #12 |
variable age | #12 |
40–48 | #12 |
diagnostic threshold | #13 |
persistence remission | #13 |
male samples | #13 |
adhd alterations | #13 |
overanxious | #13 |
genomewide significance | #13 |
studies bipolar | #13 |
symptoms attention | #13 |
permutation testing | #13 |
psychometric measure | #13 |
robust effects | #13 |
nonoral routes | #13 |
disorders sud | #13 |
adverseevents | #13 |
humans methylphenidate | #13 |
chi12 | #13 |
pkcm | #13 |
psychiatric risk | #13 |
taiwanese sample | #13 |
longallele | #13 |
convergent functional genomics | #13 |
velocardiofacial syndrome vcfs | #13 |
necrotic death | #13 |
girls | #13 |
psychotic mood | #13 |
iiv | #13 |
response inhibition adolescents | #13 |
bpd offspring | #13 |
adhd alcohol | #13 |
cognitive impulsivity | #13 |
diagnostic concepts | #13 |
ravg | #13 |
late onset | #13 |
rates comorbidity | #13 |
environment adolescent | #13 |
adhdodd | #13 |
familial risk schizophrenia | #13 |
disorder youth | #13 |
adhd diagnosis | #13 |
114 years | #13 |
risk parents | #13 |
specific hypotheses | #13 |
adderall mph | #13 |
disorder childhood | #13 |
colorado springs | #13 |
adhd cognitive | #13 |
disorders child | #13 |
morbidity risks | #13 |
scale studies | #13 |
label studies | #13 |
pair 6 chromosomes | #13 |
psychometrics reproducibility | #13 |
risk mood | #13 |
transdermal methylphenidate | #13 |
methods subjects | #13 |
weight bmi | #13 |
siblings cases | #14 |
unaffected siblings controls | #14 |
differential heritability | #14 |
studies adults | #14 |
cautiously | #14 |
n643 | #14 |
social school | #14 |
children stimulants | #14 |
worldwide prevalence | #14 |
stimulant abuse | #14 |
early precursors | #14 |
subcortical brain volume | #14 |
emotional impulsivity | #14 |
siblings probands | #14 |
ocd scz | #14 |
disorder odd | #14 |
mixed amphetamine salts | #14 |
common disorder | #14 |
symptoms psychiatric disorders | #14 |
adhd brain | #14 |
adhd phenotype | #14 |
factors schizophrenia | #14 |
lisdexamfetamine dimesylate ldx | #14 |
mph adderall | #14 |
hillside | #14 |
disorders comorbid | #14 |
wraadds | #14 |
older adults adhd | #14 |
economic psychology | #14 |
selfcontained | #14 |
cnvs park2 | #14 |
prss mdd | #14 |
diagnosis mdd | #14 |
suds | #14 |
genes schizophrenia | #14 |
comorbid condition | #14 |
disorder child | #14 |
attention executive | #14 |
familial disorder | #14 |
genetic studies schizophrenia | #14 |
relatives male probands | #14 |
children bipolar disorder | #14 |
aadhd | #14 |
children criteria | #14 |
nimh genetics | #14 |
bipolar probands | #14 |
quetiapine bipolar disorder | #14 |
associations adhd | #14 |
sud patients | #14 |
lphn3 adhd | #14 |
adhd symptoms adulthood | #14 |
geschwind | #14 |
teachers reports | #14 |
daily living administration | #15 |
adhd treatment | #15 |
diagnostic interviews | #15 |
association schizophrenia | #15 |
genderdifferences | #15 |
healthy comparison subjects | #15 |
adhd performance | #15 |
disorder evidence | #15 |
symptom count | #15 |
prodromal symptoms psychosis | #15 |
bipolar schizoaffective disorder | #15 |
adhd functional connectivity | #15 |
risk substance | #15 |
d10s1423 | #15 |
poor perception | #15 |
agents attention | #15 |
snps methylation | #15 |
methylation gene expression | #15 |
psychiatric interviews | #15 |
symptoms adulthood | #15 |
schizophrenia families | #15 |
paediatric bipolar disorder | #15 |
adhd diagnostic | #15 |
seconddegree relatives | #15 |
persons schizophrenia | #15 |
velocardiofacial | #15 |
tests psychomotor | #15 |
card sorting | #15 |
treatment xr | #15 |
pregnancy risk factor | #15 |
gxr children | #15 |
adhd disorders | #15 |
cbclpbd | #15 |
ocd comorbid adhd | #15 |
male mood | #15 |
mphmlr | #15 |
sackett | #15 |
rs2652511 | #15 |
executive function theory | #15 |
male relatives | #15 |
4669 | #15 |
behavior disorders | #15 |
wfirsp | #15 |
nhsd | #15 |
interaction genotype | #15 |
study design features | #15 |
substance disorder patients | #15 |
zranb2 | #15 |
49 children | #15 |
asd mdd | #15 |
chi2 | #15 |
adhd study | #15 |
adults substance disorders | #15 |
metabolic syndrome obesity | #15 |
disord | #15 |
dexedrine | #16 |
brainbody | #16 |
risk psychotic disorders | #16 |
adhd diagnoses | #16 |
onset anticipation | #16 |
factual factor analysis | #16 |
drug disorder | #16 |
special classes | #16 |
control participants participants | #16 |
regional cortical thickness | #16 |
“difficulty | #16 |
dbds | #16 |
ntac | #16 |
linkage findings | #16 |
hyperkinetic disorders | #16 |
geneenvironment interaction | #16 |
rdoc framework | #16 |
n424 | #16 |
youths adhd | #16 |
scz risk | #16 |
multiple test | #16 |
longitudinal assessments | #16 |
pervasive developmental disorder | #16 |
adhd symptom severity | #16 |
delayed action | #16 |
adhd anxiety symptoms | #16 |
cprsr | #16 |
parents anxiety disorders | #16 |
growth children | #16 |
adhd obesity | #16 |
familial relationship | #16 |
informant assessment | #16 |
resultsfirst | #17 |
relation adhd | #17 |
asd ocd | #17 |
studies psychiatric | #17 |
bipolar disorder subjects | #17 |
association markers | #17 |
larger sample | #17 |
association scan | #17 |
driving behaviors | #17 |
prevalence adhd | #17 |
random forest regression | #17 |
ldx children | #17 |
diagnostic statistical | #17 |
psychology schizotypal | #17 |
combined type | #17 |
medication type | #17 |
a161t | #17 |
multiple anxiety disorders | #17 |
childhood predictors | #17 |
young offspring | #17 |
prospective follow | #17 |
disability adhd | #17 |
samples children | #17 |
accn2 | #17 |
mania | #17 |
considerable overlap | #17 |
5071 | #17 |
parents adhd | #17 |
schizophrenia psychosis | #17 |
ocd age | #17 |
hyperactivity attitude | #17 |
response inhibition network | #17 |
neuropsychiatric evaluation | #17 |
method participants | #17 |
adulthood adhd | #17 |
study adhd | #17 |
rbfox1 | #17 |
condfdr | #17 |
nonparametric linkage | #17 |
depression md | #17 |
pediatric disorder | #17 |
assessment positive symptoms | #17 |
factors siblings | #17 |
pediatric samples | #17 |
substance disorders sud | #17 |
persistent adhd | #17 |
children vcfs | #18 |
unemotionality | #18 |
risk disorders | #18 |
hrr 95 | #18 |
schizophrenia patients relatives | #18 |
childhood traumas | #18 |
meet criteria | #18 |
neuropsychologic | #18 |
symptom overlap | #18 |
potential contributor | #18 |
preschool diagnostic | #18 |
fullsiblings | #18 |
prolonged therapy | #18 |
anxiety mdd | #18 |
adhd sud patients | #18 |
kcnj4 | #18 |
marijuana age | #18 |
poor tolerability | #18 |
transporter gene | #18 |
unaffected siblings | #18 |
primary substance | #18 |
adhd cannabis | #18 |
depression genetic risk | #18 |
illness twins | #18 |
operationalized | #18 |
single nucleotide severity | #18 |
bipolar major | #18 |
relatives control subjects | #18 |
minisatellite repeats | #18 |
adhd groups | #18 |
stimulant | #18 |
lisdexamfetamine dimesylate | #18 |
psuds | #18 |
4286 | #18 |
low dose naltrexone | #18 |
adhd severity | #18 |
behavior scale | #18 |
schizophrenia dtnbp1 | #18 |
dcdq | #18 |
linkage regions | #18 |
conduct disorder children | #18 |
bipolar choice trial | #18 |
scz ocd | #19 |
casecontrol sample | #19 |
familial transmission | #19 |
adolescent age | #19 |
substance adhd | #19 |
lod1 | #19 |
improvement symptoms | #19 |
symptoms adolescent | #19 |
medication trials | #19 |
candidate loci | #19 |
action preparations | #19 |
adolescent age onset | #19 |
disconfirmations | #19 |
euphoric effects | #19 |
comorbidity rates | #19 |
nature nurture | #19 |
psychosocial features | #19 |
verbal memory task | #19 |
assessing outcome | #19 |
mental health human | #19 |
rs3918342 | #19 |
hyperconnectivity | #19 |
disorders adults | #19 |
mcgue | #19 |
addicted patients | #19 |
adhd young adults | #19 |
adhd neurodevelopmental | #19 |
human ortholog | #20 |
response curve | #20 |
prenatal exposure nicotine | #20 |
rbfox1 gene | #20 |
parents risk | #20 |
sibpair | #20 |
deficits children | #20 |
depression adhd | #20 |
neuropsychologically | #20 |
transmission ratio distortion | #20 |
notch4 gene | #20 |
linkage scans | #20 |
slc6a2 | #20 |
schizophrenia attention | #20 |
manual mental | #20 |
dicap | #20 |
kiddie | #20 |
disorders polymorphism | #20 |
neuropsychological function | #20 |
nonpsychotic siblings | #20 |
inhibition children | #20 |
illness female humans | #20 |
humanhap550v3 | #20 |
outcome attention | #20 |
neuroleptic dose | #20 |
pedigree selection | #20 |
ratings adhd | #20 |
adolescent | #20 |
parent origin | #20 |
controlled pilot study | #20 |
gsma | #20 |
mflynn | #20 |
biological families | #20 |
rs778294 | #21 |
bipolar pedigrees | #21 |
cacng2 | #21 |
motor problems | #21 |
schizophrenia disease humans | #21 |
prescription stimulants | #21 |
gender comparisons | #21 |
prospective longitudinal | #21 |
life enjoyment | #21 |
chronic tics | #21 |
schizophrenia united | #21 |
linkage chromosomes | #21 |
childhood conduct disorder | #21 |
children comorbid | #21 |
genehunterplus | #21 |
agler | #21 |
psychiatric symptoms patients | #21 |
prevalent cases | #21 |
male probands | #21 |
schizotypals | #21 |
risk offspring | #21 |
comorbid adhd | #21 |
children pdd | #21 |
rat shr | #21 |
11year followup | #21 |
methods age | #21 |
sodium hydrogen exchanger | #21 |
monoamine oxidase maoa | #21 |
humans linkage | #21 |
treatment growth | #21 |
prenatal exposure alcohol | #21 |
palau | #21 |
schizophrenia taiwan | #21 |
preliminary reliability | #22 |
amygdala structure | #22 |
adhd impulsivity | #22 |
partial replication | #22 |
study methodology | #22 |
disorders major | #22 |
stimulants children | #22 |
controls | #22 |
association prs | #22 |
niacin skin | #22 |
bpd subjects | #22 |
neuropsychological profiles | #22 |
syndrome vcfs | #22 |
6 disorders | #22 |
adhd susceptibility | #22 |
depression treatment patients | #22 |
adderall xr | #22 |
youth bipolar | #22 |
adhd rating scale | #22 |
adhd anxiety | #22 |
familiality | #22 |
disruptive | #22 |
10p | #22 |
adhd stimulants | #22 |
children attention | #22 |
overtransmission | #22 |
genetic phenotype | #22 |
amphetamine methylphenidate | #22 |
diagnostic interview | #22 |
ldx | #22 |
polygenic overlap | #22 |
youth mdd | #22 |
rg022 | #22 |
pre‐school | #22 |
schizophrenia pgc | #22 |
neurocognitive performance schizophrenia | #22 |
executive functions efs | #23 |
oppositional | #23 |
comprehensively | #23 |
rs464049 | #23 |
interview dsm | #23 |
wide linkage | #23 |
neuroleptic withdrawal | #23 |
handful | #23 |
serotonin receptor gene | #23 |
n449 | #23 |
diagnostician | #23 |
disequilibrium male | #23 |
twins genetic predisposition | #23 |
notch4 receptors | #23 |
interacting molecules | #23 |
anxious mothers | #23 |
scq asd | #23 |
propylamines | #23 |
phenotype definition | #23 |
wechsler scales | #23 |
siblings | #23 |
kotkin | #23 |
male individuals | #23 |
adolescents bpd | #23 |
adhd symptoms childhood | #23 |
genetic investigation | #23 |
snapiv | #23 |
metadoxine | #23 |
syp | #23 |
intrinsic curvature | #23 |
mdd anxiety disorders | #23 |
asd scq | #23 |
heterogeneity genetic | #23 |
risk studies | #23 |
nonstimulant | #24 |
dsmiiir criteria | #24 |
ocd asd | #24 |
guanfacine extended release | #24 |
symptoms psychosis | #24 |
genome‐wide linkage scans | #24 |
chromosomes 6 | #24 |
0535 | #24 |
conduct problems adhd | #24 |
lithium bipolar disorder | #24 |
snorting | #24 |
stroop task performance | #24 |
statistical manual | #24 |
female humans illness | #24 |
mental control | #24 |
15q13 | #24 |
aggression anxiety | #24 |
child female humans | #24 |
expected growth | #24 |
quantitative phenotypes | #24 |
age regions | #24 |
actigraphy studies | #24 |
receptor d4 | #24 |
deficits | #24 |
neural activation patterns | #24 |
sassr | #24 |
amrs | #24 |
nieces | #24 |
adhd characteristics | #24 |
stress exposure | #24 |
intelligence schizophrenia | #24 |
adhd comorbidities | #24 |
adra2a | #24 |
children meeting | #24 |
refilled | #24 |
anticipation schizophrenia | #25 |
major affective disorders | #25 |
dapple | #25 |
splicing regulator | #25 |
psychiatric disorders children | #25 |
association snps | #25 |
baseline assessment | #25 |
d22s283 | #25 |
exposure adhd | #25 |
vietnam twin registry | #25 |
–environment interactions | #25 |
unique profile | #25 |
behavioral disinhibition | #25 |
psychiatric nosology | #25 |
nudt3 | #25 |
clinical interviews | #25 |
conners parent | #25 |
slc6a3 gene | #25 |
maternal criticism | #25 |
young relatives | #25 |
or194 | #25 |
efficacy atomoxetine | #25 |
wkht | #25 |
biased transmission | #25 |
dyscalculia | #25 |
symptom subtypes | #25 |
bipolar choice | #25 |
copy variants schizophrenia | #25 |
task patients | #25 |
neurocognitive predictors | #25 |
decreased volume | #25 |
school failure | #25 |
screening scale | #25 |
psychometrically | #25 |
understanding adhd | #25 |
liker | #25 |
social impairment | #26 |
gender risk | #26 |
adrenergic uptake | #26 |
screening diagnosis | #26 |
major depression md | #26 |
bipolar phenotype | #26 |
selfmonitor | #26 |
affair | #26 |
alcohol drug abuse | #26 |
n81 | #26 |
orosmethylphenidate | #26 |
label study | #26 |
structured interviews | #26 |
voxel based morphometry | #26 |
wm microstructure | #26 |
adults symptoms | #26 |
rs3730358 | #26 |
add | #26 |
htr1d | #26 |
inrich | #26 |
psychometric measures | #26 |
neurodevelopmental genes | #26 |
association allele | #26 |
controls adhd | #26 |
prenatal health | #26 |
core symptoms adhd | #26 |
efpc | #26 |
adhd mothers | #26 |
maob gene | #26 |
nonmedical prescription stimulants | #26 |
behavioral disorder | #26 |
twins humans | #26 |
agreement raters | #26 |
childreniv | #27 |
weaker effects | #27 |
intelligence male | #27 |
based association | #27 |
disorders executive | #27 |
genetic susceptibility schizophrenia | #27 |
t102c polymorphism | #27 |
d22s278 | #27 |
hyperactivity disorder adhd | #27 |
greater severity | #27 |
asherson | #27 |
rate remission | #27 |
cnvs adhd | #27 |
potential confounds | #27 |
offspring risk | #27 |
international meeting | #27 |
bipolar disorder comorbidity | #27 |
ptsd adults | #27 |
treatment atomoxetine | #27 |
schizophrenia genetic | #27 |
association signals | #27 |
aff | #27 |
osterrieth | #27 |
consecutively | #27 |
mdd asd | #27 |
child clinical | #28 |
dopamine transporter binding | #28 |
ocd disorders | #28 |
cortical gyrification | #28 |
symptom reports | #28 |
disorder compared | #28 |
symptoms inattention | #28 |
slc6a3 | #28 |
clinical correlates | #28 |
6179 | #28 |
genetic etiology | #28 |
sustained attention deficits | #28 |
emotional dysregulation | #28 |
adults study | #28 |
vigilance performance | #28 |
schizophrenia onset | #28 |
rest task | #28 |
maternal adhd | #28 |
parent teacher | #28 |
metaalgorithm | #28 |
polysomnography actigraphy | #28 |
raters | #28 |
male methylphenidate | #28 |
adhd differences | #28 |
preliminary findings | #28 |
adhd autism | #28 |
image study | #28 |
families schizophrenia | #28 |
genomewide studies | #28 |
guze | #28 |
dopamine receptor d4 | #28 |
new genetics | #28 |
subjects bpd | #28 |
assessment negative symptoms | #28 |
snp18 | #28 |
persons bipolar disorder | #28 |
childhood diagnosis | #29 |
kcnn3 | #29 |
medication misuse | #29 |
childhood antecedents | #29 |
medication usage | #29 |
offspring parents | #29 |
hyperactivity impulsivity | #29 |
disorder bipolar | #29 |
studies genes | #29 |
infants weight | #29 |
attention‐deficit | #29 |
misuse diversion | #29 |
comorbidity ptsd | #29 |
etiological heterogeneity | #29 |
adhd patients controls | #29 |
dsmiiir | #29 |
parents bipolar disorder | #29 |
bipolar disorder youth | #29 |
male polymorphism | #29 |
disorders offspring | #29 |
african‐american | #29 |
shared genetic basis | #29 |
psychosocial dysfunction | #29 |
inattention hyperactivity impulsivity | #29 |
problems attention | #30 |
robust statistical methods | #30 |
structural brain features | #30 |
treatment adolescents | #30 |
juvenile bipolar disorder | #30 |
caarsinv | #30 |
adhd child | #30 |
diagnosticians | #30 |
nonaffected | #30 |
nimh | #30 |
bmi growth | #30 |
specific psychopathology | #30 |
comorbid | #30 |
association paternal age | #30 |
antisocial behavior asb | #30 |
nicotine pregnancy | #30 |
parental predictors | #30 |
growth childhood | #30 |
relatives age | #30 |
genetic perspective | #30 |
individual studies | #30 |
hyperactive symptoms | #30 |
95 adhd | #31 |
sex effects | #31 |
reanalyzed | #31 |
twin concordance | #31 |
genotype haplotypes | #31 |
kif16b | #31 |
prs adhd | #31 |
discriminates | #31 |
neuropsychologic deficits | #31 |
variable tandem | #31 |
rgs4 schizophrenia | #31 |
smoking substance | #31 |
methylphenidate | #31 |
nonadhd | #31 |
bpd risk | #31 |
impulsivity inattention | #31 |
neuroimage | #31 |
lodscore | #31 |
potential endophenotypes | #31 |
n305 | #31 |
extant literature | #31 |
depression genetic | #31 |
charles river | #31 |
anterior insular | #32 |
gender | #32 |
bipolar disorder bpi | #32 |
studies adolescent | #32 |
schizophrenia affective psychosis | #32 |
70–80 | #32 |
slc6a4 | #32 |
adhd adolescents | #32 |
psdq | #32 |
psychiatric genetic | #32 |
anxiety disorders | #32 |
psychiatric disorders | #32 |
wiscr | #32 |
rs206936 | #32 |
aggression attention | #32 |
10p13 | #32 |
studies schizophrenia | #32 |
kremen | #32 |
attentiondeficit | #32 |
psychosis youth | #32 |
impulsecontrol | #32 |
subfields hippocampus | #32 |
asd symptoms children | #32 |
repeat length | #32 |
child psychiatric | #32 |
randomized crossover study | #32 |
parents child | #32 |
mood anxiety | #33 |
adhd patients | #33 |
single snps | #33 |
rs1130214 | #33 |
maternal smoking pregnancy | #33 |
prior findings | #33 |
neural reward processing | #33 |
frontopolar | #33 |
qsf | #33 |
original study | #33 |
briefa | #33 |
twins factor analysis | #33 |
pharmacotherapy trials | #33 |
subcortical brain | #33 |
children risk | #33 |
association genes | #33 |
youth bipolar disorder | #33 |
comorbidity cross | #33 |
neuropsychological deficits | #33 |
aspd bpd | #33 |
wfirs | #33 |
current adhd | #33 |
ld adhd | #33 |
psychiatric status | #33 |
10repeat allele | #33 |
quetiapine monotherapy | #33 |
psychiatric sample | #33 |
autism symptoms | #33 |
adhd evidence | #33 |
neuropsychiatric sle | #33 |
disorder symptom | #33 |
animal model adhd | #33 |
val allele | #33 |
rhobtb3 | #33 |
gxr | #34 |
harvard | #34 |
disorders diagnostic | #34 |
inattention | #34 |
md risk | #34 |
grm5 | #34 |
cognition interaction | #34 |
candidate gene polymorphisms | #34 |
structural brain asymmetries | #34 |
dsm5 dsmiv | #34 |
risk psychiatric disorders | #34 |
pharmacotherapy adhd | #34 |
linkage studies | #34 |
disorder traits | #34 |
disorders mood | #34 |
psychological tests | #34 |
snp4 | #34 |
emerging consensus | #34 |
treatment sud | #34 |
treatment memantine | #34 |
young adults adhd | #34 |
social anxiety children | #34 |
risk females | #35 |
catechol‐o‐methyltransferase | #35 |
recall patients | #35 |
n265 | #35 |
sample description | #35 |
schizophrenia relatives | #35 |
bipolar spectrum disorders | #35 |
choice impulsivity | #35 |
adhd rating | #35 |
schizophrenia schizotypy | #35 |
htr1b | #35 |
participants bpd | #35 |
complex figure | #35 |
bipolar disorder offspring | #35 |
schizophrenia gene | #35 |
hyperactive disorder | #35 |
humans intelligence | #35 |
adhd sleep problems | #35 |
n64 | #35 |
lifetime rates | #35 |
familial risk | #35 |
lithium quetiapine | #35 |
plink | #35 |
#35 | |
95 siblings | #36 |
suny | #36 |
adhd drug | #36 |
neurotransmissions | #36 |
d6s274 | #36 |
neurocognitive markers | #36 |
n185 | #36 |
orosmph | #36 |
siblings controls | #36 |
stimulant medications | #36 |
young adult females | #36 |
structure psychopathology | #36 |
adhd control groups | #36 |
comorbidity children | #36 |
nocebo response | #36 |
schizophrenia genes | #36 |
overanxious disorder | #36 |
infant gender | #36 |
gypc | #36 |
adult antisocial | #36 |
intracranial volume icv | #36 |
retrospective recall | #36 |
annett | #36 |
term neuropsychological | #36 |
groups adhd | #36 |
disorder bpd | #36 |
odd dimensions | #37 |
symptom criteria | #37 |
delayedaction preparations | #37 |
disorder severity | #37 |
genetics | #37 |
rs5 | #37 |
studies comorbidity | #37 |
combined sample | #37 |
dat1 gene | #37 |
adhd asd | #37 |
n278 | #37 |
lisdexamfetamine | #37 |
predictive utility | #37 |
functioning adults | #37 |
tests schizophrenia | #37 |
mapping genomic loci | #37 |
offspring association | #37 |
slc22a16 | #37 |
parents adhd children | #37 |
child behavioral | #37 |
genetic risk schizophrenia | #38 |
polymorphism gene | #38 |
height children | #38 |
methylphenidate treatment | #38 |
familial risk depression | #38 |
genome‐wide search | #38 |
16 genes | #38 |
family‐based | #38 |
dsm criteria | #38 |
d15s1360 | #38 |
boys | #38 |
pediatric adhd | #38 |
adhd problems | #38 |
pik4ca | #38 |
unfamiliar | #38 |
rs2391191 | #38 |
school age children | #38 |
kiddie schedule | #38 |
nonparanoid | #39 |
ocd adhd | #39 |
structural brain abnormalities | #39 |
mdd ocd | #39 |
wisconsin card | #39 |
antisocial traits | #39 |
mood stabilization | #39 |
manic symptoms | #39 |
increased risk adhd | #39 |
pharmacologic treatment | #39 |
female cases | #39 |
asthma systematic review | #39 |
markers genetic | #39 |
suggestive | #39 |
washu | #39 |
mlod | #39 |
git1 | #39 |
iii personality | #39 |
dsm5 criteria | #39 |
behavioral traits | #39 |
adhd behavior | #39 |
test association | #39 |
onset children | #39 |
rare copy variants | #40 |
familial effects | #40 |
reln gene | #40 |
gxe | #40 |
cardiovascular adverse effects | #40 |
anx | #40 |
genetic studies | #40 |
brainspan | #40 |
diagnosis bipolar disorder | #40 |
chromosome 10p | #40 |
onset | #40 |
rs2283265 | #40 |
genome scan | #40 |
bipolars | #40 |
heinrichs | #40 |
dsmiv criteria | #40 |
genetics schizophrenia | #40 |
psychosocial adversity | #41 |
bdnf adhd | #41 |
normal comparison subjects | #41 |
male parents | #41 |
pediatric subjects | #41 |
sirolimus patients | #41 |
fhrs | #41 |
methodological advances | #41 |
parent‐of‐origin | #41 |
methylphenidate response | #41 |
effects growth | #41 |
schizophrenia severity illness | #41 |
chromosomes 6q | #41 |
sibpairs | #41 |
neuropsychiatr | #41 |
tic disorders | #42 |
adhd deficits | #42 |
sorting test | #42 |
male panic | #42 |
disorder social | #42 |
fiveyear followup | #42 |
diagnostic comorbidity | #42 |
n262 | #42 |
schizophrenia | #42 |
schizophrenia disorders | #42 |
individual items | #42 |
gwas meta | #42 |
child female | #42 |
serotonergic pathway | #42 |
dtnbp1 schizophrenia | #42 |
adhd prs | #43 |
youngadult | #43 |
digs | #43 |
children enuresis | #43 |
disorder prevalence | #43 |
p023 | #43 |
candidate endophenotype | #43 |
simplex families | #43 |
adhd depression | #43 |
mri study | #43 |
n232 | #43 |
neuropsychological tasks | #43 |
brain scans | #43 |
n176 | #43 |
snp1 | #43 |
n242 | #43 |
p094 | #43 |
neuropsychological differences | #43 |
practitioner review | #43 |
massachusetts general | #43 |
prior studies | #44 |
n140 | #44 |
nosologic | #44 |
immediaterelease | #44 |
odds ratio association | #44 |
asd adults | #44 |
adolescents attention | #44 |
treatment adult | #44 |
sidp | #44 |
dopamine d5 | #44 |
mental disorders diseases | #44 |
secondborns | #44 |
multidimensionality | #44 |
offspring adhd | #45 |
risk schizophrenia | #45 |
uncaring | #45 |
volume reductions | #45 |
prevalence psychiatric | #45 |
tcerg1l | #45 |
genetic loading | #45 |
pharmacogenetic studies | #45 |
institute mental | #45 |
snpbased heritability | #45 |
pooled size | #45 |
controls subjects | #45 |
genetic underpinnings | #45 |
risk reduction strategies | #45 |
baseline adhd | #45 |
wnl | #45 |
inflation rate | #45 |
altered brain activation | #45 |
illness stress | #45 |
substance disorder | #45 |
schizophrenia genome | #45 |
adhd parents | #45 |
cep85l | #45 |
behavior rating | #45 |
suggestive associations | #45 |
10year followup | #46 |
referral bias | #46 |
cbt intervention | #46 |
adhd effects | #46 |
machine learning study | #46 |
nat genet | #46 |
n164 | #46 |
converging evidence | #46 |
12 months treatment | #46 |
lyons | #46 |
gender influences | #46 |
sex bias | #46 |
stronger connectivity | #46 |
previous findings | #46 |
response mph | #46 |
familial coaggregation | #46 |
natural reward | #46 |
neuropsychological performance | #46 |
parents depression | #47 |
psychiatric status rating | #47 |
trauma risk | #47 |
disorders studies | #47 |
baiap2 | #47 |
oppositional symptoms | #47 |
compromised | #47 |
childhood disorders | #47 |
genetic study | #47 |
pooled odds ratio | #47 |
shared polygenic risk | #47 |
ocd mdd | #47 |
association bipolar disorder | #47 |
or125 | #47 |
n280 | #47 |
comt | #47 |
velocardiofacial syndrome | #47 |
loci chromosomes | #47 |
abstract objective | #47 |
desipramine dmi | #47 |
schizophrenia alleles | #47 |
meehl | #47 |
disorder case | #48 |
effects gender | #48 |
n27 | #48 |
scientific foundation | #48 |
n103 | #48 |
nullhypothesis | #48 |
mpp3 | #48 |
adhd prevalence | #48 |
rtv | #48 |
association test | #48 |
shared heritability | #48 |
revised | #48 |
adhd dyslexia | #48 |
1711 | #48 |
mental disorders children | #49 |
nurture | #49 |
hyperactivity autism | #49 |
weak evidence | #49 |
drug holidays | #49 |
negative schizotypy | #49 |
volume differences | #49 |
rs2494732 | #49 |
anxa7 | #49 |
disorder cognitive | #49 |
schizophrenia cognition | #49 |
familial loading | #49 |
serotonin plasma | #49 |
snap‐25 | #49 |
inbred wky rats | #49 |
genomic relationships | #50 |
early onset schizophrenia | #50 |
wiat | #50 |
studies biomarkers | #50 |
extended pedigrees | #50 |
dsmiv dsm5 | #50 |
vdm | #50 |
geneenvironment interactions | #50 |
parent teacher ratings | #50 |
proteins polymorphism | #50 |
life outcomes | #50 |
rocf | #50 |
pair 6 | #50 |
wais | #50 |
intergenerational effects | #50 |
maoauvntr | #50 |
caseness | #50 |
n168 | #50 |
impulsivity symptoms | #50 |
psychology adult | #51 |
male personality | #51 |
1542 | #51 |
adhd knowledge | #51 |
substantial role | #51 |
bpd | #51 |
common psychiatric disorders | #51 |
disorders children | #51 |
gender association | #51 |
compelling | #51 |
manovas | #51 |
adults ocd | #51 |
peer affiliation | #51 |
epilepsy adhd | #51 |
combined adhd | #52 |
oros methylphenidate | #52 |
a218c | #52 |
selenbp1 | #52 |
schizophrenia controls | #52 |
asdadhd | #52 |
growth height | #52 |
youth asd | #52 |
bipolar disorder children | #52 |
intracranial volume | #52 |
schizophrenia sex | #52 |
adra1a | #52 |
gray matter alterations | #52 |
metaanalysis association | #52 |
chronic schizophrenia patients | #52 |
major depression | #52 |
extended‐release | #53 |
placebo children | #53 |
psychopathology | #53 |
snps candidate genes | #53 |
ppm1h | #53 |
parahippocampal gyrus | #53 |
dopamine plasma | #53 |
schizophrenia adolescent | #53 |
scales schizophrenia | #53 |
adhdc | #53 |
risktaking behavior | #53 |
smoking schizophrenia | #53 |
adoption study | #53 |
risk analysis | #53 |
n138 | #53 |
tourettes disorder | #53 |
mania depression | #53 |
genetic reproducibility | #54 |
ablim1 | #54 |
onset bipolar | #54 |
psychlit | #54 |
bpd children | #54 |
risk study | #54 |
chromosome 6p | #54 |
unphased | #54 |
schizophrenia psychotic disorders | #54 |
alcohol drug | #54 |
jackknife | #54 |
dnms | #54 |
pregnancy time | #54 |
endophenotype | #55 |
1252 | #55 |
emotional lability | #55 |
children diagnosis | #55 |
mid adolescence | #55 |
tova | #55 |
disorders risk | #55 |
longitudinal case | #55 |
neuropsychological studies | #55 |
disorders prevalence | #55 |
viloxazine | #55 |
sample children | #55 |
childhood trauma exposure | #55 |
gene interaction | #55 |
child behavior | #55 |
flat affect | #55 |
degree relatives | #56 |
tics children | #56 |
subfield | #56 |
pair chromosomes | #56 |
extendedrelease | #56 |
entry points | #56 |
alcohol substance | #56 |
cotwin | #56 |
schizophrenia offspring | #56 |
children siblings | #56 |
n43 | #56 |
hyperactive | #56 |
disorder agoraphobia | #56 |
barkley | #57 |
zdhhc8 | #57 |
atomoxetine hydrochloride | #57 |
oddsratio | #57 |
model attention | #57 |
etdt | #57 |
rating inventory | #57 |
interregional profiles differences | #57 |
apol | #57 |
brain structure function | #57 |
shared genetic etiology | #57 |
methylphenidate hydrochloride | #57 |
tests attention | #58 |
100 children | #58 |
children | #58 |
adhd atomoxetine | #58 |
comorbid psychiatric disorders | #58 |
single snp | #58 |
dbq | #58 |
function schizophrenia | #58 |
repeat alleles | #58 |
childhood young adulthood | #58 |
analysis schizophrenia | #58 |
heritable receptors | #58 |
association comt | #58 |
controls children | #58 |
conners | #58 |
compelling evidence | #58 |
vntr polymorphisms | #58 |
controlled study | #58 |
schizophrenia smoking | #59 |
mdd children | #59 |
comt schizophrenia | #59 |
risk siblings | #59 |
neuroleptic | #59 |
risk psychiatric | #59 |
mdd adhd | #59 |
rtn4r | #59 |
inattention hyperactivity | #60 |
functional remission | #60 |
3 domains | #60 |
disruptive behavior disorder | #60 |
generalize | #60 |
disorders including | #60 |
lphn3 | #60 |
duval | #60 |
executive functioning | #60 |
reported associations | #60 |
abuse dependence | #60 |
uncles | #61 |
study adults | #61 |
uninhibited | #61 |
unipolars | #61 |
study adherence | #61 |
oih | #61 |
wide scan | #61 |
disorders asd | #61 |
cronbachs alpha | #61 |
dysregulation profile | #61 |
homogeneous subgroups | #61 |
13q32 | #61 |
disruptive behavior | #61 |
comparison subjects | #61 |
substantial heritability | #62 |
schizophrenia human | #62 |
mph treatment | #62 |
1537 | #62 |
bipolar youth | #62 |
symptoms | #62 |
factors anxiety | #62 |
maternal psychopathology | #62 |
polygenic risk schizophrenia | #62 |
4 year | #62 |
tdts | #62 |
relatives schizophrenia | #62 |
inhibition memory | #62 |
accounted | #63 |
ksads | #63 |
treatments adhd | #63 |
behavioral dysregulation | #63 |
stability time | #63 |
schizophrenia schizophrenic | #63 |
structured interview | #63 |
n179 | #63 |
risk severity | #63 |
disorders bipolar | #63 |
neurocognitive | #63 |
endosomal | #64 |
child | #64 |
methylphenidate adhd | #64 |
risk trauma | #64 |
methylphenidate mph | #64 |
children mph | #64 |
diagnostic utility | #64 |
prefrontal dysfunction | #64 |
adhd 95 | #64 |
methylation cpg sites | #64 |
phacking | #64 |
qlesq | #64 |
rating scales | #64 |
childhood onset | #64 |
europeanamerican | #64 |
linkage | #64 |
treatment desipramine | #64 |
40 countries | #64 |
males association | #64 |
prior work | #65 |
adhd epilepsy | #65 |
occurrence adhd | #65 |
emo | #65 |
small sample size | #65 |
net gene | #65 |
etiology schizophrenia | #65 |
neuropsychological impairments | #65 |
emotional regulation | #65 |
schizophrenic | #65 |
disorders genetic | #65 |
male siblings | #65 |
marry | #65 |
oxidase gene | #65 |
comorbid diagnosis | #65 |
controls siblings | #65 |
function female | #65 |
zcchc4 | #65 |
temperamental | #65 |
neuropsychological profile | #66 |
vswm | #66 |
ci105 | #66 |
extended release | #66 |
tourettes syndrome | #66 |
simple phobia | #66 |
disorder chromosome | #66 |
attention hyperactivity | #66 |
adhd dcd | #66 |
study studies | #66 |
cbcldp | #66 |
global ratings | #66 |
tic disorder | #66 |
afternoons | #66 |
children mental retardation | #66 |
behavioral genetic | #66 |
entire sample | #67 |
nonrighthandedness | #67 |
grade retention | #67 |
substance disorder sud | #67 |
parents teachers | #67 |
n217 | #67 |
variance attention | #67 |
findings association | #67 |
treatment quetiapine | #67 |
subjects | #67 |
chronic tic disorder | #67 |
questionnaires treatment | #67 |
label trial | #67 |
risk bipolar | #67 |
mental diseases | #67 |
patients bipolar disorders | #67 |
snparray | #68 |
conceptual issues | #68 |
hypofrontality | #68 |
delay aversion | #68 |
offspring | #68 |
qms | #68 |
naturalistic | #68 |
brain gene | #68 |
clarifying | #69 |
chronological age | #69 |
regulatory enzymes | #69 |
symptom checklist | #69 |
stress response genes | #69 |
low adherence | #69 |
panic disorder | #69 |
impulsivity hyperactivity | #69 |
scale assessment | #69 |
illicit substances | #69 |
polymorphism schizophrenia | #69 |
people adhd | #69 |
ctgn | #69 |
physical anhedonia | #69 |
humans schizophrenia | #69 |
nonrandom mating | #70 |
subsequent diagnosis | #70 |
core adhd symptoms | #70 |
oros mph | #70 |
smoking children | #70 |
a2bp1 | #70 |
interactions genes | #70 |
neuropsychological consequences | #70 |
new diagnoses | #70 |
npl | #70 |
latrophilin | #70 |
linkage scan | #70 |
genetic | #71 |
mspi polymorphism | #71 |
objective examine | #71 |
adhd behaviors | #71 |
treated children | #71 |
genes role | #71 |
neuroimaging genetics | #71 |
vergence | #71 |
adhd anxiety disorders | #71 |
school functioning | #72 |
molecular genetic | #72 |
genetic receptors | #72 |
digital intervention | #72 |
methodological issues | #72 |
ocd subjects | #72 |
boys age | #72 |
digital health intervention | #72 |
learning disorders | #72 |
disorders childhood | #73 |
cellular models | #73 |
etiological | #73 |
youth | #73 |
adhd medications | #73 |
3372 | #73 |
schizophrenia genetics | #73 |
patients rest | #73 |
anxiety adhd | #73 |
relapse depression | #73 |
candidate endophenotypes | #73 |
cortical abnormalities | #73 |
adult | #73 |
poison control centers | #73 |
adhd subtype | #73 |
kagan | #73 |
logodds | #73 |
age schizophrenia | #74 |
allele association | #74 |
preferential transmission | #74 |
pfkfb2 | #74 |
reaction time variability | #74 |
based diagnosis | #74 |
desipramine | #74 |
transmission disequilibrium | #74 |
efficacy outcome | #75 |
neale | #75 |
linkage schizophrenia | #75 |
child china | #75 |
mind wandering | #75 |
onset anxiety | #75 |
adhd traits | #75 |
risk sample | #75 |
weight body mass | #75 |
slc1a1 | #75 |
referred | #75 |
antisocial | #75 |
akl | #75 |
drd4 gene | #75 |
impairment children | #75 |
hyperactivity adhd | #75 |
chronic tic | #76 |
child depressive | #76 |
child humans | #76 |
depression pregnancy | #76 |
yates | #76 |
adhd total | #76 |
positive schizotypy | #76 |
schizophrenia young | #76 |
centers disease control | #76 |
disorders brain | #76 |
nondeficit | #76 |
performance schizophrenia | #77 |
wcst performance | #77 |
performance adhd | #77 |
atomoxetine children | #77 |
lod score | #77 |
psychological male | #77 |
childhood adhd | #77 |
cortex schizophrenia | #77 |
predixcan | #78 |
pharmacologic treatments | #78 |
women antidepressants | #78 |
adhd impairment | #78 |
local gyrification | #78 |
disorders female | #78 |
bpi | #78 |
bipolar disorder adhd | #78 |
rare copy | #78 |
nosological | #79 |
schizophrenic patients | #79 |
studies relationship | #79 |
genetic linkage studies | #79 |
anxiety separation | #79 |
additive effects | #79 |
cardinal | #79 |
patients adhd | #79 |
obesity metabolic syndrome | #79 |
student athletes | #79 |
n46 | #79 |
disorder panic | #79 |
retrospective assessment | #79 |
age adhd | #79 |
pregnancy mothers | #79 |
total brain | #80 |
maternal smoking | #80 |
adhd drugs | #80 |
adhd rats | #80 |
siblings schizophrenia | #80 |
linkage chromosome | #80 |
clinical interview | #80 |
major diagnostic | #81 |
interregional profiles | #81 |
pathophysiology adhd | #81 |
treatment adults | #81 |
endophenotypes | #81 |
bipolar disorder | #81 |
disliking | #81 |
oral routes | #81 |
body mass diabetes | #81 |
hacking | #81 |
subcortical brain volumes | #81 |
differences age | #81 |
children parents | #81 |
eyhs | #81 |
comorbidity survey | #82 |
square distribution | #82 |
frontopolar cortex | #82 |
association maternal smoking | #82 |
genes pathways | #82 |
adults asd | #82 |
comorbidity disorders | #82 |
behavior assessment | #82 |
symptoms diagnosis | #82 |
cumulative evidence | #82 |
gene schizophrenia | #82 |
impaired quality life | #82 |
auditory verbal | #82 |
oros | #83 |
disorders anxiety | #83 |
illness | #83 |
management adhd | #83 |
multifactorial inheritance | #83 |
substance disorders | #83 |
tests risk | #83 |
adult form | #83 |
unreliability | #83 |
neurocognitive functioning | #83 |
paterson | #83 |
15q133 | #84 |
complex disorder | #84 |
21 months | #84 |
women adhd | #84 |
adhd adhd symptoms | #84 |
adhd subtypes | #85 |
wide significance | #85 |
atomoxetine | #85 |
adhd assessment | #85 |
humans risk | #85 |
monitoring response | #85 |
linkage loci | #85 |
genomics consortium | #85 |
brain asymmetry | #85 |
hyperkinetic disorder | #85 |
buprenorphine maintenance | #85 |
adhdrsiv | #85 |
european samples | #85 |
recycling endosome | #85 |
9r | #85 |
child conduct | #86 |
pord | #86 |
affective psychosis | #86 |
paranoid | #86 |
siblings children | #86 |
humans inhibition | #86 |
findings implications | #86 |
parents | #86 |
risk alleles | #87 |
3utr | #87 |
ptsd trauma | #87 |
bipolar | #87 |
bipolar spectrum disorder | #87 |
comparison children | #87 |
synaptosomal protein | #87 |
n203 | #87 |
putamen volume | #87 |
common risk | #88 |
drug effects | #88 |
hyperkinetic | #88 |
bonferroni correction | #88 |
druggable | #88 |
comorbid psychopathology | #88 |
euphoric | #89 |
chrna2 | #89 |
machine learning analysis | #89 |
empirically | #89 |
caars | #89 |
auditory attention | #89 |
metaanalytic review | #89 |
nucleotide schizophrenia | #89 |
2455 | #89 |
prenatal nicotine exposure | #89 |
22 studies | #89 |
comprehensive identification | #89 |
male neuropsychological | #90 |
verbal ability | #90 |
pervasive | #90 |
linkage genome | #90 |
association metaanalysis | #90 |
antidepressants pregnancy | #90 |
snps haplotypes | #90 |
242 | #90 |
watt | #90 |
attention deficit hyperactivity | #90 |
1month | #90 |
callousness | #91 |
naturalistic study | #91 |
assertion | #91 |
wcst | #91 |
parental socioeconomic status | #91 |
adhd males | #91 |
cortical brain | #91 |
adhd treatments | #91 |
adhd efficacy | #91 |
complicates | #91 |
identified studies | #91 |
treatment mania | #92 |
h2snp | #92 |
documenting | #92 |
adults schizophrenia | #92 |
studies association | #92 |
candidate gene | #92 |
studies sex | #92 |
raise | #92 |
controls participants | #93 |
referral consultation | #93 |
standardized differences | #93 |
rate adult | #93 |
ymrs | #93 |
lifetime cannabis | #93 |
narrowly | #93 |
social development | #94 |
gottman | #94 |
hfasd | #94 |
underachievement | #94 |
growing body | #94 |
gprc5b | #94 |
cdh13 | #94 |
sustained attention | #94 |
performance variability | #94 |
adhd measures | #94 |
aldh1l1 | #94 |
hyperactivity autistic | #94 |
brain case | #94 |
total brain volume | #95 |
executive | #95 |
cadps2 | #95 |
infa | #95 |
adolescents bipolar | #95 |
minisatellite | #95 |
asd study | #95 |
studies differences | #95 |
mdd bip | #95 |
phenotype polymorphism | #96 |
uvntr | #96 |
nominally | #96 |
scq | #96 |
chromosome 9q34 | #96 |
behavior rating inventory | #96 |
nxph1 | #96 |
hcadherin | #97 |
adolescent onset | #97 |
genome‐wide association study | #97 |
7q36 | #97 |
studies asthma | #97 |
children tics | #97 |
low cardiorespiratory fitness | #97 |
syn2 | #98 |
concerta | #98 |
hyperactivity brazil | #98 |
oppositionality | #98 |
bipolar disorder risk | #98 |
nonfamilial | #98 |
identically | #98 |
induced hyperalgesia | #98 |
driving behavior | #98 |
single nucleotide receptor | #98 |
massachusetts general hospital | #98 |
linkage study | #98 |
wdpcp | #98 |
abuse potential | #99 |
medication effects | #99 |
disease genetics | #99 |
neurodevelopmental processes | #99 |
adhd role | #99 |
motor timing | #99 |
nonspecificity | #99 |
chd6 | #99 |
substrains | #99 |
disorder diagnosis | #99 |
xp114 | #99 |
metaanalysis trials | #99 |
methodssubjects | #99 |
psychoactive | #99 |
12year | #100 |
clinical effects | #100 |
adhd methylphenidate | #100 |
reticence | #100 |
obesity abdominal obesity | #100 |
hippocampal subfield volumes | #100 |
pelham | #100 |
terror | #100 |
torture | #101 |
harlan | #101 |
diagnostic boundaries | #101 |
depression pregnant women | #101 |
cosegregation | #101 |
roh | #101 |
genomewide | #101 |
schizophrenia psychotic | #101 |
addictive drugs | #101 |
genetic risk scores | #101 |
advanced paternal age | #101 |
slc6a4 gene | #101 |
tsls | #101 |
neurocognitive impairments | #101 |
empirical test | #101 |
upsit | #101 |
disorder psychiatric | #102 |
klf13 | #102 |
individuals aud | #102 |
inhibition psychological | #102 |
sob | #102 |
male neuropsychological tests | #102 |
parents offspring | #102 |
functional pathways | #102 |
treatment seeking | #102 |
clinical picture | #103 |
genetic pedigree polymorphism | #103 |
pgc | #103 |
symptom profile | #103 |
genome wide association | #103 |
touchstone | #103 |
ocd children | #103 |
schizophrenia mood disorders | #103 |
patients 12 months | #103 |
individual sites | #104 |
controlled studies | #104 |
schizophrenia metaanalysis | #104 |
1934 | #104 |
genomic region | #104 |
motor competence | #104 |
tourette disorder | #104 |
genetic mechanism | #104 |
schizophrenia probands | #105 |
drug dyskinesia | #105 |
academic problems | #105 |
school dropout | #105 |
adhd review | #105 |
dsmiv diagnosis | #105 |
current article | #105 |
neuropsychological dysfunction | #105 |
humans lod | #106 |
children methylphenidate | #106 |
cogs | #106 |
children odd | #106 |
lenticular | #107 |
consecutive sample | #107 |
daao | #107 |
matter volumes | #107 |
adolescents bipolar disorder | #107 |
chronic tic disorders | #107 |
disorder female | #107 |
oral methylphenidate | #107 |
mothers adhd | #107 |
λs | #107 |
growth outcomes | #107 |
sequential analysis | #107 |
ldn | #107 |
functional correlates | #107 |
site differences | #108 |
proband | #108 |
origin effects | #108 |
pervasive developmental | #108 |
pediatric psychopharmacology | #108 |
aged psychiatric | #108 |
n197 | #108 |
918 | #108 |
nesarc | #108 |
maternal warmth | #108 |
association cigarette smoking | #108 |
antimanic agents | #108 |
afni | #108 |
symptoms childhood | #108 |
total scores | #109 |
irrespective | #109 |
adhd medication | #109 |
longitudinal trajectories | #109 |
worthy | #109 |
psychosis proneness | #109 |
neuroleptic medication | #109 |
gabra6 | #109 |
depression bipolar | #109 |
risk bipolar disorder | #109 |
adult adhd symptoms | #110 |
markers genome | #110 |
adhd parent | #110 |
enlistment | #110 |
linkage association | #110 |
rat models | #110 |
dimorphisms | #111 |
5httlpr genotype | #111 |
symptom ratings | #111 |
n107 | #111 |
affective psychoses | #111 |
dao | #111 |
selective reporting | #111 |
affective symptoms | #111 |
dopamine d4 receptors | #112 |
factors social | #112 |
brain gene expression | #112 |
childhood risk factors | #112 |
bipolar parents | #112 |
unmedicated | #112 |
substantial proportion | #112 |
impact exposure | #112 |
independent studies | #112 |
pediatric obsessive | #112 |
xr | #113 |
male prevalence | #113 |
neuropsychological functions | #113 |
cronbach | #113 |
functional neuroanatomy | #114 |
comorbid anxiety | #114 |
omim | #114 |
analysis statistical | #114 |
schizophrenia severity | #115 |
n34 | #115 |
nuclear families | #115 |
genet | #115 |
endorsed | #115 |
–r | #115 |
liability | #115 |
formulating | #116 |
schizophrenic psychology | #116 |
wm abnormalities | #116 |
neuropsychological | #116 |
diseases twins | #116 |
polygenic association | #117 |
trait impulsivity | #117 |
neurocognitive endophenotypes | #117 |
z29 | #117 |
current symptoms | #117 |
coordinated analysis | #117 |
prenatal smoking | #117 |
unipolar | #117 |
quality life outcomes | #117 |
grandiosity | #118 |
prevention science | #118 |
satisfaction questionnaire | #118 |
genetic receptor serotonin | #118 |
large study | #118 |
grandfathers | #118 |
major female | #118 |
definitively | #118 |
spm2 | #118 |
academic functioning | #118 |
schizophrenia linkage | #119 |
method data | #119 |
dopaminergic genes | #119 |
midadolescence | #119 |
efd | #119 |
naa ratio | #119 |
misunderstandings | #120 |
differences children | #120 |
t01 | #120 |
disorder autism | #121 |
n108 | #121 |
neurocognitive deficits | #121 |
aunts | #121 |
subfield volumes | #121 |
cgibp | #121 |
new avenues | #121 |
remittance | #121 |
disregard | #122 |
neuropsychiatric disorders | #122 |
msit | #122 |
disorder depressive | #122 |
v11 | #122 |
structural brain alterations | #122 |
refute | #122 |
urvs | #122 |
pabs | #122 |
adhd comorbidity | #122 |
anxious | #122 |
levels adhd | #122 |
psychopathology symptoms | #122 |
male risk | #122 |
brain alterations | #122 |
schizoaffective | #122 |
wechsler | #123 |
adhd ocd | #123 |
chr psychosis | #123 |
clinical status | #123 |
age initiation | #123 |
adcy2 | #123 |
9q34 | #124 |
g×s interaction | #124 |
twothirds | #124 |
maximum lod score | #124 |
p097 | #124 |
longitudinal sample | #124 |
attention regulation | #124 |
wechsler intelligence scale | #124 |
trios | #124 |
drug placebo | #124 |
treatment subjects | #124 |
laboratory observations | #124 |
machine learning prediction | #125 |
anxiety problems | #125 |
disorder risk | #125 |
psychosis individuals | #125 |
segregation analysis | #125 |
patients chronic schizophrenia | #125 |
caregiver strain | #125 |
developmental aspects | #126 |
positive negative symptoms | #126 |
complex genetics | #126 |
parent version | #126 |
odd conduct disorder | #126 |
drug disorders | #126 |
biological parents | #126 |
memory adhd | #126 |
familial influences | #126 |
psychiatric diagnoses | #127 |
attention child | #127 |
disinhibited | #127 |
genes | #127 |
adult alleles | #127 |
taiwanese population | #127 |
stevenson | #127 |
drd2 | #127 |
neuropsychological measures | #128 |
aged 6 | #128 |
opiate antagonists | #129 |
familial | #129 |
n102 | #129 |
behavioral outcome | #129 |
implicate | #129 |
intactness | #129 |
personality assessment | #129 |
1990a | #130 |
families | #130 |
retrospective data analysis | #130 |
adhd inattention | #130 |
kinesthesia | #131 |
snps | #131 |
incapacitation | #131 |
pair 15 chromosomes | #131 |
animals attention | #131 |
bip mdd | #131 |
moderating effects | #131 |
differed | #131 |
strong evidence | #131 |
adolescents ocd | #131 |
register study | #131 |
mood anxiety disorders | #131 |
p074 | #132 |
learning disabilities | #132 |
late adolescents | #132 |
entire brain | #132 |
hkd | #132 |
childhood anxiety disorders | #132 |
large european cohort | #132 |
child cognition | #132 |
n79 | #132 |
linkage humans | #132 |
sodas | #132 |
male prospective | #132 |
heroin dependence | #133 |
mph | #133 |
onset bipolar disorder | #133 |
vntr | #134 |
children adults | #134 |
disorders social | #134 |
preliminary examination | #134 |
male massachusetts | #135 |
social deficits | #135 |
association analyses | #135 |
social environments | #136 |
tspan8 | #136 |
adolescents young | #136 |
olfactory identification | #136 |
firstborns | #136 |
relied | #136 |
risk factors smoking | #136 |
sorcs3 | #136 |
adolescent bipolar | #137 |
association asthma | #137 |
expressed emotion | #137 |
psychological male memory | #137 |
gaming | #137 |
longitudinal evidence | #137 |
schizophrenia affective disorders | #137 |
memantine treatment | #137 |
studies examined | #137 |
biomarkers diagnosis | #138 |
mtor activation | #138 |
asds | #138 |
6q | #138 |
control individuals | #138 |
evidence association | #138 |
n129 | #139 |
fhr | #139 |
symptoms disorders | #139 |
mgh | #139 |
neuropsychiatric | #139 |
schizophrenia studies | #139 |
meet | #139 |
schizotypal traits | #140 |
parental anxiety | #140 |
n115 | #140 |
intriguing | #140 |
emotional symptoms | #141 |
disorder comorbidity | #141 |
prss | #141 |
haplotype block | #141 |
genetic vulnerability | #141 |
disorders psychotic | #142 |
covid19 restrictions | #142 |
22q112 deletion syndrome | #142 |
5ht1b receptors | #142 |
neurotrophic | #142 |
disorders personality | #142 |
molecular genetics | #143 |
peripheral biomarkers | #143 |
conduct | #143 |
hydrogen exchangers | #143 |
fetal movement | #143 |
risk factors obesity | #143 |
humans linear | #144 |
g72 | #144 |
child psychopathology | #144 |
agents tricyclic | #144 |
diagnosed attention | #144 |
rfg | #144 |
diagnostic procedure | #144 |
statistical female humans | #144 |
elston | #144 |
blind study | #144 |
common genetic variants | #145 |
affs | #145 |
n105 | #145 |
major psychoses | #145 |
pcb exposure | #145 |
early initiation | #145 |
genome‐wide association studies | #145 |
p00018 | #145 |
individual symptoms | #145 |
studies depressive | #145 |
drug alcohol | #145 |
genetic heterogeneity | #145 |
adult psychopathology | #146 |
twin studies | #146 |
atypicality | #146 |
intelligence quotient | #146 |
warranted | #146 |
prenatal nicotine | #146 |
oppositional behavior | #146 |
genders | #146 |
abbreviated | #147 |
p0016 | #147 |
intraindividual variability | #147 |
lras | #147 |
histrionic | #147 |
comprising | #147 |
sabp | #148 |
single locus | #148 |
basc | #148 |
cognitive variables | #148 |
adolescent young | #148 |
adhd symptoms children | #149 |
schizotypy | #149 |
cdrsr | #149 |
risk mdd | #149 |
brain correlates | #149 |
parental substance | #149 |
impulsive | #150 |
chrnb2 | #150 |
highlighting | #150 |
adhd relationship | #150 |
sud treatment | #150 |
nonmedical | #150 |
categorical | #150 |
higher burden | #151 |
consisted | #151 |
synaptic biology | #151 |
functional impairment | #152 |
implicates | #152 |
httlpr | #152 |
autistic traits | #152 |
undegraded | #152 |
parent report | #152 |
diagnostic systems | #152 |
increases risk | #152 |
linkage disequilibrium mapping | #152 |
large sample | #152 |
metaanalytic | #152 |
copy variants cnvs | #152 |
xq21 | #152 |
atxn1 | #152 |
schizophrenia diagnosis | #152 |
placebo subjects | #152 |
alcohol conditions | #153 |
marginally | #153 |
genomewide linkage | #153 |
schizophrenia bipolar disorder | #153 |
caucasian children | #153 |
schizophrenia deficits | #153 |
demoralization | #153 |
5 httlpr | #153 |
editions | #153 |
humans learning | #153 |
disorder phenotype | #154 |
emphasizing | #154 |
schizophrenia magnetic resonance | #154 |
wisc | #154 |
atomoxetine placebo | #154 |
exposure maternal | #154 |
dsm | #154 |
snpheritability | #155 |
humans polymorphism | #155 |
clarification | #155 |
ncsr | #155 |
genomewide scan | #155 |
year follow | #155 |
genetic risk | #156 |
interpersonal functioning | #156 |
tests male | #156 |
n84 | #156 |
600000 | #156 |
prospective controlled study | #156 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
new knowledge | #157 |
dopamine d4 | #157 |
ppp2r2b | #158 |
clinical diagnostic | #158 |
greatest | #158 |
adolescents | #158 |
sledai | #158 |
myo5b | #158 |
primary setting | #158 |
htr2c | #158 |
genetic linkage | #158 |
cognitive tempo | #158 |
drd4 genotype | #158 |
oprm1 | #158 |
nonpersistent | #159 |
quetiapine treatment | #159 |
patients substance | #159 |
teachers parents | #159 |
dav | #159 |
adult human brain | #159 |
selfratings | #159 |
humans impulsive | #160 |
separation anxiety disorder | #160 |
age onset | #160 |
smds | #160 |
medial temporal | #160 |
population samples | #161 |
hyperactivity disorders | #161 |
tic symptoms | #161 |
schizophrenia bipolar | #161 |
adult adhd patients | #161 |
behavioral difficulties | #161 |
genetic component | #161 |
cooccurring disorders | #162 |
rats wky | #162 |
disorder clinical | #162 |
empirical tests | #162 |
disorder depression | #162 |
140 | #162 |
ksadspl | #162 |
dn cells | #163 |
5htt | #163 |
dsmiv | #163 |
paternal age | #163 |
neurobiology | #163 |
neuropsychological tests | #163 |
sample | #163 |
anxiety attention | #164 |
diagnostic status | #164 |
illness schizophrenia | #164 |
impairments | #164 |
complex phenotype | #164 |
familial liability | #164 |
years children | #165 |
risk subsequent | #165 |
neurocognitive performance | #165 |
washington university | #165 |
boys girls | #165 |
linkage genetic | #166 |
antidepressant therapy | #166 |
domain criteria | #166 |
symptom reduction | #166 |
alcohol disorders aud | #166 |
shared environment | #166 |
cotwins | #166 |
receptor gene | #166 |
12–14 | #166 |
earlyonset schizophrenia | #166 |
genetic influence | #166 |
ipsych | #167 |
moderates | #167 |
association obesity | #167 |
children 6 years | #168 |
wisciii | #168 |
polygenic architecture | #168 |
neurocognitive functions | #168 |
leonard | #168 |
duration illness | #169 |
perseverations | #169 |
multifactorial | #169 |
matter microstructure | #169 |
n111 | #169 |
international congress | #169 |
genetic association analysis | #169 |
conditional probability | #170 |
single nucleotide schizophrenia | #170 |
risk gene | #170 |
traumas | #170 |
lgi | #170 |
disorders young | #170 |
arrb2 | #170 |
anxiety child | #170 |
cfg | #170 |
pharmacodynamic properties | #170 |
functional laterality humans | #171 |
genesets | #171 |
child psychiatry | #171 |
n91 | #171 |
treatment studies | #172 |
immune disorders | #172 |
inattention impulsivity | #172 |
enuresis | #173 |
disorders study | #173 |
interpersonal sensitivity | #173 |
male mental | #174 |
gabbr1 | #174 |
large samples | #175 |
tics | #175 |
subsyndromal | #175 |
development schizophrenia | #176 |
confounds | #176 |
mph placebo | #176 |
hyperactive children | #177 |
confounded | #177 |
ascertainment | #177 |
kraepelin | #177 |
disorders sex | #177 |
suicide death | #177 |
independent datasets | #177 |
patients opioid | #177 |
cortical surface | #178 |
n78 | #178 |
parent rated | #178 |
strong genetic component | #178 |
behaviorally | #179 |
underpinnings | #179 |
pregnancy children | #179 |
atomoxetine atx | #179 |
genetic confounding | #179 |
strongest evidence | #179 |
gene interactions | #179 |
connectivity networks | #180 |
nagelkerke | #180 |
cvlt | #180 |
copy variants | #180 |
perceptual disorders | #181 |
mothers pregnancy | #181 |
unemotional traits | #181 |
combinatory | #181 |
htr4 | #182 |
scz bip | #182 |
control participants | #182 |
phenocopies | #182 |
271 | #182 |
structured | #182 |
psychometric testing | #183 |
studies gwas | #183 |
mechanistic target | #183 |
genotype humans | #183 |
rating | #183 |
wei | #184 |
reading difficulties | #184 |
effects atomoxetine | #184 |
based morphometry | #184 |
phenocopy | #185 |
pdd | #185 |
reward sensitivity | #185 |
genome human | #185 |
allison | #185 |
long acting | #185 |
n‐acetylcysteine | #185 |
218 | #186 |
biomarker studies | #186 |
predominately | #186 |
statistical female | #186 |
hyperactivity symptoms | #186 |
risperidone placebo | #187 |
schizophrenia evidence | #187 |
schizophrenia major depression | #187 |
stratifying | #187 |
blood biomarkers | #188 |
depression treatment | #188 |
enigma | #188 |
3 untranslated region | #188 |
parahippocampus | #188 |
autocorrelation | #188 |
undertreatment | #189 |
bna | #189 |
differential association | #189 |
genetic correlations | #189 |
scwt | #190 |
medication adhd | #190 |
linkage evidence | #190 |
functioning children | #190 |
childhood | #190 |
mood disorder | #191 |
schedule female | #191 |
mph children | #191 |
psychiatric phenotypes | #191 |
fsiq | #191 |
dopamine genes | #191 |
social dysfunction | #191 |
greater activation | #191 |
implicated | #191 |
clarify | #191 |
association response | #192 |
612 years | #192 |
iasp | #192 |
joseph | #194 |
freedman | #194 |
inconsistent findings | #194 |
placebo p001 | #195 |
polymorphisms snps | #195 |
cognitive endophenotypes | #195 |
clinical global | #195 |
sza | #195 |
overactivity | #197 |
dependence symptoms | #197 |
arhgef9 | #197 |
neural substrates | #197 |
wm performance | #197 |
perinatal complications | #197 |
developmentally | #198 |
lifetime diagnosis | #198 |
mdd scz | #198 |
g×s | #198 |
snps schizophrenia | #198 |
ptk2b | #198 |
male | #199 |
raises | #199 |
bsd | #199 |
male phenotype | #199 |
specific genes | #199 |
asic1a | #199 |
childhood symptoms | #199 |
childhood attention | #200 |
asd adhd | #200 |
neuropsychological battery | #200 |
small samples | #200 |
mri data | #200 |
disruptive disorders | #200 |
parents schizophrenia | #201 |
disorder humans | #201 |
functional genomics | #201 |
catecholomethyltransferase | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
stopsignal task | #203 |
unaffected | #203 |
childhood adulthood | #203 |
genetic liability | #203 |
neuropsychological correlates | #203 |
control association | #203 |
pdq | #203 |
concurrent validity | #204 |
extend | #204 |
respond | #204 |
microsatellite marker | #204 |
schizophreniform | #204 |
attentional control | #204 |
adolescent psychiatry | #204 |
uptodate | #206 |
genes risk | #206 |
nonshared | #206 |
selfdirectedness | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
prkg1 | #208 |
prolactin levels | #208 |
susceptibility schizophrenia | #208 |
parental alcohol | #208 |
variable expression | #209 |
baseline follow | #209 |
clinical benefits | #209 |
60mg | #210 |
correspondence | #210 |
maudsley | #210 |
5year followup | #210 |
acds | #210 |
park2 | #210 |
n96 | #210 |
predisposition disease | #211 |
vntr polymorphism | #211 |
greater risk | #211 |
dimensional models | #212 |
hkdc1 | #212 |
ps005 | #212 |
grm7 | #212 |
adult patients adhd | #212 |
stroop task | #212 |
apoe4 allele | #212 |
trauma ptsd | #213 |
sampling strategy | #213 |
sought | #213 |
negative outcomes | #213 |
replication studies | #213 |
schizophrenia chinese | #214 |
cvltii | #214 |
disorders models | #214 |
rare cnvs | #214 |
suggestive evidence | #214 |
humans neuropsychological | #214 |
continuous performance test | #214 |
male mental disorders | #215 |
lifetime version | #215 |
bilag | #215 |
adult cognition | #215 |
functional mri study | #216 |
vivo correlation | #216 |
male schizophrenia | #217 |
chromosome 15 | #217 |
glr | #217 |
antisocial personality | #217 |
gene based | #218 |
parental | #218 |
hippocampal subfield | #218 |
trim31 | #218 |
panic | #218 |
polygenic | #219 |
study selection | #219 |
misunderstood | #219 |
snpa | #220 |
normal controls | #220 |
drug double | #220 |
symptoms adults | #221 |
telephone interview | #221 |
triangularis | #221 |
irritable mood | #221 |
parental psychopathology | #221 |
studies cognition | #221 |
patient engagement | #222 |
score male | #222 |
diagnoses | #222 |
childhoodonset | #222 |
methyltransferase comt | #222 |
n76 | #222 |
revisited | #223 |
learning disability | #223 |
study findings | #223 |
effective treatments | #224 |
adhd sleep | #224 |
abnormalities schizophrenia | #224 |
axis disorders | #224 |
sensing ion | #224 |
gria2 | #224 |
bipolar spectrum | #225 |
default network | #225 |
coordination disorder | #225 |
inattentiveness | #226 |
subfields | #226 |
children placebo | #226 |
hk3 | #226 |
disorder study | #227 |
individual variability | #227 |
dependent variables | #227 |
unemotional | #227 |
subcortical regions | #227 |
criteria diagnosis | #227 |
scales psychotic | #227 |
control based | #228 |
male twins | #228 |
age subjects | #228 |
atomoxetine treatment | #228 |
comorbid anxiety disorders | #228 |
birth complications | #229 |
structural abnormalities | #229 |
overlapped | #229 |
equally | #229 |
psychiatric outcomes | #230 |
commission errors | #231 |
risk indicators | #231 |
heritable | #231 |
4years | #231 |
international multicenter | #231 |
hyperactivity behavior | #232 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
worse performance | #234 |
candidate genes | #234 |
study sample | #234 |
disorder medication | #235 |
probabilistic forecasts | #235 |
discriminating | #235 |
shr wky rats | #236 |
reliably | #238 |
fifty years | #238 |
agoraphobia | #238 |
route administration | #238 |
placebo response | #238 |
allelic heterogeneity | #239 |
healthy siblings | #240 |
acid oxidase | #240 |
pdag | #240 |
nosology | #240 |
scientific data | #240 |
patients siblings | #240 |
symptoms quality | #241 |
adequately | #241 |
doubleblind | #241 |
disorder asd | #241 |
adolescent offspring | #241 |
reward processing | #242 |
sodium hydrogen | #242 |
psychiatric comorbidities | #242 |
joint analysis | #242 |
impulsive choice | #242 |
neurodevelopmental model | #242 |
aggressive behaviors | #243 |
valid | #243 |
onset obsessive | #243 |
patients relatives | #243 |
female | #243 |
n74 | #244 |
giftedness | #244 |
population differences | #245 |
adversity | #245 |
interregional | #245 |
5ht2a receptor | #245 |
paliperidone | #245 |
disorder ptsd | #245 |
dsmivtr | #246 |
cadm2 | #246 |
expression genetic | #246 |
community controls | #246 |
motor performance | #247 |
812 | #247 |
chinese families | #248 |
epigenetic studies | #248 |
studies associations | #248 |
cigarette smoking | #248 |
developmental disorder | #249 |
behavioral characteristics | #251 |
childs | #251 |
german patients | #252 |
hypoactivation | #252 |
intellect | #253 |
genomewide association | #253 |
female subjects | #253 |
tourette | #253 |
iqs | #253 |
kappas | #254 |
study schizophrenia | #254 |
benzodiazepine | #254 |
schizophrenia adult | #254 |
studies metaanalysis | #254 |
cpt performance | #254 |
conduct problems | #255 |
cacna1c gene | #256 |
biochemical studies | #256 |
larsson | #256 |
shared genetic | #256 |
carlson | #257 |
children adhd symptoms | #257 |
parental depression | #259 |
year study | #259 |
endorsement | #259 |
n61 | #260 |
piq | #260 |
pharmacotherapy | #261 |
anxiety depressive disorders | #261 |
dexamphetamine | #261 |
diagnosis | #261 |
sex factors | #263 |
genomewide linkage scan | #263 |
22q11ds | #263 |
obsessive compulsive disorder | #263 |
selfreports | #263 |
fluid intelligence | #263 |
confirm | #264 |
disorder personality | #264 |
conceptualized | #264 |
distinct subtypes | #264 |
attention problems | #264 |
adverse health | #264 |
long term outcomes | #265 |
schizophrenia cases | #266 |
ptsd risk | #266 |
diagnostic validity | #266 |
5090 | #266 |
new models | #266 |
phenotype schizophrenia | #267 |
scz mdd | #267 |
neuropsychological impairment | #268 |
diagnosis schizophrenia | #268 |
strong support | #268 |
genetic approaches | #268 |
years baseline | #269 |
diagnostic process | #269 |
test scores | #269 |
age effects | #270 |
phlda1 | #270 |
segregate | #270 |
largest | #270 |
withdrawn | #270 |
circadian genes | #271 |
genetic overlap | #271 |
sibling pairs | #271 |
adult psychiatric | #271 |
symptoms assessed | #271 |
social adversity | #271 |
diagnostic issues | #272 |
structural brain | #272 |
4year | #273 |
statistics topic | #273 |
szs | #273 |
alcohol smoking | #273 |
search terms | #273 |
rora | #273 |
444 | #273 |
schizophrenia siblings | #273 |
age | #273 |
sleep behavior | #274 |
22 years | #274 |
reading disability | #275 |
surgency | #275 |
underlie | #275 |
maf1 | #275 |
missingness | #276 |
t102c | #276 |
familial schizophrenia | #276 |
2q | #276 |
adolescent risk | #277 |
mania symptoms | #277 |
nicotinic schizophrenia | #277 |
adhd healthy controls | #277 |
growing evidence | #277 |
synaptosomal | #278 |
manual | #278 |
clinical setting | #278 |
early psychosis | #278 |
nr3c1 | #278 |
ocd | #279 |
intelligence scale | #279 |
nicotine dependence | #279 |
silico approach | #279 |
remitted | #280 |
rating scale | #280 |
n47 | #280 |
polygenic risk | #280 |
cognition female | #280 |
abuser | #280 |
acting | #280 |
child parent | #280 |
brain volumes | #280 |
disorders adult | #281 |
individuals | #281 |
psychotic bipolar | #281 |
phenotyped | #281 |
premature death | #281 |
5ht1b | #282 |
response inhibition | #282 |
collaborative analysis | #282 |
reading problems | #282 |
onset ocd | #282 |
antisocial behaviors | #283 |
titrated | #283 |
velo | #283 |
continue | #283 |
aspd | #284 |
neoffi | #285 |
3untranslated region | #285 |
gria3 | #285 |
neuroanatomical | #285 |
normal variation | #285 |
quantitative traits | #285 |
scale children | #286 |
clues | #286 |
explication | #286 |
quantitative analyses | #286 |
swanson | #286 |
siblings patients | #286 |
effects age | #287 |
schizophrenia abnormalities | #288 |
deficit schizophrenia | #288 |
postmortem brain | #289 |
bmisds | #289 |
psychiatric traits | #290 |
pediatric ocd | #290 |
disease haplotypes | #290 |
22q112 | #290 |
low serum levels | #291 |
subcortical volumes | #291 |
publication bias | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
cognition disorders | #294 |
subjective responses | #294 |
salary | #294 |
hypertensive rat | #294 |
post‐traumatic stress disorder | #295 |
risk factors children | #295 |
dtnbp1 | #295 |
interference control | #295 |
european populations | #295 |
psychosis schizophrenia | #295 |
adverse impact | #295 |
ldsc | #296 |
continuous performance | #296 |
executive functions | #296 |
asd traits | #297 |
anxiety disorder | #297 |
obesity overweight | #297 |
early onset | #297 |
reanalysis | #298 |
discriminated | #298 |
diagnostic approach | #298 |
predisposition | #299 |
negative symptom | #299 |
qvalues | #300 |
cortical thickness | #300 |
effects stress | #300 |
roc analysis | #301 |
psychiatric hospitalization | #301 |
cognitive measures | #301 |
intrasubject variability | #302 |
prefrontal function | #302 |
states adolescent | #302 |
published literature | #302 |
emotional problems | #302 |
permuted | #303 |
psychometrics | #303 |
height body | #303 |
psychiatric conditions | #304 |
795 | #304 |
case subjects | #305 |
manifest | #305 |
ats | #305 |
interviewers | #305 |
affective disorders | #305 |
aggressive behavior | #305 |
dsm5 | #305 |
early morning | #306 |
dopamine transporter | #306 |
learning disorder | #307 |
n62 | #307 |
general psychopathology | #308 |
membrane transport | #309 |
documented | #309 |
perseveration | #309 |
spencer | #309 |
gene environment | #309 |
omission errors | #309 |
myh9 | #309 |
adolescent aggression | #310 |
life social support | #310 |
efficacy treatment | #310 |
memory wm | #310 |
motor domain | #310 |
genetic schizophrenia | #310 |
rdoc | #311 |
childhood adolescence | #312 |
stroop test | #312 |
gender age | #312 |
mainstays | #312 |
npsr1 | #313 |
mapping female | #313 |
genetic analyses | #314 |
underscore | #314 |
bedtimes | #315 |
risk estimation | #315 |
asb | #317 |
replicated | #317 |
dorsolateral prefrontal cortex | #317 |
schizophrenia review | #318 |
demonstrable | #318 |
n55 | #319 |
individual genes | #319 |
5ht2c | #319 |
adolescent adrenergic | #320 |
intelligence tests | #321 |
shared genetic influences | #321 |
addictive disorders | #321 |
gene | #321 |
127 | #322 |
risperidone treatment | #322 |
humans longitudinal | #322 |
bipolar type | #322 |
robins | #322 |
time variability | #323 |
abusers | #323 |
conceptual models | #324 |
nolan | #324 |
guanfacine | #324 |
manic | #325 |
sex characteristics | #326 |
yielded | #326 |
neonatal abstinence syndrome | #326 |
spurious | #327 |
impaired | #327 |
xq26 | #327 |
status female | #327 |
comprised | #328 |
etiologic | #328 |
8q | #329 |
disorders pervasive | #329 |
overrepresented | #330 |
metaanalyses | #330 |
sexdifferences | #330 |
htr2a | #331 |
scores patients | #331 |
drug response | #331 |
women schizophrenia | #332 |
familial factors | #333 |
txndc5 | #333 |
naltrexone | #333 |
expression brain | #333 |
obesity diabetes | #334 |
cognitive dysfunctions | #334 |
multiple comparisons | #334 |
adler | #335 |
24weeks | #335 |
forthcoming | #335 |
mood disorders | #335 |
persist | #336 |
methylphenidate placebo | #336 |
inferior parietal lobule | #336 |
humans mental | #336 |
rey | #336 |
neuropsychological test | #337 |
asd individuals | #337 |
mobp | #337 |
777 | #337 |
tph2 | #337 |
disentangle | #338 |
psychopathological | #339 |
evening | #339 |
patients attention | #339 |
replications | #339 |
consistently | #340 |
disorder ocd | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
pnmt | #340 |
placebo effects | #341 |
intelligence | #341 |
encompassing | #341 |
treatment bipolar | #341 |
maoa genotype | #342 |
multicenter analysis | #342 |
neuroimaging studies | #342 |
bipolarity | #342 |
phobic | #342 |
visual memory | #342 |
frontal pole | #344 |
tbv | #344 |
comorbid diagnoses | #344 |
schizoaffective disorder | #344 |
mood problems | #344 |
integrated analysis | #344 |
casecontrol studies | #345 |
systematically | #345 |
catechol methyltransferase | #345 |
gifts | #346 |
864 | #346 |
mdd bpd | #347 |
confused | #347 |
study genotype | #347 |
tic severity | #348 |
psychotic | #348 |
converging | #348 |
temporal processing | #349 |
schizotypal personality disorder | #349 |
collaborative study | #349 |
methylphenidate atomoxetine | #350 |
aetiological | #350 |
adolescent anxiety | #350 |
suspiciousness | #351 |
receptor genes | #352 |
distractibility | #352 |
disequilibrium | #352 |
adults children | #352 |
disease genome | #353 |
impairing | #353 |
child attention | #354 |
disorders middle | #354 |
brain atlas | #354 |
maob | #354 |
executive attention | #354 |
genetic environmental | #354 |
substantial | #354 |
gabra1 | #354 |
reln | #354 |
male adolescent | #355 |
prodh | #355 |
dsmiii | #355 |
rgs4 | #355 |
heterogeneous disorder | #356 |
phobic disorders | #356 |
schizophrenia data | #356 |
chrna7 | #357 |
children anxiety disorders | #357 |
measures attention | #357 |
gottesman | #358 |
maternal cigarette smoking | #359 |
persists | #359 |
deviant | #359 |
disorder patients | #359 |
psychiatric symptoms | #359 |
symptom scores | #360 |
linkage analysis | #360 |
n54 | #361 |
neuroleptic treatment | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
elevated risk | #366 |
core symptoms | #366 |
confirmation | #366 |
pediatric populations | #367 |
memory load | #367 |
771 | #367 |
study entry | #368 |
bpd mdd | #368 |
comparison groups | #368 |
risk psychopathology | #368 |
young adulthood | #369 |
differential involvement | #369 |
702 | #369 |
hyperactivityimpulsivity | #369 |
differential susceptibility | #370 |
nervousness | #370 |
representativeness | #370 |
schizophrenia risk | #371 |
current concepts | #371 |
damphetamine | #371 |
prevention strategies | #372 |
replicate | #372 |
endorse | #372 |
comt gene | #372 |
5httlpr | #373 |
executive function | #373 |
genomewide association studies | #373 |
driving performance | #374 |
snp heritability | #374 |
small sample | #374 |
dozens | #375 |
wide analysis | #375 |
scz | #375 |
916 | #375 |
teenage | #376 |
emphases | #376 |
medication children | #376 |
data studies | #377 |
children medication | #377 |
memory short | #377 |
genetic architecture | #377 |
sas | #377 |
child adolescent | #377 |
schizotypal personality | #378 |
children adolescents | #378 |
impression | #378 |
marriages | #379 |
control adults | #379 |
pearson | #380 |
ht1b | #380 |
youths | #380 |
opd | #380 |
converged | #380 |
overlap | #381 |
receptors dopamine | #381 |
culmination | #381 |
methylphenidate children | #381 |
relevant articles | #381 |
disorder diagnostic | #381 |
general cognitive ability | #381 |
invaluable | #381 |
adolescent patients | #382 |
chisquare | #382 |
psychopathologies | #383 |
carefully | #383 |
antimanic | #383 |
psychopharmacological treatment | #383 |
summary statistics | #384 |
researched | #384 |
7r | #385 |
gad2 | #385 |
multigenerational | #386 |
treatment children | #386 |
18p | #386 |
chinese subjects | #387 |
neural activation | #387 |
npas2 | #388 |
versa | #388 |
contrasted | #388 |
evenings | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
brain circuits | #390 |
perinatal morbidity | #390 |
lefthandedness | #390 |
handedness | #390 |
studies children | #390 |
disorder symptoms | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
comorbid substance | #392 |
lambert | #392 |
schizophrenia susceptibility | #392 |
p54 | #393 |
genes expression | #394 |
substance users | #394 |
function humans | #395 |
hippocampal subfields | #395 |
dopamine norepinephrine | #395 |
adolescents adults | #396 |
fbat | #397 |
disorders schizophrenia | #397 |
3methoxy4hydroxyphenylglycol | #397 |
mental health children | #397 |
psychometric | #397 |
schizophrenia disorder | #397 |
clinical risk psychosis | #398 |
wandering | #398 |
earlier onset | #398 |
spm8 | #398 |
neuropsychological testing | #400 |
control sample | #401 |
inattention symptoms | #402 |
core symptom | #402 |
suffocation | #402 |
academic outcomes | #402 |
implications findings | #403 |
inconsistencies | #403 |
relations male | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
parahippocampal | #406 |
diagnosis children | #406 |
neuropsychiatric conditions | #406 |
n52 | #406 |
vntrs | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
0038 | #409 |
behavior genetics | #409 |
communitybased | #409 |
substance | #410 |
distinct subsets | #410 |
reading comprehension | #411 |
children studies | #411 |
impulsive behavior | #411 |
twin study | #411 |
dextroamphetamine | #411 |
neanderthal | #412 |
interview | #412 |
apoe4 | #412 |
childhood anxiety | #412 |
psychotic disorders | #412 |
tourette syndrome | #412 |
consistent evidence | #412 |
moderated | #413 |
anticipation | #413 |
systematic literature search | #413 |
performance tests | #414 |
151 | #414 |
reviewing | #414 |
volition | #415 |
polymorphism snp | #415 |
genetic receptor | #416 |
elucidating | #416 |
schizotypal | #416 |
effects brain | #417 |
functional effects | #417 |
adolescent psychiatric | #418 |
conferred | #418 |
adult intelligence | #418 |
srsa | #419 |
genetic association | #419 |
questionnaires adolescent | #419 |
deletion syndrome | #419 |
antidepressive agents | #420 |
dopamine d4 receptor | #420 |
daily doses | #420 |
kdm4a | #420 |
sexes | #421 |
modestly | #421 |
adult subjects | #421 |
operating characteristic | #422 |
cdis | #422 |
drug dependence | #422 |
iccs | #422 |
reliability validity | #423 |
medicated | #423 |
tricyclic | #423 |
characteristic curve | #424 |
gcta | #424 |
transport proteins | #425 |
discovery sample | #425 |
subtests | #425 |
parent ratings | #426 |
cardiff | #426 |
attain | #427 |
hum | #427 |
spectrum disorders | #428 |
diversion | #428 |
brain volume | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
teacher | #432 |
operating characteristics | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
12q | #436 |
cprs | #436 |
1433 | #436 |
perceptual organization | #436 |
frequency genotype | #436 |
lower scores | #437 |
disorder brain | #437 |
relatives patients | #437 |
grin2a | #437 |
visual learning | #438 |
adolescent psychopathology | #438 |
impulsiveness | #438 |
correlation coefficients | #438 |
toddlerhood | #438 |
srs2 | #438 |
genetic genetic predisposition | #439 |
digit span | #439 |
risk psychosis | #439 |
22q112ds | #439 |
nominal | #439 |
snps association | #440 |
aged neuropsychological | #440 |
method female | #440 |
major risk factor | #440 |
post hoc analysis | #441 |
allelic association | #441 |
meaningful | #441 |
white matter microstructure | #441 |
trex | #441 |
corroborated | #441 |
gmo | #441 |
virtual histology | #442 |
logistic regression model | #442 |
adult analysis | #442 |
disorders autism | #442 |
planum temporale | #442 |
female functional | #442 |
n80 | #443 |
differential female | #444 |
10 year | #444 |
disorders surveys | #444 |
emphasize | #444 |
conferring | #444 |
pcdh10 | #445 |
534 | #446 |
statistic | #446 |
862 | #446 |
ntrk3 | #446 |
nucleotide receptors | #446 |
holland | #447 |
motor coordination | #448 |
originally | #448 |
behavior child | #448 |
genome wide | #448 |
expressiveness | #449 |
earlier age | #449 |
wistar kyoto | #450 |
early response | #450 |
risk variants | #450 |
exceptions | #451 |
sex | #451 |
subsequent risk | #452 |
clinical expression | #452 |
prevalence correlates | #452 |
brain abnormalities | #452 |
children adolescent | #456 |
chat | #456 |
79 | #457 |
psychiatry | #457 |
zscores | #457 |
masse | #458 |
structural magnetic | #458 |
preliminary study | #458 |
independently | #458 |
lander | #460 |
psychotic disorders schizophrenia | #460 |
522 | #460 |
polygenic risk score | #460 |
genetic correlation | #460 |
22q112 deletion | #460 |
smoking pregnancy | #461 |
hyperkinesis | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
affection | #465 |
decrements | #465 |
pregnancy complications | #465 |
life treatment | #465 |
control rates | #466 |
gene sets | #466 |
runs | #466 |
anxiety depressive | #467 |
mini | #467 |
inbred wky | #467 |
bpad | #468 |
subjects patients | #469 |
genetic effects | #470 |
patient adherence | #470 |
disorders treatment | #470 |
cacna1c | #470 |
receiver operating | #471 |
remission relapse | #471 |
risk allele | #472 |
psychology adolescent | #472 |
response remission | #473 |
chrna4 | #473 |
norepinephrine transporter | #474 |
plp1 | #474 |
environmental risk factors | #474 |
developmental coordination | #476 |
cautious | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
multiplex families | #479 |
5th | #479 |
dysthymia | #479 |
adds | #480 |
genetic risk variants | #480 |
humans | #480 |
symptom | #480 |
cortex child | #481 |
semistructured | #481 |
diagnostic categories | #481 |
data extraction | #482 |
genotyped | #482 |
maternal anxiety | #482 |
arithmetic | #483 |
etiology | #483 |
sml | #484 |
verbal learning | #484 |
conception | #484 |
nfil3 | #484 |
treatment methylphenidate | #484 |
adulthood | #485 |
agents bipolar | #485 |
756 | #485 |
baseline age | #486 |
epidemiologically | #486 |
outcome variables | #486 |
symptom dimensions | #487 |
123 | #487 |
adult anxiety | #487 |
evaluates | #487 |
spontaneity | #488 |
genetic disorders | #489 |
female adolescents | #489 |
unpublished | #489 |
longterm effects | #489 |
administration schedule | #490 |
neuropsychiatric disorder | #490 |
schizophrenia autism | #490 |
shared environmental | #490 |
common variant | #492 |
smoking prevention | #492 |
schizophrenia age | #492 |
pnds | #493 |
overlapping | #493 |
antisocial personality disorder | #495 |
late adolescence | #495 |
frequency genetic | #495 |
schizophrenia patients | #497 |
pair human | #497 |
restlessness | #497 |
anxiety | #497 |
separation anxiety | #497 |
psychobiology | #497 |
bonferroni | #498 |
longitudinal studies | #498 |
placebos | #499 |
daoa | #499 |
genetic mechanisms | #499 |
addressed | #499 |
candidate | #499 |
identifying | #500 |
comt val158met polymorphism | #500 |
case reports | #500 |
nocebo | #501 |
rat strains | #501 |
d4 receptors | #501 |
verbal memory | #503 |
865 | #503 |
additional evidence | #503 |
circadian clock genes | #505 |
child executive | #505 |
fallacy | #506 |
subscale | #506 |
n26 | #506 |
cooperativeness | #507 |
continued | #507 |
tobacco disorder | #508 |
reflecting | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
educational status | #511 |
dichotomous | #511 |
shared | #511 |
95 death | #512 |
p80 | #512 |
obsessive compulsive | #512 |
identifiable | #512 |
risk haplotype | #513 |
lod | #513 |
coaggregation | #514 |
disproportionate | #514 |
phis | #515 |
disorders depression | #515 |
morning | #515 |
assessments | #515 |
total sample | #516 |
normal control | #516 |
contributing | #517 |
cognitive traits | #517 |
n39 | #517 |
15q | #518 |
missing link | #519 |
fn1 | #520 |
pbat | #520 |
environmental influences | #520 |
specificity ppv | #521 |
dichotic | #521 |
gyrus cinguli | #521 |
disorder obsessive | #522 |
social class | #522 |
selfreport | #522 |
polymorphism single | #522 |
attention memory | #523 |
dibenzothiazepines | #523 |
dedication | #524 |
assortative | #524 |
dmi | #524 |
phg | #524 |
adult bipolar | #524 |
sciencedirect | #525 |
clinical diagnoses | #525 |
pacific island | #525 |
covariates | #525 |
disorder treatment | #525 |
affiliations | #526 |
functioning | #527 |
persistence | #527 |
criminality | #527 |
design study | #528 |
depression anxiety disorders | #528 |
adolescent children | #528 |
symptomatic remission | #528 |
adverse life events | #528 |
compulsive disorder | #529 |
abrupt | #529 |
community samples | #529 |
ruled | #529 |
parental reports | #529 |
flnc | #529 |
control children | #530 |
tagsnps | #530 |
increased burden | #531 |
medications | #531 |
strongest | #531 |
existing studies | #532 |
n40 | #532 |
autism schizophrenia | #532 |
clinical sample | #533 |
subjects age | #533 |
temperament character | #534 |
analyses conducted | #534 |
intercorrelations | #535 |
asd | #535 |
selective review | #535 |
global impression | #537 |
parsing | #537 |
autistic symptoms | #538 |
models genetic | #538 |
child adhd | #538 |
d4 receptor | #539 |
personality factors | #541 |
milder | #541 |
lobe humans | #542 |
taiwanese | #543 |
disease genotype | #543 |
single nucleotide | #543 |
independent samples | #544 |
complexities | #544 |
severe symptoms | #544 |
population sample | #545 |
ld | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
computer program | #548 |
functional variant | #548 |
healthy control subjects | #548 |
nonclinical sample | #549 |
behavior male | #549 |
oral route | #549 |
clash | #549 |
schizophrenia study | #549 |
risk children | #549 |
patients schizophrenia | #549 |
dichotomized | #549 |
765 | #550 |
fam | #550 |
genetic pathways | #550 |
ideally | #551 |
case control | #551 |
motor inhibition | #551 |
define | #551 |
performance test | #552 |
major diagnosis | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
suggests | #555 |
viewed | #555 |
prs schizophrenia | #555 |
release oral | #555 |
phenotypic features | #556 |
spectrum disorder | #556 |
child anxiety | #557 |
neuropsychiatric diseases | #557 |
nogo task | #557 |
neurodevelopmental | #558 |
africanamerican | #558 |
equivocal | #558 |
justify | #559 |
response variability | #560 |
gray matter volumes | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
risk smoking | #565 |
adolescents risk | #565 |
risky behaviors | #566 |
patients sud | #566 |
4th edition | #566 |
twins female | #566 |
intermediate phenotypes | #566 |
3050 | #567 |
haplotype | #567 |
neurocognitive impairment | #567 |
unaffected relatives | #568 |
replication study | #569 |
environment interaction | #570 |
diverging | #570 |
onsets | #570 |
10−8 | #570 |
keywords | #571 |
birthday | #571 |
risk genes | #571 |
dose reduction | #573 |
obesity body mass | #574 |
irritability | #574 |
white matter abnormalities | #574 |
inbred shr | #575 |
questionnaires adult | #575 |
spaced | #576 |
gyri | #576 |
asd diagnosis | #576 |
schizophrenia sample | #577 |
individually | #577 |
parent | #577 |
medical genetics | #577 |
chromosomes human | #577 |
impulsivity | #578 |
82 | #578 |
finetuning | #578 |
symptoms children | #579 |
subsample | #579 |
5httlpr polymorphism | #580 |
development anxiety | #580 |
preschool age | #580 |
cold pressor test | #580 |
haplotype analysis | #581 |
drd1 | #582 |
rdc | #582 |
apol1 | #582 |
psychiatric association | #582 |
3rd | #583 |
delinquent behavior | #583 |
new approaches | #584 |
hk1 | #584 |
separately | #585 |
data children | #585 |
fine mapping | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
examine | #588 |
compared controls | #588 |
nback task | #588 |
defaultmode network | #588 |
138 | #589 |
haplotypes humans | #590 |
estonian | #591 |
behavior adult | #591 |
patients comorbid | #591 |
40mg | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
nonpharmacologic | #597 |
snap25 | #597 |
generalizable | #597 |
discounted | #597 |
899 | #598 |
new directions | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnosing | #604 |
clinical settings | #604 |
diagnostic specificity | #604 |
performance children | #606 |
clinician | #606 |
cognitive outcomes | #606 |
disorganized | #606 |
social environment | #607 |
personality traits | #607 |
sizeable | #608 |
small fraction | #608 |
4 6 | #608 |
gold standard | #609 |
true | #609 |
executive dysfunctions | #609 |
antisocial behavior | #609 |
functional outcomes | #610 |
polygenic risk scores | #610 |
informant | #611 |
complex disorders | #612 |
pleiotropic | #612 |
chromosome 6 | #613 |
schizophrenia brain | #614 |
educational achievement | #614 |
grandmothers | #614 |
snp markers | #615 |
behavior disorder | #615 |
curve analysis | #615 |
disease etiology | #615 |
genetic epidemiology | #616 |
prevalence severity | #616 |
memory deficits | #616 |
tscores | #617 |
genome scans | #617 |
genetic associations | #618 |
differ | #618 |
african children | #618 |
val158met | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
executive control | #625 |
executive dysfunction | #625 |
misconceptions | #625 |
mood stabilizers | #626 |
attentional deficits | #627 |
seeks | #627 |
hrr | #627 |
fibromyalgia | #629 |
child gender | #629 |
treatment disorder | #629 |
schizophrenia findings | #630 |
deficits schizophrenia | #631 |
reject | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
generalisability | #638 |
icv | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
ranks | #641 |
adult outcomes | #641 |
advertisement | #641 |
illness duration | #642 |
inconsistent | #643 |
gateway | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
functioning autism | #646 |
subjects schizophrenia | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
treatment effects | #652 |
gene association | #652 |
avoidant | #652 |
physical conditions | #653 |
128 | #653 |
hyperactivity inattention | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
bipolar disorder schizophrenia | #656 |
random allocation rats | #656 |
reward anticipation | #656 |
studies evidence | #657 |
psychosocial treatment | #658 |
impairment | #658 |
groups compared | #658 |
boldness | #658 |
hypomanic | #659 |
volumes | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
referrals | #662 |
peer relations | #662 |
structural alterations | #662 |
digeorge syndrome | #665 |
lowlevel | #665 |
permission | #665 |
dacc | #666 |
subcortical | #666 |
psychiatric illnesses | #667 |
mood | #668 |
swedish population | #669 |
prominent | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
sleep difficulties | #679 |
129 | #679 |
mental disorders humans | #680 |
psychopathological symptoms | #680 |
middle childhood | #680 |
neurotic | #681 |
gene frequency | #681 |
trait | #682 |
soviet union | #682 |
semantic fluency | #682 |
quetiapine | #682 |
severe phenotype | #683 |
east asian | #685 |
remitting | #685 |
scales | #685 |
p0019 | #687 |
children groups | #688 |
chromosomal region | #688 |
17q | #688 |
younger children | #689 |
postmortem brains | #689 |
fibromyalgia patients | #689 |
disorder schizophrenia | #694 |
average age | #694 |
tcas | #694 |
testretest reliability | #695 |
participants | #696 |
parcellation | #696 |
cortical surface area | #696 |
4–5 | #697 |
pharmacokinetic profile | #697 |
5years | #697 |
relevant studies | #699 |
drug abuse | #699 |
122 | #699 |
effects methylphenidate | #700 |
adult mental | #701 |
quota | #701 |
illness surveys | #701 |
nonrandom | #701 |
gwa studies | #704 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
follow studies | #705 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
p009 | #709 |
school settings | #709 |
children diagnosed | #710 |
chronic schizophrenia | #713 |
informative | #713 |
misuse | #714 |
maternal report | #714 |
dysphoric | #714 |
eric | #714 |
prs | #714 |
disorders substance | #715 |
728 | #715 |
ethanol consumption | #715 |
stress disorder | #715 |
3 weeks | #716 |
641 | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
multiple genes | #721 |
clinical population | #721 |
recurrence risk | #722 |
household income | #722 |
memory | #723 |
cognitive load | #724 |
proponents | #725 |
cinguli | #725 |
male adolescents | #726 |
gender dysphoria | #726 |
common snps | #726 |
lateonset | #726 |
schizophrenics | #727 |
attention deficits | #727 |
dizygotic | #728 |
statistical | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
786 | #730 |
fmri study | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
git | #733 |
correlates | #733 |
voxel based | #733 |
finding | #734 |
phenotypic heterogeneity | #734 |
wky | #735 |
health intervention | #737 |
life cycle | #737 |
gyrification | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
polygenic score | #739 |
inflation | #739 |
validating | #740 |
rapid cycling | #741 |
refill | #742 |
caudate | #742 |
boston | #742 |
time task | #743 |
amphetamines | #744 |
comparators | #744 |
soviet | #745 |
bupropion | #745 |
topic twins | #745 |
compulsive | #746 |
neuropsychological status | #746 |
manifested | #747 |
child interaction | #748 |
duplications | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
molecular genetic analysis | #754 |
347 | #754 |
post hoc | #755 |
comt val158met | #755 |
neuroleptics | #756 |
mental disorders | #756 |
recalled | #756 |
bipolar depression | #756 |
nhe | #757 |
schizophrenia scz | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
likelihoods | #765 |
humans logistic | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
emerged | #772 |
comt polymorphism | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
depressive | #777 |
behavioral phenotypes | #777 |
human pair | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
weaknesses | #780 |
risky behavior | #780 |
schizophrenia relationship | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
combined analysis | #783 |
questioning | #783 |
fourth edition | #783 |
mega | #784 |
emerging roles | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
963 | #787 |
adolescence | #787 |
pbd | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
spelling | #791 |
behavioral | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
symptom burden | #794 |
motivations | #794 |
association polymorphisms | #794 |
delinquent | #796 |
caveats | #796 |
separate | #797 |
363 | #800 |
additional studies | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
dysfunction | #805 |
superior frontal | #805 |
clinically | #805 |
latent classes | #806 |
male memory | #806 |
novelty seeking | #806 |
dorsolateral | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
dopamine serotonin | #811 |
preschool female humans | #811 |
adjusting | #811 |
phonemic | #811 |
blind | #813 |
coadministration | #815 |
mhpg | #816 |
declarative | #816 |
lasting | #817 |
cfb | #817 |
breakthroughs | #817 |
tryptophan hydroxylase | #817 |
quantitative measures | #817 |
epigenetic factors | #818 |
single gene | #818 |
substance dependence | #818 |
memory attention | #818 |
meeting | #820 |
cortical development | #820 |
rated | #821 |
patients psychotic disorders | #821 |
counties | #821 |
hme | #822 |
switches | #822 |
prefrontal regions | #824 |
parental report | #824 |
transcriptomic analysis | #824 |
common genetic | #825 |
rare coding variants | #825 |
humans models | #827 |
adolescents asd | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
prevalent | #831 |
lifetime prevalence | #831 |
multiple testing | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
sleep disorder | #837 |
gray | #837 |
n60 | #837 |
matter humans | #838 |
aversion | #838 |
inbred shr rats | #838 |
symptom profiles | #839 |
obstetric complications | #839 |
prescription | #839 |
neurocognition | #841 |
parenthood | #842 |
sporadic cases | #843 |
participants completed | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
exception | #847 |
dnm | #847 |
dysregulated | #848 |
gwas summary | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
putative | #857 |
nonsignificant | #857 |
estimated prevalence | #858 |
schizophrenia healthy | #858 |
heightened risk | #858 |
putamen | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
seventy | #866 |
global assessment | #866 |
glossary | #866 |
crosssectional studies | #867 |
mental | #869 |
nnt | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
shr rats | #874 |
pediatric | #874 |
perseverative errors | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
positive symptoms | #876 |
genetic counseling | #876 |
manova | #876 |
hypotheses | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
psychedelics | #886 |
12p | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
obsessive | #893 |
n95 | #893 |
n17 | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
biological psychiatry | #903 |
anterior cingulate | #903 |
genetic contribution | #904 |
weight body | #904 |
bipolar illness | #904 |
aptitude | #904 |
reinforcer | #904 |
sibling | #904 |
visit | #905 |
psychosocial functioning | #906 |
826 | #906 |
late childhood | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
pedigrees | #912 |
amygdala reactivity | #912 |
psychosocial | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
versions | #914 |
underlying pathophysiology | #914 |
association age | #916 |
school performance | #917 |
disorder specific | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
dysthymic | #925 |
vulnerability | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
cpg sites | #930 |
nucleotide | #930 |
participating | #930 |
194 | #933 |
heroin addiction | #933 |
permutation | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
diagnostic | #938 |
study designs | #938 |
female genotype | #938 |
irrs | #940 |
robustly | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
sles | #948 |
22q | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
amphetamine | #954 |
relapsers | #954 |
personality disorder | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
clinical disorders | #960 |
qam | #960 |
cytoarchitecture | #962 |
children epilepsy | #963 |
clinical assessment | #963 |
female frontal | #963 |
cgis | #965 |
scores | #965 |
tandem repeat | #965 |
dopamine uptake | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
mtbi | #970 |
schizophrenia association | #970 |
pharmacological treatment | #970 |
examined | #970 |
medication treatment | #971 |
risky sexual behavior | #972 |
aggression | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
psychosis risk | #978 |
resolve | #978 |
vmat2 | #978 |
2–4 | #980 |
neurodevelopmental disorder | #980 |
pertaining | #982 |
educational | #982 |
459 | #982 |
seriousness | #985 |
alleles | #986 |
logistic regression models | #986 |
symptoms age | #986 |
patients sle | #987 |
difficulties | #988 |
ranked | #990 |
small proportion | #990 |
tci | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
diathesis | #999 |
detoxification | #999 |
keystone | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
allele | #1007 |
long‐term outcome | #1007 |
confounding factors | #1007 |
preschool cohort | #1007 |
daughter | #1007 |
0016 | #1007 |
norms | #1008 |
structural mri | #1008 |
qualifications | #1009 |
risk alcohol | #1009 |
posttraumatic stress disorder | #1009 |
multiplex | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
metabotropic | #1020 |
maturational | #1020 |
conclusive | #1021 |
relates | #1024 |
risk prediction | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
analytic | #1031 |
frontostriatal | #1031 |
wwwclinicaltrialsgov | #1031 |
patients panic disorder | #1032 |
symptoms child | #1032 |
73 | #1034 |
predicted | #1034 |
preface | #1034 |
– compulsive | #1034 |
brain disorders | #1035 |
negative symptoms | #1035 |
rodent models | #1035 |
total score | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
gaf | #1044 |
mental health treatment | #1044 |
heightened | #1045 |
relate | #1045 |
inv | #1046 |
antecedents | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
vice | #1056 |
psychiatric morbidity | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
genes involved | #1063 |
illicit | #1063 |
199 | #1063 |
memory disorders | #1064 |
paediatric patients | #1065 |
europe female | #1065 |
pooled | #1068 |
heritability | #1068 |
childhood trauma | #1068 |
awakenings | #1068 |
paranoia | #1068 |
negative impact | #1069 |
memantine | #1069 |
emotional | #1069 |
human genetics | #1070 |
memory impairments | #1070 |
word reading | #1070 |
social problems | #1071 |
reading ability | #1071 |
controlled clinical | #1071 |
single nucleotide receptors | #1071 |
genetic model | #1071 |
risk scores | #1071 |
4q | #1072 |
character inventory | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
studying | #1075 |
3′utr | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
adult antipsychotic | #1082 |
schizophrenia social | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
psds | #1086 |
autoreceptors | #1086 |
onset psychosis | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
irritable | #1096 |
scientific literature | #1096 |
semistructured interview | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
external validity | #1103 |
daughters | #1103 |
future work | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
diagnostic groups | #1107 |
psychosis | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
psychoses | #1110 |
experimental test | #1110 |
prioritized | #1110 |
share | #1111 |
10−5 | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
quantifies | #1128 |
similarities | #1128 |
dysthymic disorder | #1128 |
enriched | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
n28 | #1134 |
attention performance | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
laterality humans | #1138 |
blood pressure response | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
early adolescent | #1145 |
cognitive domains | #1145 |
prodromal | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
emotionality | #1147 |
measurement invariance | #1147 |
refine | #1149 |
children association | #1150 |
discounting | #1150 |
humans intellectual | #1150 |
discriminability | #1150 |
quick | #1152 |
continents | #1152 |
developmental model | #1152 |
generalizability | #1153 |
normals | #1153 |
refinements | #1153 |
sensory gating | #1154 |
clinical profiles | #1154 |
alspac | #1154 |
differential humans | #1160 |
uncorrected | #1160 |
ht2c | #1160 |
phenotype | #1161 |
” “ | #1163 |
review findings | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
clinical groups | #1166 |
deteriorated | #1166 |
affective | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
cohen | #1176 |
bpd patients | #1176 |
gwas data | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
persisting | #1182 |
childhood exposure | #1182 |
cinguli humans | #1182 |
reward | #1182 |
nonverbal | #1183 |
addressing | #1184 |
triads | #1184 |
paradox | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
onequarter | #1198 |
compulsivity | #1198 |
addictions | #1198 |
placebo | #1199 |
wm | #1199 |
asian continental | #1200 |
230 | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
nationwide cohort study | #1209 |
problems children | #1209 |
externalizing symptoms | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
prospects | #1222 |
child cognitive | #1222 |
study role | #1224 |
profile | #1226 |
partly | #1227 |
approximated | #1227 |
0011 | #1229 |
subgroup | #1232 |
molecular alterations | #1232 |
refining | #1232 |
poster | #1233 |
pregnancy prenatal | #1234 |
health organization | #1234 |
children ages | #1235 |
gprotein | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
avenues | #1247 |
kf | #1247 |
risk asthma | #1247 |
enjoyment | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
delineate | #1251 |
roc | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
serotonin transporter | #1256 |
risk ratio | #1256 |
summarize | #1256 |
goal | #1257 |
nervous | #1257 |
dysfunctions | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
386 | #1277 |
developmental pathways | #1277 |
entire | #1277 |
n24 | #1278 |
study evidence | #1281 |
04 | #1281 |
priori | #1282 |
paternal | #1282 |
increased rates | #1283 |
hopes | #1283 |
behavior adolescent | #1283 |
neuroimaging | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
orbitofrontal | #1288 |
somatic complaints | #1288 |
male nerve | #1288 |
warmth | #1289 |
aspect | #1289 |
1hmrs | #1291 |
dual psychiatry | #1291 |
unmyelinated | #1291 |
posttraumatic | #1291 |
clomipramine | #1292 |
misclassification | #1292 |
quantitative trait | #1292 |
animal conditioning | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
prediction accuracy | #1309 |
sgas | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
factor analyses | #1313 |
motor speed | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
short | #1323 |
parents adolescents | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
polysubstance | #1334 |
measures | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
fronto | #1338 |
obsessive–compulsive disorder | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
registry data | #1344 |
542 | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
early adulthood | #1353 |
compared children | #1353 |
psychoticism | #1355 |
diagnostic tool | #1356 |
cocaine abuse | #1356 |
loci genetic | #1356 |
variabilities | #1357 |
flush | #1357 |
simon | #1357 |
seekers | #1358 |
antidepressive | #1359 |
gene discovery | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
unexplored | #1369 |
uptake inhibitors | #1369 |
school teachers | #1369 |
neuronal development | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
highlighted | #1386 |
new onset | #1386 |
dimensional approach | #1389 |
familial aggregation | #1391 |
6 years | #1391 |
prodrome | #1391 |
treatment depression | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
manuscripts | #1395 |
thalamic | #1395 |
satisfying | #1395 |
rats shr | #1395 |
racial | #1398 |
emotional stimuli | #1399 |
timely | #1399 |
lability | #1400 |
suggesting | #1400 |
17 | #1402 |
blinded | #1403 |
sufficient | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
impressions | #1416 |
prepubertal children | #1416 |
332 | #1417 |
carry | #1419 |
logical | #1419 |
humans memory | #1421 |
discoveries | #1422 |
parents children | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
taps | #1431 |
163 | #1431 |
interaction effects | #1432 |
cognitive profiles | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
443 | #1448 |
psychotic illness | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
78 | #1453 |
square | #1453 |
height | #1453 |
ewas | #1453 |
hypermethylation | #1454 |
population stratification | #1454 |
switching | #1455 |
replicability | #1457 |
collaborations | #1457 |
dorsal striatum | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
biological pathways | #1463 |
stronger | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
partial remission | #1468 |
untranslated | #1468 |
valuable | #1468 |
hippocampi | #1469 |
groups differences | #1469 |
contrast effects | #1472 |
statistically | #1474 |
cognition patients | #1474 |
openlabel | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
smaller | #1497 |
allele carriers | #1497 |
mri studies | #1497 |
lifespan | #1499 |
twins monozygotic | #1499 |
small sample sizes | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
ddc | #1505 |
male mothers | #1505 |
multisite | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
existing literature | #1511 |
objectivity | #1511 |
emotions female | #1513 |
reports | #1513 |
attained | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
114 | #1523 |
cna | #1523 |
bipolar patients | #1526 |
inconsistency | #1526 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
default | #1541 |
nucleotide risk | #1541 |
adult life | #1542 |
poses | #1542 |
dopamine receptor | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
influenced | #1554 |
problem behaviors | #1554 |
857 | #1556 |
automobile | #1556 |
failed | #1559 |
early exposure | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
insular | #1565 |
subscales | #1565 |
475 | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
191 | #1573 |
swedish | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
located | #1582 |
findings studies | #1582 |
single nucleotide polymorphism | #1582 |
network dmn | #1583 |
models male | #1583 |
cutoffs | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
firstepisode schizophrenia | #1588 |
major depressive | #1588 |
rs4680 | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
tpv | #1599 |
moderators | #1599 |
psychotropic medications | #1601 |
statistics nonparametric | #1601 |
jan | #1602 |
managed | #1603 |
suffer | #1604 |
utr | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
proneness | #1610 |
1979 | #1610 |
monoamine oxidase | #1611 |
alcoholism | #1613 |
emotional faces | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
risk mental | #1622 |
distinguishing | #1622 |
large body | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
paucity | #1626 |
snp | #1626 |
spatial organization | #1627 |
ht2a receptor | #1627 |
dysphoria | #1628 |
louis | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
kyoto | #1630 |
study children | #1630 |
emrs | #1631 |
memory task | #1631 |
ambiguous | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
social communication | #1643 |
alpha7 | #1643 |
rack1 | #1643 |
tendency | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
maximize | #1658 |
detect | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
comorbid depression | #1663 |
presentations | #1663 |
asm | #1664 |
510 | #1665 |
mood symptoms | #1666 |
dlpfc | #1666 |
chronic patients | #1666 |
association analysis | #1667 |
human rights | #1670 |
indexed | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
statements | #1675 |
early signs | #1675 |
alcohol spectrum | #1675 |
53 | #1677 |
calling | #1678 |
introns | #1678 |
registers | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
mildly | #1684 |
prescribed | #1684 |
46 | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
autistic disorder | #1689 |
github | #1689 |
mdd | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
recruited | #1698 |
motor skills | #1698 |
diagnose | #1699 |
91 | #1702 |
memory consolidation | #1704 |
item | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
rater | #1712 |
health records | #1712 |
neuroscience | #1712 |
personality characteristics | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
107 | #1731 |
inhibitory control | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
identical | #1736 |
stand | #1736 |
predictors | #1739 |
aimed | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
curated | #1746 |
forum | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
selfreport measures | #1753 |
02 | #1753 |
questionnaires young | #1755 |
326 | #1756 |
sertraline | #1756 |
5ht2a | #1758 |
120 | #1758 |
ventral striatum | #1761 |
genetic models | #1761 |
social | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
chance | #1765 |
includes | #1765 |
adult onset | #1766 |
operant | #1768 |
mystery | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
treatment implications | #1773 |
dizygotic twins | #1773 |
patients systemic | #1775 |
depressive episode | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
commonalities | #1786 |
major | #1786 |
higher doses | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
male motor | #1791 |
frustration | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
disabilities | #1797 |
causal variants | #1797 |
positive association | #1797 |
autism spectrum disorders | #1800 |
members | #1801 |
aged models | #1801 |
reporters | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
146 | #1813 |
european descent | #1813 |
aetiology | #1813 |
internationality | #1815 |
frequently | #1815 |
brain imaging | #1816 |
purchases | #1816 |
hippocampal volume | #1819 |
lds | #1819 |
cohens | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
foundation | #1833 |
binocular | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
distinctions | #1845 |
initiative | #1845 |
twins | #1845 |
literacy | #1846 |
psychological | #1847 |
pertinent | #1847 |
environmental risk | #1848 |
warrant | #1848 |
polymorphisms | #1849 |
limited | #1850 |
fearful | #1851 |
vocabulary | #1851 |
individual | #1851 |
nonparametric | #1852 |
young | #1853 |
brainderived neurotrophic factor | #1853 |
differentiating | #1853 |
persons | #1855 |
auditory hallucinations | #1856 |
abuse | #1856 |
prevalence | #1859 |
tph | #1859 |
behavioral measures | #1860 |
incentives | #1860 |
affiliation | #1861 |
cnb | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
multilevel | #1865 |
switch | #1865 |
vocalization | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
histograms | #1879 |
roc curve | #1879 |
animal model | #1880 |
shrs | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
false | #1888 |
differs | #1888 |
substance abuse | #1890 |
metaanalysis studies | #1890 |
heterogeneous | #1894 |
spanning | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
majority | #1909 |
epidemiologic | #1909 |
ads | #1910 |
disorders mental | #1911 |
support vector machine | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
liking | #1923 |
satisfied | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
sleep problems | #1928 |
251 | #1928 |
advertising | #1928 |
empirical studies | #1929 |
ssri | #1930 |
asd children | #1934 |
95 cis | #1934 |
simulation study | #1937 |
borderline personality disorder | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
traumatic brain injury | #1950 |
representing | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
correctly | #1972 |
clinical implications | #1972 |
depression | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
repeats | #1977 |
child depression | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
chinese population | #1984 |
common mental disorders | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
asian continental ancestry | #2005 |
formulations | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
muscle function | #2014 |
absence | #2014 |
akt1 | #2014 |
sms | #2015 |
noradrenergic | #2015 |
cognitive deficits | #2016 |
possibility | #2016 |
prescribers | #2021 |
159 | #2023 |
schoolage children | #2023 |
serve | #2026 |
phenomenology | #2030 |
sleep disturbances | #2030 |
memory verbal | #2031 |
brain responses | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
227 | #2046 |
cognitive processing | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
common diseases | #2061 |
insula | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
demography | #2066 |
overweight obesity | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
functional mri | #2069 |
massachusetts | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
wake disorders | #2079 |
descent | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
43 | #2090 |
latent class | #2090 |
factors child | #2093 |
49 | #2095 |
aud | #2096 |
wky shr | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
specific genetic | #2112 |
nicotinic | #2112 |
child relations | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
monoamine | #2119 |
relative age | #2119 |
poorer | #2119 |
postpartum period | #2119 |
84 | #2121 |
career | #2122 |
51 | #2122 |
pgs | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
dbh | #2137 |
episode schizophrenia | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
pvs | #2145 |
methods participants | #2145 |
behavioral disorders | #2146 |
105 | #2147 |
receptors adrenergic | #2147 |
intraclass | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
glutamatergic | #2150 |
232 | #2150 |
finemapping | #2150 |
represents | #2150 |
repositioning | #2151 |
assessing | #2151 |
mao | #2153 |
rrr | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
differing | #2168 |
genetic association studies | #2168 |
differential diagnostic | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
adversely | #2171 |
mb | #2171 |
prevalences | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
moderating | #2181 |
externalizing | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
processing speed | #2189 |
differential expression | #2189 |
generalized anxiety disorder | #2192 |
scale | #2192 |
regular | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
ages | #2201 |
confounding | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
remained | #2209 |
ottawa | #2209 |
169 | #2209 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
accidents | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
hippocampal formation | #2220 |
completed | #2220 |
biologically | #2220 |
complex diseases | #2220 |
autism | #2221 |
val66met | #2222 |
visuospatial | #2225 |
cognitive task | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
prototypical | #2241 |
hexokinase | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
cigarette | #2264 |
earlier | #2264 |
criterion | #2265 |
bds | #2266 |
pathways | #2266 |
rewards | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
cognitive development | #2275 |
gray matter volume | #2275 |
remain | #2275 |
axis | #2275 |
tend | #2276 |
random allocation | #2277 |
mtl | #2277 |
imaging male | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
diverse populations | #2294 |
regions | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
biology | #2304 |
239 | #2304 |
clinic | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
difficult | #2310 |
lupus | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
covariate | #2335 |
disorganization | #2335 |
archives | #2335 |
early risk | #2336 |
depression female | #2340 |
utility | #2342 |
lesser extent | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
providing | #2353 |
time perception | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
antipsychotic agents | #2379 |
catecholamine | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
essence | #2401 |
gray matter | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
term outcome | #2429 |
bdnf | #2429 |
confounders | #2431 |
fmri data | #2431 |
241 | #2433 |
protein interactions | #2433 |
clinical trial | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
dimorphism | #2448 |
timepoints | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
prefrontal cortical | #2456 |
overweight children | #2456 |
systemic lupus erythematosus | #2456 |
moderately | #2458 |
genetic susceptibility | #2459 |
myoinositol | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
logistic | #2461 |
concordance | #2461 |
traumatic stress | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unclear | #2473 |
unique | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
higher scores | #2489 |
prescriptions | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
hoc analysis | #2496 |
180 | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
establish | #2504 |
original | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
quotient | #2515 |
thresholds | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
psychotic features | #2553 |
risky | #2553 |
depressive disorders | #2554 |
quantitative | #2555 |
neural responses | #2555 |
exploratory study | #2555 |
memory tasks | #2557 |
bipolar affective disorder | #2557 |
chronological | #2560 |
risk loci | #2560 |
income | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
30 years | #2573 |
numerous | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
correction | #2585 |
elucidate | #2585 |
brothers | #2586 |
problems | #2586 |
pvalues | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
exist | #2595 |
disrupted | #2595 |
229 | #2596 |
brain response | #2598 |
internalizing externalizing | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
multiple levels | #2624 |
evidence role | #2624 |
psycinfo | #2625 |
kynurenine | #2625 |
mothers | #2630 |
bdnf gene | #2633 |
imaging studies | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
fetal alcohol | #2642 |
global functioning | #2642 |
preschool female | #2644 |
genetic variants | #2644 |
behavior | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
periodicals | #2665 |
puzzle | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
88 | #2670 |
chromosome | #2670 |
genetic evidence | #2670 |
polysomnography | #2671 |
pcps | #2675 |
spectrum | #2675 |
inconclusive | #2676 |
mediating | #2676 |
partially | #2676 |
physiotherapy | #2678 |
memory tests | #2678 |
adolescent development | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
triad | #2689 |
conditional | #2689 |
age range | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
immaturity | #2698 |
evidenced | #2698 |
extended | #2700 |
chr | #2701 |
attenuate | #2702 |
interrogation | #2702 |
neurite | #2702 |
flares | #2703 |
delinquency | #2707 |
ext | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
aggressive | #2714 |
occurring | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
curve | #2731 |
teens | #2731 |
awakening | #2732 |
thicker | #2733 |
doubt | #2733 |
systematic literature review | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
naa | #2760 |
patients bipolar disorder | #2760 |
collaboration | #2760 |
gt | #2761 |
manifestations | #2762 |
unadjusted | #2765 |
4 years | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
clinical heterogeneity | #2783 |
mechanisms underlying | #2783 |
children symptoms | #2784 |
bivariate | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
dna copy | #2791 |
411 | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
monetary | #2809 |
misdiagnosis | #2809 |
397 | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
indexes | #2823 |
circuitry | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
treatment study | #2843 |
reelin | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
continental ancestry | #2863 |
depression scale | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
mothers children | #2867 |
internal external | #2867 |
cognition humans | #2868 |
discordance | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
shifting | #2885 |
age differences | #2885 |
citations | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
institutes | #2919 |
biological mechanisms | #2919 |
variability | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
725 | #2983 |
qtl | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
symptoms patients | #3039 |
difficulties questionnaire | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
brain health | #3107 |
076 | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
articles | #3123 |
amygdala hippocampus | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
european countries | #3146 |
nation | #3146 |
99 | #3150 |
exploratory | #3150 |
ancestry | #3151 |
behavior social | #3152 |
oxford | #3157 |
pharmacokinetic | #3157 |
explanations | #3165 |
spd | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
imaging study | #3187 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
initial treatment | #3202 |
attempt | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
situation | #3229 |
discontinuity | #3229 |
scanner | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
correlated | #3257 |
211 | #3257 |
caudate nucleus | #3265 |
publicly | #3265 |
interactive effects | #3266 |
humans magnetic | #3266 |
17p | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
ambiguity | #3336 |
clock gene | #3336 |
metropolitan | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
frontal regions | #3371 |
battery | #3371 |
glycolysis | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
typically developing | #3386 |
impaired performance | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
cnp | #3393 |
accounting | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
children mothers | #3448 |
showing | #3448 |
lca | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
hallucinations | #3466 |
genomewide association study | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
postmortem | #3482 |
transmission | #3482 |
slower | #3488 |
convergent | #3489 |
exposure pregnancy | #3489 |
lesser | #3489 |
epidemiological study | #3492 |
applying | #3492 |
083 | #3497 |
short stature | #3497 |
social behaviors | #3497 |
aged polymorphism | #3497 |
alpha2 | #3497 |
matched healthy | #3502 |
p002 | #3506 |
identifier | #3506 |
brain function | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
basis | #3527 |
pediatricians | #3527 |
constitutes | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
cognitive behavioral therapy | #3544 |
sleep wake | #3544 |
fact | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
neuronal function | #3558 |
ecgs | #3558 |
preventive interventions | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
mpfc | #3587 |
neurite outgrowth | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
international | #3744 |
therapy cbt | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
neurophysiological | #3758 |
333 | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
male marijuana | #3844 |
exchanger | #3844 |
disease genes | #3850 |
children aged | #3850 |
developmental disorders | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
influences | #3876 |
74 | #3876 |
208 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
neurology | #3898 |
plasma membrane | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
frontal gyrus | #3937 |
specific factors | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
categorization | #4000 |
preliminary evidence | #4000 |
factorial | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
modeled | #4051 |
discussion | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
contextual factors | #4058 |
jointly | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
cag | #4068 |
magnetic resonance | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
temporal lobe | #4098 |
lobe | #4098 |
maternal depression | #4100 |
genetic variations | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
plausible | #4121 |
comprises | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
dosing | #4145 |
german | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
route | #4216 |
helpful | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
predict | #4253 |
gpcr | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
potential targets | #4315 |
adequacy | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
exists | #4375 |
relation | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
clarity | #4383 |
psychological adolescent | #4383 |
solving | #4391 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
striatal dopamine | #4449 |
human studies | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
valuation | #4516 |
visits | #4516 |
disorders cognitive | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
postnatal day | #4540 |
considerable | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
employment | #4553 |
higher level | #4553 |
birth | #4564 |
preschool children | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
q1 | #4643 |
clinical risk | #4643 |
question | #4648 |
trouble | #4651 |
unmet | #4651 |
regression model | #4652 |
marriage | #4658 |
centers | #4660 |
microsatellite | #4660 |
deliveries | #4660 |
anterior cingulate cortex | #4661 |
trajectories | #4662 |
243 | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
hazards models | #4715 |
vector machine | #4715 |
estimate | #4716 |
smd | #4717 |
sed | #4719 |
mbr | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
conflict | #4760 |
77 | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
samples | #4791 |
noncarriers | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
cognitive tests | #4825 |
modafinil | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
subsamples | #4881 |
young age | #4881 |
cigarettes | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
hemispheric | #4949 |
delays | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
distinguish | #5040 |
correct | #5040 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
auc | #5047 |
sga | #5050 |
marital | #5051 |
convergent validity | #5051 |
early | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
gender identity | #5067 |
bidirectional | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
screening | #5104 |
103 | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
single nucleotide polymorphisms | #5132 |
mediation | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
inherent | #5146 |
difference | #5146 |
pharmacogenomics | #5147 |
involves | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
ws | #5278 |
daytime sleepiness | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
trend | #5295 |
billion | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
072 | #5308 |
life events | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
social interactions | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
penetrance | #5380 |
higher frequency | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
risk individuals | #5468 |
york | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
155 | #5547 |
modulate | #5547 |
elevated | #5549 |
closely | #5549 |
prevention | #5551 |
restraint | #5552 |
flanking | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
european ancestry | #5567 |
15 | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
perinatal | #5663 |
lower risk | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
1999 | #5686 |
40 years | #5686 |
gene variants | #5687 |
vbm | #5688 |
markov | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
databases | #5696 |
normal | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
council | #5910 |
imputation | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
statement | #5928 |
region | #5928 |
linked | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
moderating role | #6005 |
rois | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Open the FULL List in Excel | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Known for Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Known for Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Known for Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Known for Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Known for Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Known for Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Known for Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Known for Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Known for Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Known for Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Known for Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Known for Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Known for Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Known for Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Key People For Hyperactivity Disorder
Stephen V Faraone∗:Expert Impact
Concepts for whichStephen V Faraone∗has direct influence:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:KOL impact
Concepts related to the work of other authors for whichfor which Stephen V Faraone∗ has influence:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |